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SUMMARY 
All the biochemical, physiological or behavioural processes whose period is about 24 
hours possess a circadian rhythm. Circadian rhythms are very well conserved in beings of 
different levels of complexity since they provide evolutionary advantages by anticipating 
external changes. Indeed, circadian rhythms control almost all aspects of human daily 
behaviour and physiology, from the sleep-wake cycle to memory and alertness. The 
disruption of circadian rhythms leads to many diseases, including depression, cancer and 
metabolic syndromes. Understanding the mechanisms and function of circadian rhythms is 
essential to a better treatment of circadian pathologies and to avoid the exacerbation of 
co-morbidities such as depression, metabolic syndromes and vascular diseases. However, 
the study of human circadian rhythms in subjects in vivo is expensive, very time 
consuming and may involve the use of invading devices. In complex animals like 
mammals circadian rhythms are organized in a hierarchic fashion: suprachiasmatic 
nucleus (SCN) is master clock and governs the circadian rhythms of all peripheral 
oscillators, virtually all the other cells of the body. SCN and peripheral oscillators share the 
same circadian molecular machinery. It is thus possible to use peripheral oscillator as 
model to study molecular mechanisms of circadian rhythms. 
The aim of the thesis was to establish the use of human primary skin fibroblasts as 
a valuable model to study different aspects of human circadian rhythms. To visualize in 
real-time cellular circadian rhythms, fibroblasts were infected with a lentivirus coding for 
the circadian reporter firefly luciferase under a clock gene promoter (Bmal1). After the 
synchronization of circadian rhythms, the measurement of the light emitted by the cells 
gives a representation of fibroblast circadian oscillations. Several circadian parameters 
can be analysed by the measurement of fibroblast bioluminescence, such as phase (e.g. 
the phase of sleep-wake cycle that is different between the “larks”-early chronotypes - and 
“owls”-late chronotypes), period length (the time spent for one complete cycle), amplitude 
(the magnitude of change in an oscillating variable) and damping rate (e.g. progressive 
reduction of the circadian amplitude due to desynchronization).  
This thesis was designed to (1) validate the human skin fibroblast model, ascertaining that 
this in vitro model parallels in vivo human circadian parameters, and (2) to study human 
age-related circadian impairments. Moreover, skin fibroblasts were used (3) to investigate 
the role of melatonin as zeitgeber on peripheral oscillators. Melatonin is secreted in a 
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circadian fashion and was demonstrated to influence SCN circadian rhythms; however, 
melatonin functions on peripheral cells are still unclear. 
 (1) The protocols to study human physiological or behavioural circadian rhythms - 
which are normally governed by the SCN of the brain hypothalamus - involve extensive 
subject observation under special controlled conditions. Since SCN and peripheral 
oscillators share the same circadian molecular machinery, we have measured human in 
vivo period length and compared with skin fibroblast period length isolated from the same 
subjects. In vivo period length was determined by the analyses of melatonin or melatonin 
metabolite content in two groups of sighted subjects and one group of blind participants, 
each using different protocols. In all the three groups of subjects a very good correlation 
was found between the in vivo and the in vitro period length. Interestingly, although the in 
vivo period obtained from the blind group was longer than the in vivo period obtained from 
the sighted groups, the in vitro period length from the three groups of subjects was similar, 
revealing that human skin fibroblasts are insensitive to the after-effects caused by light. 
This finding reveals the importance of skin cells as a tool to study human circadian 
rhythms: the factors that determine plasticity in human period do not interfere with 
fibroblast period length. In summary, human circadian period can be approximated by 
measurement in fibroblasts. 
 (2) Ageing is a process that leads to impairments of many physiological processes, 
including circadian rhythms: the sleep-wake cycle of elder persons is disrupted and animal 
studies revealed an earlier phase of gene expression in some peripheral organs and a 
shorter SCN period length. Moreover, young subjects have a later chronotype than older 
subjects. To investigate the molecular mechanisms which lead to circadian changes that 
occur in humans during ageing, fibroblast circadian parameters from a group of young and 
older donors were characterized. No differences in amplitude, phase and period length 
were found between cells from the two groups. These results revealed that, during ageing, 
the molecular components of the skin fibroblast oscillators do not change per se; however, 
since age-related circadian differences can be observed in peripheral organs, hormone 
levels, human age-related alterations might be caused by one or more circulating factors. 
In support of this hypothesis, human fibroblasts in the presence of sera from older donors 
(instead of foetal bovine serum used under standard conditions) showed a reduced period 
length and a shorter phase of entrainment compared to the same cells measured in the 
presence of sera from young donors. These differences are likely due to one or more 
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thermolabile substances, since heat-inactivation of sera from older donors almost undid 
the reduction of the circadian period length. In summary these results suggest that during 
ageing the molecular machinery of peripheral circadian clocks does not change per se, but 
some age-related circadian changes observed in vivo might be caused by circulating 
molecules. 
(3) Melatonin was previously shown to regulate the SCN firing rate and to entrain 
the sleep-wake cycle of most mammals and humans. The circadian presence of melatonin 
is well conserved in all biological fluids, suggesting that melatonin may be one of the 
molecules that the master clock uses to synchronize peripheral oscillators. This hypothesis 
was tested in damped fibroblasts, using a wide range of concentrations of melatonin to 
restore the amplitude of the rhythms. However, no increase of amplitude or phase shift of 
the rhythms was observed after treating cells with melatonin. Moreover, the application of 
the hormone to newly synchronized oscillators decreased their bioluminescence. Although 
these experiments demonstrated that melatonin does not directly synchronize human 
fibroblasts, they cannot exclude indirect effects of melatonin to entrain cellular circadian 
rhythms: indeed, decreasing the amplitude of a rhythm may render it more sensitive to 
phase shifting, for example by substances other than melatonin. In summary, the 
experiments demonstrated that melatonin does not play a direct role as peripheral 
oscillator zeitgeber. 
In conclusion, the studies of the present thesis succeeded in revealing three primary 
findings: first, fibroblast circadian rhythms parallel human circadian physiology, such as 
circadian period length. Second, apparently, during ageing the molecular components of 
peripheral circadian clocks in skin fibroblasts do not change per se, but some age-related 
circadian changes observed in vivo might be caused by one or more heat-sensitive 
substances present in the blood of older subjects. Finally, melatonin does not possess 
direct synchronizing properties on peripheral oscillators like fibroblasts, although it may 
render the cells more sensitive to further synchronizing signals. In total, the present thesis 
revealed that primary human skin fibroblasts are an easily accessible, cheap and reliable 
model to enlighten our understanding of human circadian mechanisms. 
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1. INTRODUCTION 
1.1 CIRCADIAN RHYTHMS 
Circadian oscillations, which occur with a period of about 24 hours, play a key 
physiological role in the adaptation of living organisms to the alternation of day and night 
by anticipating the external changes. For example, the circadian clock of plants allows 
them to produce photo-system I and II components already before sunrise, so that 
photosynthesis can commence as soon as light energy is available [1]. On a similar note, a 
nocturnal rodent possessing a circadian timekeeper can anticipate dusk in his 
underground habitat and does not have to forage periodically to examine whether sunset 
is approaching. Such anticipation may considerably reduce exposure to day-active 
predators and thus provide a selective advantage. In liver the accumulation of about 5–
10% of all messenger ribonucleic acid (mRNAs) undergoes a daily oscillation [2-5]. The 
identification of these cyclic transcripts has led to the conclusion that a large fraction of 
circadian genes are involved in metabolism. Thus, many enzymes playing important roles 
in the utilization or degradation of proteins, lipids, carbohydrates and xenobiotic 
substances appear to be synthesized in a rhythmic fashion. Reactions catalised by the 
cytochrome p450 (CYP), enzymes involved in the hepatic detoxification of xenobiotic 
substances, can generate reactive oxygen species (ROS) [6]. CYP expression is mostly 
circadian, with peak expression during the absorptive phase [7-8], probably to schedule 
the production of harmful side molecules in a time window where also the scavengers are 
produced. Within the circulatory system, heartbeat and blood pressure vary in circadian 
fashion and rhythmic expression of genes involved in fibrinolysis are believed to account 
for the prevalence of infarctus at morning hours [9]. Also daily variations in mood and 
alertness are circadian and might be explained by circadian expression of ion channels, 
neuronal receptors and hormones [10-11]. 
1.1.1 Clock genes and circadian machinery 
The molecular mechanisms that regulate circadian rhythm are present in several levels of 
organism complexity, from bacteria to plants to animals. That genes control circadian 
rhythms was first established in the fruit fly after the demonstration that certain point 
mutations in Drosophila melanogaster cause altered circadian rhythms [12]. The mutated 
gene, period (per), was subsequently isolated [13] and was found to be expressed in a 
circadian pattern [14]. This finding and similar data from bacteria, fungi, and plants, has led 
1. INTRODUCTION 
  2  
to the general idea that periodically expressed genes constitute the physiological basis of 
circadian clocks in all living organisms [15-17]. The maintenance of a rhythm of about 24 
hours long is made possible by the so called transcriptional-translational feedback loop 
model. In this model it can be possible distinguish positive components (basically 
transcription factors) and negative components (inhibitors of the transcription factors).  
Some of the proteins that control the circadian process in mammals are related to those 
found in fruit flies [18-19]. The locomotor activity of Drosophila is circadian. Indeed, under 
light-dark conditions flies show two peaks of activity: in the morning, around the time of 
lights-on and in the evening, around the time of lights-off. Drosophila activity increases in 
advance of both dark-to-light and light-to-dak transition, a phenomenon termed 
anticipation. The behaviour of flies is also sensitive to masking, by changing their 
behaviour in relation to unexpected changes in lighting. When flies are located in constant 
darkness their activity occurs at approximately the same time each day corresponding 
roughly to the evening activity peak and reflecting circadian clock function with a near-24 
hours period [20]. The circadian behaviour in Drosophila is driven by clock genes: per and 
timeless (tim) genes are transcriptional activated by the binding of dCLOCK (dCLK) and 
CYCLE (CYC, also called dBMAL-1) transcription factors to the E-boxes present in their 
genes. After dusk per and tim levels peak. In the cytoplasm PER and TIM form the 
complex PER/TIM protein. The rate of appearance of this complex is delayed by the 
activity of DOUBLE-TIME (DBT), a Casein kinase (CK) Iε homologue, which helps create a 
4–6 hours lag between the peak levels of per and tim RNAs and proteins. PER/TIM 
complex enter into the nucleus at midnight. TIM is degraded and PER is liberated as a 
nuclear monomer that is progressively phosphorylated and subsequently degraded after 
dawn [21]. 
Similarly (Fig. 1), the mammalian players of the negative key components of this genetic 
circuitry are the four genes encoding Cryptochrome 1 (Cry1), Cryptochrome 2 (Cry2), 
Period 1 (Per1) and Period 2 (Per2). These genes are regulated by the two PER-ARNT-
SIM (PAS) domain basic helix-loop-helix transcription factors CLOCK and BMAL1, the 
positive key components of the circadian oscillator. CLOCK and BMAL1 form a 
heterodimer that binds E-Boxes sequences present in Per and Cry promoters. The binding 
to E-boxes by CLOCK-BMAL1 complex activates the transcription of Per and Cry genes. 
PER and CRY proteins form heteropolymeric complexes of unknown stoichiometry and 
once these complexes have reached a critical concentration in the cell nucleus, they 
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interact with the CLOCK-BMAL1 heterodimer inhibiting CLOCK-BMAL1 dimerization and 
their binding to E-boxes, leading to a block of per and cry expression. As a consequence 
cry and per mRNAs and proteins decrease in concentration and once the nuclear levels of 
the CRY–PER complexes are insufficient for auto-repression, a new cycle of Per and Cry 
transcription can start [22-23] (see also 6.1 Appendix 1). Many additional components 
contribute to the robustness of this molecular clockwork circuitry. For example, the orphan 
nuclear receptor and repressor REV-ERBα interconnects circadian transcription of the 
positive and negative “limbs” of the oscillator. REV-ERBα transcription is activated by 
CLOCK-BMAL1 complex through the binding to E-box sequences present in its promoter, 
resulting in its circadian accumulation. REV-ERBα protein leads to periodic repression of 
Bmal1 and Clock transcription. This repression leads to a rhythmic expression of bmal1 
and (to a lesser extent) clock mRNA in antiphase with Rev-Erbα expression [24]. 
Posttranslational mechanisms such as protein phosphorylation also play important roles in 
generating oscillations of approximately 24 h. For example, CK1ε, initially identified as an 
essential Drosophila clock component [25], phosphorylates PER, CRY, and BMAL1 
proteins [26-28]. CK1δ, a close paralog of CK1ε, has also been found to be associated 
with PER–CRY complexes and may therefore perform a similar function as CK1ε [29]. 
Hypophosphorylated PER proteins have a higher metabolic stability than their 
hyperphosphorylated counterparts and this may lead to an increased accumulation of PER 
proteins.  
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Fig. 1. Molecular circadian clock machinery. 
(A) The positive key components of the 
negative feedback loop, BMAL1 (B, red 
octagon) and CLOCK (C, green esagon), 
dimerize, bind to specific promoter sequences, 
E-Box, and activate the transcription of the 
negative elements Per (P, violet ellipse), Cry 
(C, green rhomb) and Rev-Erbα(R, yellow 
ellipse). In the cytoplasm PER and CRY protein 
form a complex of unknown stochiometry with 
CKIε/CKIδ (ε/δ, orange ellipse), that enter in the 
nucleus, binds the heterodimer 
BMAL1/CLOCK. (B) The complex 
PER/CRY/CKI inhibits BMAL1/CLOCK binding 
to E-Box sequences and the heterodimerization 
of BMAL1 with CLOCK. At the same time REV-
ERBα inhibits the transcription of Bmal1, 
decreasing BMAL1 content in the cell. (C) As a 
consequence, also the negative key 
components CRY and PER and REV-ERBα 
decrease their concentration in the cell. (D) 
Once the presence of the negative components 
of the feedback is reduced, BMAL1 protein is 
produced again, probably through an activator 
(A, brown ellipse). (Adapted from [23]). 
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Circadian rhythms are conserved also in fungi. The widely used model to study fungal 
circadian rhythms is Neurospora crassa. In Neurospora the most obvious circadian output 
is the formation of a mass of spores, called conidia. Conidiation is a time-consuming 
process that is initiated after dusk and reaches a peak in the late (subjective) night. 
Conidiation is driven by clock genes machinery: by late subjective night, frequency (frq) 
mRNA levels are low. WHITE COLLAR (WC)1 and WC-2 act together as a transcription 
factor, the white collar complex (WCC), by binding to a specific sequence (the Clock Box 
[30]) on the Frq promoter in order to drive transcription. FRQ protein appears by between 
late night and morning. By early subjective morning FRQ proteins are synthesized [31] and 
they dimerize [32] and interact with the RNA helicase FRH [33] before entering the nucleus 
[34]. As soon as FRQ appears, it begins to be phosphorylated by several kinases (i.e. 
casein kinase I and II). Phosphorylation of FRQ serves to facilitate interaction of FRQ with 
the ubiquitin ligase FWD-1 that targets FRQ for turnover in the nucleosome [35]. In the 
nucleus, specific interactions occur between the FRQ–FRH complex and the WCC [36-38] 
that block the activity of the WCC [30], probably by affecting the phosphorylation status of 
either or both WC-1 and WC-2. As a result, by mid-subjective day WCC activity declines to 
its lowest level [30, 39] and this dampened expression of frq RNA also causes its level to 
begin to fall.  
The simplest organisms known to show circadian rhythms are the photoautotrophic 
cyanobacteria [40] where a robust circadian cycling has been observed even under 
constant darkness. In cyanobacteria many processes are under circadian control, 
including global gene expression: the entire chromosome undergoes daily cycles of 
topological changes and compaction. In Synechococcus elongatus many processes 
conform optimally to the daily cycle, including photosynthesis, nitrogen fixation, and gene 
expression [41]. In contrast to eukaryotic clock models the cyanobacterial clock operates 
independently of transcription and translation processes. Three genes, KaiA, KaiB, and 
KaiC, play essential roles in the circadian clockwork of a cyanobacterium [40, 42]. Multiple 
phosphorylation states [43], allosteric rearrangement [44], KaiA sequestration [45], 
monomer exchange [46-47] or different combinations of them [48-49] have been 
suggested to serve as basic mechanisms producing synchronized oscillations. In a 
proposed model KaiC represses the expression of kaiB and kaiC and thus constitutes a 
negative feedback loop [40, 50]. KaiA catalyzes the phosphorylation of KaiC [51] and KaiB 
attenuates the kinase activity of KaiA [52], where KaiA interacts with KaiC mostly in the 
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KaiC phosphorylation phase and the KaiB activity is most evident in the KaiC 
dephosphorylation phase [53-54]. 
1.1.2 Sleep 
One of the classical examples of circadian rhythms in animals is the sleep-wake cycle. 
Sleep is an active and as yet poorly understood process, during which many physiological 
and cerebral events occur. In general, the daily sleep/wake cycle is under circadian 
control, although the urge to sleep appears to be controlled by brain functions that are 
independent of the circadian system [55]; thus, sleep-wake cycles are regulated by the 
interplay of a homeostatic mechanism, which regulates sleep depth, and the circadian 
clock, which regulates timing of sleep. 
1.1.2.1 Sleep architecture 
When humans and animals fall asleep some characteristic behaviours, such as reduced 
motor activity, decreased response to stimulation, stereotypic postures (in humans, for 
example, lying down with eyes closed) and relatively easy reversibility (distinguishing it 
from coma, hibernation, and estivation) occur. Despite the typical reduction of motor 
activity sleep is not a static process. Several stages of sleep, coded in 2004 by the 
American Academy of Sleep Medicine as non-rapid eye movement (NREM) sleep (divided 
in stage N1-N4) and rapid eye movement (REM) sleep (stage R) [56], come one after the 
other, normally cycling from NREM sleep and then REM sleep. Human adults usually 
begin sleep by progressing from stage 1 through stage 4 of NREM sleep. This progression 
is intermittently interrupted by body movements and partial arousals. After about 70-80 
minutes the sleeper usually returns briefly to stage 3 or stage 2 and then enters the first 
REM phase of the night, which lasts about 5-10 minutes. In humans the length of the cycle 
from the start of NREM sleep to the end of the first REM phase is about 90-110 minutes. 
This cycle of NREM and REM sleep is typically repeated four to six times a night. In 
successive cycles the duration of NREM stages 3 and 4 decreases while the length of 
REM phases increases. In young adults the largest amount of sleep time (50-60%) is 
spent in stage 2 NREM sleep; REM phases constitute 20-25% of total sleep time, stages 3 
and 4 NREM about 15-20%, and stage 1 NREM about 5%. Sleep stages can be monitored 
via electromyography, to measure muscle activity, electro-oculography, to measure eye 
movements and electroencephalography, to measure the collective activity of cortical 
neurons.  
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NREM sleep is characterized by low neuronal activity, metabolic rate and brain 
temperature. In addition, sympathetic outflow decreases and heart rate and blood pressure 
decline. Conversely, parasympathetic activity increases and then dominates during the 
NREM phase, as evidenced by constriction of the pupils. Muscle tone and reflexes are 
intact. 
NREM sleep stages are: 
Stage 1: this stage represents the transition from wakefulness (low voltage 
eletroencephalography (EEG) activity, that normally ranges between 10-30 µV and 16-25 
Hz) to the onset of sleep (EEG appearance of alpha activity, a sinusoidal activity ranging 
between 20-40 µV and 10 Hz) and lasts several minutes. In stage 1 and throughout the 
NREM phase there is some activity of skeletal muscle but no rapid eye movements. 
Stage 2: stage 2 is characterized by bursts of sinusoidal waves called sleep spindles (12-
14 Hz) and high-voltage biphasic waves called K complexes, which occur episodically 
against a background of continuing low-voltage EEG activity. 
Stage 3: during stage 3 NREM sleep delta waves (0.5-2 Hz) in the EEG occur. 
Stage 4: in that stage the presence of slow-wave activity dominates the EEG record. 
In humans stages 3 and 4 are also called slow-wave activity sleep.  
REM sleep comes after NREM sleep. In humans REM sleep is characterized by an EEG 
presenting a low-voltage and mixed-frequency pattern that in some cases resembles those 
during active wakefulness. Indeed certain neurons (those in the pons, the lateral 
geniculate nucleus, and the occipital cortex) actually fire in more intense bursts during 
REM sleep than during wakefulness. These intense bursts of high-voltage firing, called 
ponto-geniculo-occipital spikes (PGO spikes) for brain structures in which the spikes 
appear most prominently, correlated with the bursts of eye movements in REM sleep. 
Tipically, during REM sleep, brain temperature and metabolic rate rise, atonia of almost all 
skeletal muscle occur (with the exceptions of muscles controlling the movements of the 
eyes, middle ear ossicles, and diaphragm) even if some small phasic twitches may 
happen. Miosis reflects the high ratio of parasympathetic to sympathetic output to the 
pupil. Homeostatic mechanisms are attenuated: respiration is relatively unresponsive to 
changes in blood CO2 and responses to heat and cold are greatly reduced or even absent. 
As a result, body temperature drifts toward ambient temperatures. 
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1.1.2.2 Sleep regulation 
The latest proposed model of sleep regulation posits the interaction between two main 
independent regulatory processes, the circadian process and the homeostatic process 
[57], that together determine timing, duration and quality of both sleep and wakefulness. 
Where the circadian system determines the distribution of sleep over the day, the 
homeostatic process tracks sleep need. Sleep need and the propensity to initiate sleep 
increase during wakefulness and decrease while asleep. The daily (circadian) sleep–wake 
alternation also makes the homeostatic process appear as a 24 hours oscillation with the 
important distinction that this oscillation is imposed or driven by the sleep–wake 
distribution whereas circadian rhythm is self-sustained. One of the best protocol to study 
the interaction between these two processes in humans is the forced desynchrony protocol 
[58]. Trought the use of forced desynchrony protocol it was possible to understand that the 
circadian system generates a sleep–wake propensity rhythm that is timed to oppose 
homeostatic changes in sleep drive. This enables us to stay awake and alert throughout 
the day despite an accumulating need for sleep and asleep during the night despite a 
waning of sleep need [59]. Slow wave activity (delta power) reflects the sleep need and so 
it is considered as a measure of sleep homeostasis [60], whereas circadian clock 
pacemaker firing rate is a measure of the circadian time. From forced desynchrony and 
constant routine studies it seems that sleep homeostasis and circadian rhythms are two 
processes that interact in a non-additive and perhaps independent manner in order to 
create, for instance, human sleep-wake cycle. Indeed, in humans the amplitude of the 
observed circadian variation in alertness, performance and numerous sleep variables 
depend on the status of the sleep homeostat [59]. Moreover, several clock genes are 
implicated in sleep homeostasis, suggesting that the molecular circuitry used to set 
internal time-of-day might equally be utilized to track and anticipate sleep need [61]. 
Circadian rhythms and sleep homeostasis are physically interconnected: the circadian 
pacemaker located in the suprachiasmatic nucleus (SCN) is physically connected to brain 
areas involved in sleep, such as the pedunculopontine tegmental nucleus and the 
laterodorsal tegmental nucleus [62] who project cholinergic input. These regions are 
known to be involved in REM sleep regulation [62]. In addition, the serotonergic 
projections from the raphe dorsalis [63], which are involved in NREM/REM sleep cycling 
[62], constitute a potential pathway for feedback of vigilance state onto the SCN. 
Moreover, the vigilance state modulates the SCN firing rate [64] and animal data reporting 
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a circadian phase difference [65] and different clock gene expression [66] after sleep 
deprivation indicate that sleep and wake states are able to influence circadian rhythms. 
1.1.2.3 Clock genes and sleep  
The genes that are responsible to drive circadian oscillations, clock genes, could also 
underlie the sleep–wake-driven relaxation oscillator that represents the sleep homeostat. 
These clock genes are transcriptional regulators and their nature makes them well suited 
not only to keep track of waking activity and sleep time but also to influence processes that 
may underlie sleep function at the cellular level. In addition, Per1, Per2, Per3, Npas2, 
Clock and Bmal1 all encode proteins containing one or more so-called PAS signal-sensor 
protein domains. Based on both functional and phylogenetic considerations, PAS 
containing transcriptional regulators can be classified as either α-class proteins that act as 
sensors of environmental signals or as β-class proteins that act as more general 
dimerization partners [67]. The PER proteins, NPAS2 and CLOCK qualify as α-class PAS 
proteins whereas BMAL1 is considered a β-class PAS protein. Many PAS-domain proteins 
can sense oxygen, redox, voltage or light and are implicated in environmental and 
developmental signalling pathways. 
To better understand the reciprical influence of clock genes and sleep, animal and human 
studies tried to unravel for several years the sleep phenotype caused by a genetic 
mutation. Bmal1-/- mice showed increases in total sleep time, sleep fragmentation and 
EEG delta power under baseline conditions and an attenuated compensatory response to 
sleep deprivation [68].  
Mice lacking Npas2 were found to sleep less in the latter half of the dark period, a time of 
day when sleep need is high conceivably to discharge accumulated sleep pressure [69]. 
When sleep pressure was increased by means of an 8 hours sleep deprivation, Npas2−/− 
mice were incapable of initiating the appropriate compensatory behavior (i.e. sleep) during 
the circadian phase in which mice are usually awake, i.e. the dark period [69].  
Mice lacking the transcription factor D-site albumin promoter-binding protein (Dbp), a 
clock-controlled gene [70], showed decreased NREM sleep consolidation and EEG delta 
power and a reduced compensatory rebound in REM sleep after sleep deprivation [71].  
From studies on clock gene mutant or knock-out animals, Per genes were found to have a 
major potential to modulate sleep. In knock-out animals per1 and per2 expression levels 
positively correlates with sleep homeostasis: the arrhythmic in dark/dark (DD) Cry1/2-/-, 
whose per1 and 2 levels are increased, shows an increased sleep need [66, 72-73], 
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whereas the opposite case is Clock knock-out animals, whose per1 and per2 levels are 
decreased, have less sleep pressure [70, 74]. On the other hand, sleep pressure is able to 
influence Per1 and Per2 expression levels: in sleep deprived animals, per1 and per2 levels 
are increased in the cortex, thalamus and cerebellum, but after only two hours of recovery 
sleep the Per levels drop down [66, 73]. However, only in the forebrain does per 
expression seem to consistently follow NREM sleep propensity, noticeably independent of 
the circadian oscillation of Per expression in the SCN [75]. In Per1,2 double-mutant mice 
slow-wave activity seemed enhanced to a greater extent after sleep deprivation than in 
wild-type mice [76], suggesting that Per signaling is also functionally implicated in sleep 
homeostasis. In human studies Per3 gene polymorphisms were shown to be involved in 
sleep homeostasis: individuals with Per34/4 polymorphism show a stronger decrement in 
performance sleep-loss-induced compared to Per35/5 individuals, suggesting a different 
susceptibility on sleep homeostasis [77]. 
1.1.3 Entrainment  
In mammals, entrainment of the central clock in the SCN is an exclusively ocular process. 
Environmental light is transduced from the retina via both conventional rod and cone 
photoreceptors containing the photopigment rhodopsin and via a special class of retinal 
ganglion cells containing the pigment melanopsin [78]. These cells project directly to the 
suprachiasmatic nucleus. Without these retinal cells – e.g. in some totally blind or 
enucleated individuals – the circadian clock “free-runs” at a period length that often differs 
slightly from the solar day, leaving affected people with chronic jetlag-like symptoms [79]. 
Entrainmnent is defined as the alignment of a circadian system's period and phase to the 
period and phase of an external rhythm. Entrainment is the most common and a very 
important state for circadian system. In laboratory conditions single cues are studies, but 
the interplay between the intensities of different signals that occur in the wild is still far from 
being understood. 
Signals that can entrain circadian system, also called zeitgeber (time cue), are: light, 
temperature, nutrients and non photic cues such as social entrainment. 
In humans light is the most potent zeitgeber for the biological clock. Light pulses are able 
to reset circadian rhythm in a new phase. Moreover, the circadian rhythms of the majority 
of subjects that lack the physiological light responses (such as melatonin suppression by 
light) run free [80]. In other subjects lacking light responses whose circadian rhythms 
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period length is close to 24 hours, other weaker zeitgebers, such as social time cues, can 
entrain circadian rhythms [81].  
Temperature, that can contribute to the human sleep-wake cycle rhythms [82] and 
nutrients are other zeitgebers whose abilities to entrain circadian rhythms are higher in 
lower living being such as Neurospora crassa [83] or Gonyaulax polyedra [84]. 
Masking is another parameter very important in real life. This is the case of signals that 
affect the overt circadian rhythms in a positive (enhancing) or a negative (depressing) 
manner but they are not related to the process of entrainment. An example of masking 
effect is periodic light-dark rhythms with period length between 23 and 25 hours, which 
constrain the sleep-wake cycle rhythms in a period length that is not physiological. Indeed, 
when subjects are kept in constant dark condition, their sleep-wake behaviour free-run, 
revealing the masking effects of light [85].  
1.1.4 The chronotype  
People vary in their diurnal preference for the timing of activity and sleep and this 
preference is paralleled in their physiology. The human phase of entrainment is called the 
"chronotype" (Fig. 2) and is largely regulated by the circadian clock. Several 
questionnaires were developed to assess the human chronotype. The most used 
questionnaires are the Horne-Östberg rating questionnaire [86] and the Munich 
Chronotype Questionnaire [87].These questionnaires score the subjects in morning, 
normal or late types on the basis of information about sleep-wake behaviour and 
propensities during working or free days. In morning types, wake time, the temperature 
nadir, and the plasma melatonin rhythm occur at earlier clock times than in evening types 
[88-89] (see chapter 1.4 for further details about melatonin). These aspects are consistent 
also when the subjects are in conditions without time cues and in absence of sleep.  
Chronotype correlates with circadian period length: circadian period of subjects with 
different chronotype was correlated with chronotype such as that early types show a 
shorter period length than evening types [90]. The same finding was found analysing the 
period length of fibroblast circadian rhythms [91]. Moreover, fibroblasts harvested from 
early and late types with the same period length show significant changes in other 
circadian parameters such as amplitude and phase shifting properties, suggesting that 
human chronotype may be influenced also by amplitude and phase of circadian 
components, as well as by the period length [91]. 
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Fig. 2. Chronotype. Upper panel: schematic representation of 12 days of human sleep-wake cycle in three 
different types of chronotypes (early types in orange, normal types in green, late types in blue); bars represent 
hypothetical 8 hours of sleep. Lower panel: gene expression behaviour from the three different chronotypes. (A) 
In entrained condition (left), such as in real life, early chronotype (like larks), have an earlier phase of sleep 
compared to normal chronotypes, or late chronotypes (like owls). Without time cues (right), in free running 
condition, the period of the three “birds” is different: larks show a period shorter than 24 hours, normal 
chronotypes have a period of about 24 hours, while owls possess a period longer than 24 hours. (B) As well as 
human behaviour, gene expression in the different chronotypes has the same trend: in entrained conditions (left) 
the early chronotypes have an earlier phase of expression compared to normal or late chronotypes, while in free 
running conditions (right) larks have a shorter period than normal chronotypes or late chronotypes. (Adapted 
from [92]). 
1.1.5 Circadian rhythm sleep disorders  
Since the human sleep-wake cycle is generated through interactions of circadian 
rhythmicity, sleep homeostasis, entrainment properties, as well as feedback from the 
sleep-wake cycle onto these processes, the alterations in these processes and their 
interactions may lead to sleep and wakefulness occurring at abnormal clock times (altered 
external timing) and/or out of phase with endogenous circadian rhythms (altered internal 
timing).  
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The so-called "circadian rhythm sleep disorders" can result from alterations in the 
properties of the endogenous circadian clock (e.g., delayed sleep phase and advanced 
sleep phase) or changes in the physical environment in relation to the endogenous clock 
(shift work disorders and jet lag). When internal (circadian clock) and external time are not 
aligned circadian pathologies can occur. 
1.1.5.1 Delayed sleep phase disorder  
Althought their sleep architecture is normal, subjects affected by delayed sleep phase 
disorders (DSPD) have a the sleep schedule, nadir of the core body temperature (CBT) 
rhythm and dim light melatonin onset delayed by 3 to 6 hours compared to a normal sleep 
schedule [93-98]. The chronotype of these subjects is “evening” types [99-100]. The 
prevalence of this pathology is around 0.17% in the population [98], with a higher 
incidence in adolescents and young adults [98], even if it increases till 5-10% considering 
chronic insomnia patients [93]. 
There are some evidences that the etiology of DSPD has genetic causes: some 
polymorphisms in clock genes have been shown to be more or less associated to DSPS, 
such as Per3 polymorphism containing 4- or 5-repeat sequences of potential CK1ε 
phosphorylation, or Clock polymorphisms [101-104]. Other causes of this pathology may 
be an unusually long endogenous circadian period [105-106] or alteration in the 
entrainment mechanisms of the circadian clock to synchronizing agents such as light that 
may lead to a higher suppression of nocturnal melatonin [107]. Other possible explanation 
for the causes of DSPD are an advanced portion of the phase response curve (PRC) to 
light abnormally small [108] or a lack of exposure to light in the phase advance region (due 
to sleeping later in the morning) [97]. 
1.1.5.2 Advanced sleep phase disorder  
On the contrary of the DSPD, subjects affected by advanced sleep phase disorders 
(ASPD) present a sleep schedule and circadian parameters advanced by several hours 
compared to a normal subject. The chronotype of these subjects is “morning” types. The 
analyses of the polysomniogram shows decreased sleep latency, decreased total sleep 
time, and moderately short rapid eye movement (REM) sleep latency [109]. 
ASPD is often associated with aging [110] and may be caused by changes in the ability to 
phase delay as a result of a dominant phase advance region of the PRC to light or 
decreased exposure or weakened response to entraining agents, such as light and 
physical activity [111]. The prevalence of non-age-related ASPD is believed to be rare 
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[112]. In the reported cases of familial ASPD the disease segregates with an autosomal 
dominant mode of inheritance [113] indicating a genetic influence on the etiology of the 
pathology. In a family the source of the circadian change has been mapped to a change 
from serine to glycine at residue 662 of the Per2 gene. This mutation leads to a reduction 
kinase activity of CK1ε [114], resulting in a shortening of period length of circadian rhythm 
[115]. In another family, a mutation in CKIδ gene was reported [116].  
1.1.5.3 Free-running disorder  
Free-running disorders occur when the entrainment with the external environment is not 
effective: this is the case of most of blind individual lacking the photopigments contained in 
rods, cones and retina ganglion cells [117], whereas in sighted individuals this pathology is 
less common and has in some cases arisen following head injury [118], or after a scorrect 
chronotherapy to treat DSPD [94, 119]. Free-running disorders are then characterized by 
periods of good sleep (i.e., long duration sleep, no daytime napping) during the days in 
which the non-entrained circadian pacemaker is in phase with conventional sleep and 
wake times and periods of poor sleep (i.e., short duration sleep with daytime naps) that 
occur when the internal circadiadian rhythms is misaligned compared to the external 
environment. In subjects affected by free-running disorders napping has been shown to be 
good indicator of a desynchronised circadian system: napping increases during an 
abnormal circadian phase and decreases during a normal circadian phase. Measurement 
of circadian rhythm markers, such as dim light melatonin onset or the CBT minimum at 
regular intervals may be used to confirm the diagnosis by demonstrating a drift in circadian 
rhythms other than sleep [120]. 
Other potential causes of free-running disorder include decreased sensitivity of the 
circadian clock to light, or an alteration in entrainment pathways that result in weakened or 
lack of entrainment of endogenous circadian rhythm [121]. 
1.1.5.4 Irregular sleep-wake rhythm  
Irregular sleep-wake rhythm (ISWR) is a rare circadian disease characterized by a very 
poorly consolidation of sleep that leads to several sleep episodes every night [122]. 
Causes of this pathology may be a poor sleep hygiene, a voluntary irregular sleep 
schedule, a reduced exposure to external zeitgebers, such as light and activity, that is 
often seen in institutionalized care, or when irregular sleep-wake rhythms is a comorbidity 
to other major pathologies, such as dementia, mental retardation in children and brain 
injury [123-124].  
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1.1.5.5 Shift work sleep disorder 
Shift work is another phenomenon that causes misalignment between internal and external 
time. The impact of shift work on sleep and daily functioning varies and not all shift 
workers have difficulties [125]. There are several factors, both internal and external, that 
can influence the ability to cope with shift work including age [126], domestic 
responsibilities [127], commute times, diurnal preference, type of work schedule, and other 
sleep disorders (e.g., sleep apnea, narcolepsy). Working on atypical shifts has important 
socioeconomic effects, since an estimated 20% of the workforce in many industrialized 
countries is employed in a job that requires shift work and it leads to an increased risk of 
accidents [128-131]. Shift work has been associated with a number of health problems 
including peptic ulcer disease, coronary heart disease, metabolic syndrome, certain 
cancers, undesirable pregnancy outcomes as well as increasing or aggravating of an 
existing medical condition [132-133]. Night shift work is also associated with an increased 
perception of mental and physical fatigue [134].  
1.1.5.6 Jet lag 
One of the most obvious manifestations of the misadjustment of circadian phase is due to 
travel through time zones. Flight dysrhythmia, more commonly known as jet lag, comprises 
a constellation of symptoms consisting of daytime fatigue, impaired alertness, nighttime 
insomnia, loss of appetite, depressed mood, poor psychomotor coordination and reduced 
cognitive skills [135]. The severity of jet lag symptoms is affected by both the number of 
time zones crossed and the direction of travel. Eastward travel tends to cause difficulty in 
falling asleep while westward travel usually interferes with sleep maintenance [136]. Not all 
travelers crossing time zones suffer from jet lag to the same degree. These differences 
probably result from individual variation, similar to those reported for adaptation to shift 
work. 
The severity of jet lag symptoms has also been found to be greater in older individuals, 
inasmuch as proneness to illness and physical stress generally tend to increase with age 
[137-138]. A subtype of the jet lag is the “social jet lag”. Social jet lag occurs when social 
schedule modifies considerably individual sleep preferences [139]. The disruptive effect of 
jet lag has been documented at the molecular level of clock genes in the SCN [140] as 
well as in clock genes present in peripheral tissues [141]. Experiments indicate that 
endogenous circadian rhythms are lost and grafted tumors develop more rapidly in mice 
subjected to such chronic jet lag schedules [142]. 
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1.1.5.7 Seasonal affective disorder (SAD) 
SAD (winter depression), is a syndrome characterized by recurrent depressions that occur 
at the same period every year [143]. Depressive phases are associated with hypersomnia, 
overeating, and carbohydrate craving. Abnormalities in circadian rhythms in SAD include 
sleep disturbances [143] and alteration of many circadian rhythm markers secretion [144-
148].  
1.1.5.8 Circadian disorders in depression 
One striking feature of circadian rhythm sleep disorders is that they are often associated 
with other mood disorders. Indeed, a part of this association is by definition: an established 
clinical symptom of diseases like major depressive disorder (MDD) and bipolar disorder 
(BD) is abnormal sleep/wake, appetite, and social rhythms [149-150] which are also 
hallmarks of circadian rhythm disorders. Nevertheless, an increasing body of evidence 
suggests that there exists an interesting genetic basis for this correlation. Several 
circadian markers show abnormalities in depression [151-155]. One hypothesis of the 
involvement of circadian rhythm disturbances and development of depression is that, 
perhaps, depression may involve a weaker coupling process between internal pacemakers 
and involve abnormal sensitivity to environmental cues such as light [153]. This could be a 
result of mutant clock genes or allelic variations, leading to abnormal clock cycles or 
altered photosensitivity. In BD, a single nucleotide polymorphism in the 3' flanking region 
of the Clock gene associates with a higher recurrence rate of bipolar episodes [156]. This 
mutation is specific to bipolar depression: a similar association is not found in MDD (or 
unipolar depression) [157]. Another mutation, this time linked to the onset of illness in BD, 
has been localized to the glycogen synthase kinase 3β promoter [158]. This enzyme is the 
target of lithium, a common treatment for BD, and can phosphorylate the clock component 
REV ERBα [159].  
1.1.5.9 Treatments  
Prolonged disruption of circadian rhythms, or misalignment compared to the external 
environment, is believed to have significant adverse health consequences (i. e. 
development or exacerbation of cardiovascular disease and cancer [160-162]). 
Chronotherapy and other forms of manipulation of the zeitgeber or sleep were 
demonstrated to be very effective for the treatment of circadian disorders pathology, or 
circadian disorders associated pathologies. 
1. INTRODUCTION 
  17  
Chronotherapy is the progressive manipulation of sleep times to adjust it to a final normal 
bedtime schedule [93]. Another effective acute treatment for depressed and SAD patients 
is advancing the sleep and awake times on two occasions by 6 hours earlier than normal 
for a period of two weeks [163]. Sleep deprivation is also another effective treatment for 
unresponsive to antidepressant drugs depressed subjects. After one night of sleep 
deprivation many depressive symptomps are remitted [164].  
Bright light therapy is another effective treatment that involves the use of bright light in 
specific time window to reset the human circadian clock and increase the entrainment of 
the subjects [165]. Exposure to bright light in the morning for 1 to 2 hours results in an 
advance of the phase of circadian rhythms, whereas evening light exposure causes phase 
delay. When SAD and depressed patients are exposed in the morning to bright light this 
elevates mood and stabilises circadian rhythm markers [147]. Although timed bright light 
appears to have potential utility, the timing, intensity and duration of treatment remain to 
be defined. 
To adjust the sleep-wake timing to a normal schedule it is possible to perform 
pharmacotherapy with hypnotics or with melatonin. Administration of the hormone 
melatonin at specific times of the day can also reset the circadian clock in humans [166]. 
Several studies have demonstrated the potential effectiveness of melatonin administered 
especially to DSPD [167-168] and free-running individuals [169] (for further details about 
melatonin functions see chapter 1.4).  
A strategy to block relapse in many patients includes therapeutic interventions combining 
sleep deprivation, sleep-wake cycle phase advance and light therapy.  
1.2 ORGANIZATION OF THE CIRCADIAN SYSTEM 
In complex organisms, like mammals, the circadian system is organised in a hierarchical 
manner: the master clock receives light information that elaborates and sends output 
signals to synchronize all the other peripheral oscillators. 
1.2.1 The master clock 
The SCN of the anterior hypothalamus (Fig. 3) is the site of a master circadian clock in 
mammalian brain [170] (see also 6.1 Appendix 1). Indeed, SCN lesioned animals are 
arrhythmic in entrained condition [171]. A seminal demonstration of the clock function of 
the SCN was made possible using the tau mutant hamster [172] (for further details see 
paragraph 1.2.3.1). The tau mutation shortens circadian period from about 24 hours in the 
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wild type to about 20 hours in homozygote mutant animals. Results from in vitro 
experiments with SCN slices have also shown that the tau mutation is expressed at the 
level of the circadian clock in the SCN [173]. Tau mutant hamsters thus were used in SCN 
transplantation studies to show that the period of the restored rhythm is determined by the 
genotype of the donor, not the host [174]. 
The record of spontanueos action potential from individual SCN neurons gave the first 
demonstration that the oscillatory machinery of the SCN is cell autonomous [175]. Indeed 
SCN dispersed neurons in the same culture express circadian rhythms of widely different 
phases and different period lengths despite functional synapses. The mean of the 
circadian period length was very similar to the mean of the period length of behavioral 
rhythms (studied in constant darkness) in the same strain of rat [175-176]. However, the 
standard deviation was higher in SCN cells compared to animal behaviour. A possible 
explanation of this difference is that the free-running period in vivo is determined by the 
mean period of clock cells in the SCN. The interactions among clock cells in the whole 
SCN serve to coordinate or synchronize individual circadian clocks to generate a common 
circadian output. A proposed oscillator network model shows that a completely 
synchronized network will oscillate at a frequency close to the sample mean of the 
frequencies of the population [177]. The oscillators near the centre of the distribution lock 
together in frequency, whereas the outlying oscillators continue to oscillate near their 
natural frequency. With further increases in the coupling, more of these outlying oscillators 
are pulled in, until eventually the whole system is synchronized. A hypothesis for the 
lacking of coupling in isolated cells is the eventual dilution of some diffusible substances 
necessary for coupling that occur in culture system. A biological advantage of a coupled 
multioscillator system is the flexibility that is provided in terms of entrainment of the 
circadian clock. This oscillator network model predicts that when a portion of the oscillators 
in the network are phase-shifted, the whole network will resynchronize to a new phase. 
Therefore, only a subpopulation of clock cells needs to respond to a specific entraining 
stimulus to generate a phase-shift in the whole network.  
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Fig. 3. Circadian rhythm hierarchy in mammals and humans. Environmental light is detected by the 
retina (1) that, through the retina-hypothalamic tract (2), sends signals to the master clock, the 
suprachiasmatic nucleus (SCN) of the hypothalamus. SCN elaborates these light information and 
synchronizes its circadian rhythm with the external light-dark rhythm. Moreover, through different stimuli (3), 
SCN synchronizes all the peripheral oscillators, virtually all cells of the body. 
The cellular heterogeneity of clock properties probably serves a definite function. Although 
the day length on our planet is fixed to 24 hours, the period of light during this time can 
vary dramatically in lateral clines. To cope with these differences, the circadian clock is 
able to track both light onset (dawn) and light offset (dusk). Because of cellular differences 
in the SCN, some of its cellular clocks are phased earlier, thereby “track” dawn, while 
others are phased later to track dusk – a hypothesis formed long before the existence of 
cellular clocks was discovered [178] and recently confirmed in rodent SCN neural activity 
studies [179] and luciferase imaging experiments [180]. To keep SCN cells locally 
synchronized, neurochemical coupling mechanisms are used [181-182] and probably gap 
junctions as well [183]. Elimination of these components in mice results in dramatically 
dampened circadian oscillations. 
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1.2.1.1 Coupling mechanisms 
Although the precise nature of the coupling interaction among SCN neurons is not yet 
known, one reasonable neurochemical candidate for such coupling activity is γ-
aminobutyric acid (GABA). It is known that most SCN neurons are interneurons and they 
interact with each other within the SCN. Virtually all SCN neurons are GABAergic and 
respond to GABA [184-186]. The recent discovery that GABA differentially affects SCN 
neuronal firing, depending on the time of day of application, supports the synchronizing 
potential of GABA [187]. Moreover, GABA analogs phase shift the circadian clock both in 
vivo and in vitro [188-189]. It is also possible that diffusible substances other than GABA, 
such as nitric oxide (NO) or even neuropeptides, or a combination of these factors, serve 
as coupling factors among SCN neurons. Glia, through an insulating and/or a biochemical 
interaction, may also affect coupling among clock cells [190].  
The SCN responds to timing signals received from afferent pathways and drives overt 
circadian rhythms through its efferent connections [191-193]. The SCN consists of neurons 
that synthesize a variety of neuropeptides, including vasoactive intestinal peptide (VIP), 
arginine vasopressin (AVP), somatostatin (SS), and these molecules appear to play 
multiple roles in circadian timekeeping [194-195]. AVP and SS have been shown to 
modulate the function of the SCN. AVP neurons provide endogenous excitatory tone to the 
SCN [196], whereas SS administration inhibits SCN neuronal firing in vitro [197]. SS 
neurons are also involved in regulating the phase of circadian rhythms. Depletion of SS 
induces phase advances in locomotor activity rhythms and SCN electrical activity rhythms 
and permits rhythmic release of VIP from the SCN in vitro [198-199]. The demonstration 
that VIP neurons receive synaptic inputs from the retinohypothalamic tract, the 
geniculohypothalamic tract and the serotonergic projection from the median raphe nucleus 
suggests that the VIP neurons are involved in entrainment of the circadian pacemaker 
[200-202]. This concept is supported by finding that VIP microinjections in the SCN region 
induce phase-dependent phase shifts in locomotor activity rhythms [203-205]. 
1.2.1.2 Anatomy of the SCN 
The SCN can be divided into two regions, a core and a shell, which have different 
properties [206-207]. Cells of the core receive light information via the retina-hypotalamic 
tract (RHT) [208] whereas cells of the shell show intrinsic rhythmicity but are only little 
innervated from the retina via the RHT [209]. When the majority of core cells is ablated, 
circadian rhythmicity is lost. SCN core cells seem to gate photic input depending on their 
1. INTRODUCTION 
  21  
internal phase, thus leading to differential phase shifts of rhythmic cells of the SCN shell 
[210].  
1.2.1.3 Input signals of the SCN 
The different responsiveness of the SCN is enabled by a daytime and a nighttime domain 
[211] at which only certain substrates efficiently adjust clock phase [211]. In the early night, 
sensitivity to light is mediated by glutamate and elevation of intracellular calcium levels 
[212], correlating with the timing of phase delays [213-214]. Responsiveness of the SCN to 
pituitary adenylate cyclase-activating peptide (PACAP) might modulate nocturnal 
responses both to light and to glutamate [215]. In the late night, glutamate induces phase 
advances by a cyclic guanosine monophosphate (cGMP) mediated pathway [213, 216]. 
During dawn and dusk, the SCN shows responsiveness to melatonin [217], a hormon 
produced during night mainly in the pineal gland [218]. (See in the next chapters for SCN 
responsiveness to melatonin). 
1.2.1.4 Output signals of the SCN 
The SCN “master clock” is entrained by light and it in turn entrains “slave” oscillators 
located in several brain areas and the periphery via a myriad of redundant cues. One 
important class are direct nervous signals. The neurons of the SCN demonstrate 
spontaneous firing patterns in daily fashion and project to many other brain nuclei, where 
they are presumed to be important for sleep-wake cycles and cognitive function. Many 
hypothalamic nuclei receive SCN projections and mediate the circadian control of multiple 
systemic cues. For example, both direct and indirect projections from the SCN make 
synaptic contact with corticotropin-releasing hormone (CRH) neurons of the 
paraventricular nucleus (PVN). These neurons in turn impose rhythmic adrenocorticotropic 
hormone (ACTH) release from the pituitary and subsequent circadian corticosterone 
secretion from the adrenal glands [219]. The sleep/arousal, reproductive, and endocrine 
systems are also regulated by the SCN in part through neuroanatomic connections. 
Hormonal signals are capable of entraining peripheral oscillators, as glucocorticoids 
agonists can effectively shift peripheral clock gene expression in mice [220]. The precise 
role of other cyclically secreted hormones such as growth hormone (GH) and prolactin 
(PRL) in peripheral phase entrainment is yet to be examined. In addition, it has been 
demonstrated the existence of SCN connections to all major organs via both sympathetic 
and parasympathetic pathways, which implies a critical role of the autonomous nervous 
system in synchronizing peripheral physiology [219]. The SCN reaches the autonomic 
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neurons of the PVN that project to the intermediolateral column of the spinal cord, where 
preganglionic sympathetic neurons are located [221].  
Paradoxically, the first line of communication from the SCN to centers controlling 
locomotor activity is probably hormonal: animal experiments show that implantation of 
SCN neurons encapsulated in porous plastic are still capable of rescuing rhythmicity in 
SCN-lesioned animals [222].  
A second class of signals is indirect products of the regulation of other brain centers by the 
SCN. Body temperature is one important class: even though daily body temperature varies 
by only 1-4°C in mammals, these faint daily fluctua tions – probably controlled by SCN 
enervation of the preoptic anterior hypothalamus and by daily activity patterns – are 
sufficient to entrain peripheral tissues [223]. Similarly, daily patterns of feeding are likely 
cues for the entrainment of peripheral clocks in tissues throughout the body [224-225], as 
well as a separate “food-entrainable” brain oscillator that can control locomotor activity in 
the absence of the known circadian clock [226-227]. In animals, alterations of either of 
these classes of signals effectively “decouples” the central clock from oscillators in other 
tissues: either reversal of daily body temperature rhythms or of daily feeding rhythms can 
inverse the timing of local clocks in peripheral organs such as liver, kidney, heart, and 
pancreas, leaving SCN rhythms unaffected [224]. It was then hypothesized that, besides 
the light entrainable circadian clock, another clock exists which can be entrained by food, 
the food entrainable oscillator (FEO) [228]. Brain-regulated corticosterone rhythms 
probably serve as a stabilizing influence: in animals lacking the glucocorticoid receptor in 
the liver, hepatic clocks are much more rapidly shifted by alterations in daily feeding 
patterns [229]. Hormones and metabolites related to feeding, such as insulin and glucose, 
are likely involved in the phase setting of peripheral clocks [230].  
Activity rhythms as well as circadian outputs from other tissues can feed back on the SCN 
and on other peripheral oscillators. For example, melatonin released from the pineal gland, 
which is itself under SCN control through autonomic pathways, functions as a circadian 
input signal for both the SCN and the anterior pituitary [231].  
1.2.2 Peripheral oscillators 
When the first core genetic components of the mammalian circadian clock was identified, it 
was discovered that these “clock genes” are expressed rhythmically outside the SCN [232] 
and even outside the brain [233] in many peripheral tissues [234] (see also 6.1 Appendix 
1). The use of a transgenic Drosophila that expresses either luciferase or green 
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fluorescent protein driven from the promoter of the clock gene period permitted to follow in 
real-time the oscillation of circadian rhythm in peripheral tissues such as head, thorax, and 
abdominal tissues [235-237]. These rhythms are entrainable by light and free-run in 
constant darkness [235]. From dissociated cells of different body segments (head, thorax, 
or abdomen) rhythmic bioluminescence was obtained, demonstrating that autonomous 
circadian oscillators are present throughout the body of a fly. 
Presence of circadian rhythm in several peripheral tissues has been widely demonstrated 
also in mammals. The mRNA expression of main clock genes (mBmal1, mNpas2, mRev-
erbα, mDbp, mRev-erbβ, mPer3, mPer1 and mPer2) have been examined in cells 
obtained from different peripheral systems (heart, lung, liver, stomach, spleen, kidney, and 
testis) [238]. Circadian mRNA expression patterns were similar in each tissue with the 
exception of testis, where weak or no rhythm was observed. In the peripheral tissues 
mRNA peaks occurred approximately 4 hours later than those in the central pacemaker, 
SCN [24, 233, 239-242].  
Real-time clock gene expression of peripheral tissues can be obtained through explants of 
peripheral tissues from transgenic mPer1::luc rats [243] and in transfected fibroblasts [244-
245]. Rhythmic clock gene expression can even be found also in immortalized mammalian 
cell lines like Rat-1 fibroblasts [246]. Unlike the SCN explants, the peripheral cells or tissue 
rhythms tend to damp out within a few cycles until restarted by serum shock or medium 
change. 
The difference in damping between SCN and other tissues appears to be quantitative 
rather than qualitative. However through single cell resolution, detecting bioluminescence 
of Rat-1 fibroblasts acutely transfected with an mBmal1::luc plasmid and primary 
fibroblasts dissociated from mPer2-Luciferase-SV40 (mPer2::Luc-SV40) knockin mice 
[247] permitted the observation that damping is explained by loss of synchrony among 
cells rather than damping of individual cell rhythms.  
1.2.3 Circadian parameters 
It is possible to determine the genetic linkage between human behavioural disorders and 
the circadian oscillator by measuring the properties of the human circadian clocks that 
determine behaviour. Parameters that can be measured are free-running period, or the 
length of one oscillation under constant environmental conditions and phase 
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response/entrainment, the ability of the clock to alter its phase in response to external 
stimuli and the amplitude of the rhythm, that is the force of the oscillations (Fig. 4). 
Fig. 4. Parameters of an hypothetical 
rhythm. Given a variation of an element “χ” 
in units of time “t”, several parameters of a 
rhythm can be measured, such as 
amplitude (A, in violet, defined as the 
maximum absolute value of a periodically 
varying quantity), period length (τ, in green, 
the time spent between two peaks) and 
phase (φ, in red, that represents the 
position of a peak compared to the time 
unit). 
1.2.3.1 Period length 
One of the first connection that have been made between the behaviour of a living being 
and the behaviour of single cells comes from the analyses of tau mutant Syrian hamsters. 
Tau is a missense mutation within the substrate recognition site of CKIε (CKIεtau) . CKIε 
and the closely related CKIδ are widely expressed serine-threonine kinases implicated in 
development, circadian rhythms and DNA metabolism. In CKIεtau the enzyme has a much 
reduced overall catalytic activity. The period length of the free-running behaviour is 
different from wild-type (+/+), heterozygous (tau/+), and homozygous (tau/tau) tau mutant 
Syrian hamsters. The mean periods of wild-type, heterozygous, and homozygous clock 
cells (electrical activity of single SCN neurons) correlated nicely with the respective 
circadian periods in behaviour (wheel running behaviour) in the whole animal [177]. 
Similarly, a strong correlation has been found between in vivo free-running behaviour from 
different mouse strains and period length of primary adult dermal fibroblasts of mouse tail. 
Mouse fibroblasts were infected with Bmal1::luc reporter gene. The period length of 
fibroblast was determined by the measurement of the bioluminescence emitted by the cells 
[248]. The advantage of this finding is that the central clock of the SCN that specifies 
behaviour is quite difficult to access at a molecular level whereas the sampling of 
peripheral cells, that appear to use many of the same components as the SCN, is more 
feasible also in human. Hence, a major breakthrough for mammalian circadian biologists 
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has been the ability to use peripheral oscillators as proxies—albeit imperfect ones—for the 
clocks of the SCN. 
1.2.3.2 Phase  
The phase of entrainment is the position of a parameter compare to the internal time. In 
human studies there are several parameters that can be chosen to determine the phase of 
entrainment. These parameters include temperature (the moment of minimum of the CBT), 
melatonin onset and melatonin offset. In cell lines the phase of entrainment can be 
determined by the analyses of the position of the peak of a circadian marker, such as per 
or bmal-1. It can also be determined in real-time using the luciferase reporter gene under a 
clock gene promoter. As for a circle the degrees of phase can be 360, with the convention 
that 0° is the phase of the fitted peak of the lumi nescence rhythm. Commercial fibroblast 
lines have the same phase behaviour respect to primary fibroblast. After synchronization 
of circadian rhythm the phases of individual fibroblasts are clustered. Losing of phase 
determines the damping of the circadian rhythm of peripheral oscillators. Indeed, after few 
days of bioluminescence recording the cells lose synchronization and the phase is 
randomly distributed [247]. 
1.2.3.3 Amplitude 
Amplitude is the magnitude of change in an oscillating variable, with each oscillation, 
within an oscillating system. In human the amplitude can be defined for parameters such 
as melatonin and CBT. In cells parameters are gene expressions or protein oscillation. 
1.2.3.4 PRC 
Entraining signals advance or delay circadian rhythms according to the time they are 
experienced. The direction and magnitude of the change in timing (phase shift) is 
described by a PRC. The time base of a PRC is ‘circadian time’ (CT) which is effectively 
internal biological time usually defined in humans by the timing of the CBT rhythm or 
melatonin secretion. To entrain to the daily light/dark cycle, the circadian oscillator 
responds differently to light at different phases of its cycle. This differential effect is most 
easily visualized as a PRC, which plots phase shifts of a circadian rhythm as a function of 
the circadian phase that a stimulus is given. In biological oscillators, the "dead zone" 
(phase 12 and 24) is usually much larger and can span over several hours. PRCs are 
determined experimentally by first keeping the organisms of investigation (e.g. mouse) 
under constant condition, e.g. complete darkness (DD). Different organisms receive then a 
pulse of a stimulus with a certain duration and intensity at regular intervals within 24 hours. 
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The phase shift of the circadian marker, e. g. the onset of activity, is measured for every 
group of organisms and can be plotted as a PCR.  
In human beings, the measurement of either the phase response is very expensive and 
labor-intensive because it demands extensive subject observation under controlled 
laboratory conditions. However the same phase response experiment can be conducted 
with cells. Cells are synchronized and after one cycle independent cell cultures are 
exposed to a phase-shifting agent at regular intervals within 24 hours. The plot of PRC is 
obtained analysing the position of the peak obtained treating cells at a certain time with the 
peak obtained without shifting-agent. 
1.2.4 In vivo human studies  
Several protocols were developed to reveal the endogenous circadian component of 
human rhythms. The major issue in the study of human circadian rhythms is the masking 
effect that are caused by light, temperature (environmental and CBT), body position, food 
intake, several hormones (i. e. cortisol) and many other factors. In the protocols developed 
to study human circadian rhythms all factors that may contribute to masking of circadian 
rhythms are controlled. 
In these protocols one or more circadian markers are measured to investigate circadian 
rhythms. The analyses of the circadian rhythms of these markers can give hints about 
circadian parameters, such as amplitude, phase and period length. Melatonin, cortisol and 
CBT are the best circadian markers that used to investigate human circadian rhythms.  
1.2.4.1 Circadian markers  
CBT (Fig. 5) is a parameter that is very easy to measure and for this reason is one of the 
frequentely used to analyse human circadian rhythms. Its measurements can be done in 
continuous without much disturbances for the subjects through a rectal probe and data can 
be analysed in real-time. However, many factors contribute to mask the CBT. These 
factors include: behaviors such as postural changes, physical activity and meals, and also 
external conditions, such as ambient temperature, sound, humidity, and bright light [249-
250]. Age is another factor that influences CBT: CBT nadir is earlier in elderly people 
compared to young people [251]. 
Cortisol: among the hormones that show a strong circadian rhythms melatonin and plasma 
cortisol are most frequentely used to investigate circadian rhythms. Within the cortisol 
rhythms the nadir (acrophase), onset of the evening rise and the start or end of quiescent 
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period are the mainly analysed cortisol parameters [252-253]. However, many factors are 
known to mask cortisol rhythms such as: physical and psychological stress, light, ageing, 
sleep onset and deep sleep and highly proteic meals [250]. 
Melatonin (Fig. 5) is another hormone whose cycles can be used to study human circadian 
rhythms. Melatonin levels can be measured in several biological fluids: in blood and saliva 
melatonin levels are proportional. Alternatively, the melatonin metabolite 6-
sulfatoxymelatonin can be easily detected in the urine of subjects [254], which strongly 
correlates with the plasma and serum melatonin levels [255]. The dim-light melatonin 
onset (DLMO) is considered to be one of the most reliable markers, as it is thought to be 
minimally masked by exogenous factors. Melatonin can be masked by posture, exercise, 
sleep and sleep deprivation, caffeine, and certain drugs, for instance, nonsteroidal anti-
inflammatory drugs (NSAIDs) and beta blockers [256-258]. However, these factors are 
easy to control in human studies (for further details about melatonin, see chapter 1.4). 
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Fig. 5. Circadian 
expression of circa-
dian markers in en-
trained (on the left, 
habitual sleep/wake 
cycle) and free run-
ning condition (on the 
right, constant routine) 
of 6 subjects. Triangles 
represent the mean of 
circadian phase for each 
marker. Grey bars 
represent the sleeping 
episodes; light grey bars 
represent habitual sleep 
periods. Bars represent 
SEM. (A) Core body 
temperature (CBT). (B) 
Plasma melatonin 
(MLT). (C-E) Respec-
tively, gene ex-pression 
levels of human Per1 
(HPER1), human Per2 
(HPER2) and human 
Bmal1 (HBMAL1) in 
peripheral blood mono-
nuclear cells. (From 
[259]). 
 
1.2.4.2 In vivo protocols 
Constant darkness and free-running protocol: Many of the early data on the human 
circadian system were collected on subjects studied in isolated environments free of time 
cues. Under these conditions, the subject's circadian pacemaker was believed to oscillate 
at its intrinsic period of ~25 h. The condition of an ambient that lacks time cues and other 
environmental agents that may affect the period of the oscillation is called free-running. 
Until recently the free-run protocol has been the "gold standard" for assessing the intrinsic 
properties of the circadian system. It is now appreciated that light, even at the level of 
ordinary room lighting, can shift the circadian pacemaker and that the period estimated 
under free-run conditions is not the intrinsic period of the human circadian pacemaker 
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[260]. This is because the human circadian pacemaker, like those of lower animals, has a 
well-defined phase response curve (PRC) to light [165]. Under free-run conditions, a 
subject self-selects his/her light-dark cycle and, hence, the phase at which the light is self-
administered. Because of the asymmetric structure of the human PRC, this self-selection 
results more frequently in light administered during phases that favor delays of the human 
pacemaker, rather than advances, and therefore in an observed period that is longer than 
the pacemaker's intrinsic period. Alternatively, circadian period can be measured under 
constant dim light for several days without time cues [261]. In this way the shifting effects 
of light are reduced. A circadian parameter is measured at specific days for 24 hours and 
the period length is measured by interpolating the peaks of the circadian parameter. 
A further special case employs totally blind individuals, whose circadian pacemaker cannot 
be entrained by the environmental light-dark cycle and who can therefore be measured 
during daily life because it free runs [79]. 
Constant routine: the constant-routine protocol controls environmental conditions and a 
subject's level of activity to identify accurately the circadian component of an observed 
biological rhythm [262]. This protocol was developed as an alternative to longer free-run 
studies, as a mean of assessing the properties of an individual's circadian system in a 
shorter study interval. The protocol calls for subjects to remain continuously awake for 30-
60 hours in a semirecumbent posture exposed to constant indoor light (~150 lux) and to 
consume their daily caloric intake in evenly divided snacks at approximate hourly intervals 
[263]. Physiological and behavioral circadian variables are recorded and the properties of 
the circadian pacemaker are studied by characterizing the phases and amplitudes of these 
marker rhythms such as core temperature, plasma melatonin levels, and plasma cortisol 
levels [165]. The pacemaker period cannot be determined, because, at best, only 1.5-2.5 
cycles of the oscillation are observed on this protocol [264-265]. An advantage of this 
protocol is that it minimizes the effects of environmental conditions and level of activity on 
a subject's observed circadian rhythm. 
One major issue in the use of this protocol is that during all this protocol sleep pressure 
increases. To minimize the masking effects of sleep homeostasis a modification to the 
costant routine protocol was developed. In this protocol, called “multiple nap protocol”, 
alternating sleep-wake cycles of 75:150 minutes duration are scheduled for a total duration 
of the protocol of more than 60 hours. In this protocol the waking time are performed in 
constant dim light levels, semi-recumbent posture in bed, food and liquid intake at regular 
intervals, no access to time cues, whereas during the scheduled sleep episodes a supine 
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posture is allowed and the lights were turned off (0 lux) [266]. Virtually with this protocol it 
is possible to unmask circadian rhythms from the homeostatic modulation: indeed 
sleepiness exhibits a prominent circadian regulation [267]. 
Forced desynchrony: under ‘forced desynchrony’ conditions the sleep-wake cycle is 
scheduled to day-lengths that are outside the range of entrainment for the circadian 
pacemaker (longer than 27 hours or shorter than 21 hours) [260]. During two-thirds of the 
light-dark cycle, the lights are maintained continuously switched on at a fixed intensity (i. e. 
20 lux or lower), whereas during the remaining one-third of the cycle, the subject is 
maintained in total darkness.The behavior of the clock is monitored by recording marker 
rhythms such as CBT, plasma cortisol, and plasma melatonin levels [260]. Because the 
light levels during forced desynchrony are low and because the clock cannot synchronize 
to a light-dark cycle whose period is outside the range of entrainment, the circadian 
pacemaker oscillates at its intrinsic period.  
1.2.5 Cell culture and ex-vivo studies 
In vivo human studies are very expensive and labor intensive. Moreover the techniques to 
measure circadian markes are often invasive, decreasing the compliacy of subjects to 
these protocols. Taking advantage of the presence of the clock circadian machinery in 
virtually all cells of the body, it is possible to perform circadian studies in cell cultures. The 
use of cells isolated from an animal or human tissue permitted the development and the 
validation of ex-vivo protocols. 
Many studies of circadian-regulated gene expression require the accurate and long-term 
monitoring measurement of transcriptional responses to intra- and extracellular signals. 
Classical methods needing the destruction of tissue to measure steady-state RNA or 
reporter enzyme levels in vitro have significant limitations for temporal studies owing to 
noise and reproducibility [268]. Analysis of clock gene transcription is considerably more 
versatile in a real-time reporter system established for clock genes. The first reporter 
system that has been developed in Drosophila involved the measurement of per mRNA 
levels for reporter genes such as lacZ [269-270]; however β-galactosidase activity does 
not cycle when the per promoter is fused directly to lacZ [269]. This is most likely due to 
the approximately 1 day half-life of the enzyme in the fly [271]. 
A second reporter gene assay developed to study circadian rhythms involves the 
enzymatic reaction of luciferase [235, 272-274]. Luciferase-mediated bioluminescence is 
proving to be a convenient and powerful reporter in organisms ranging from microbes to 
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mammals [268]. Firefly luciferase has been the most common choice for the analysis of 
promoter function in eukaryotic systems [275-276]. The firefly enzyme catalyzes the 
oxidative decarboxylation of beetle luciferin using oxigene and magnesium ± adenosine-5'-
triphosphate (ATP) as substrates. A photon is released at 560 nm in 90% of catalytic 
cycles: this light emission can be quantified with high sensitivity, most commonly in a 
luminometer. In mammalian cell cultures, the half-life of luciferase is approximately 3 hours 
[277-278].  
A significant application of luciferase reporter has come from its use as real-time marker to 
detect real-time emission of bioluminescence of circadian rhythms and was first used in 
experiments aiming at identifying novel rhythm mutants [273, 279]. 
Luminescence imaging is also well suited to analyse gene expression of a transgenic 
mouse in vivo through whole-animal imaging [280].  
Single-cell bioluminescence imaging has also been achieved in mammalian systems and 
has revealed important new insights about the cellular construction of the master circadian 
clock in the brain. Through the single-cell resolution and long-term monitoring of 
bioluminescence rhythms of SCN brain slices cultured from an mPer1::luc transgenic 
mouse it was possible to observe a stable pattern of phase differences among cells: in the 
SCN dorsal cells tended to peak earlier than ventral cells. When dorsomedial or 
ventrolateral portions of the SCN were isolated from each other, cells in both portions 
remained rhythmic, but dorsomedial cells drifted out of synchrony while ventrolateral cells 
remained synchronized. This observation suggests a role for the ventrolateral SCN in 
maintaining coupling of cellular oscillators throughout the SCN [281]. Single-cell resolution 
of bioluminescence can be obtained also from peripheral mammalian oscillators. Circadian 
rhythm can be monitored through bioluminescence rhythms for 1–2 weeks in Rat-1 cells 
transfected with an mBmal1::luc reporter and in primary fibroblasts cultured from 
mPer2::Luc knockin mice. After few days the circadian rhythm damping is observed in 
peripheral oscillators. Single-cell analyses of bioluminescence allowed finding that the 
damping of the ensemble rhythm observed at the level of a cell population resulted from a 
gradual loss of synchrony among independent cellular oscillators and not from the 
damping of individual cellular rhythms. Thus, individual fibroblasts contain self-sustained 
circadian oscillators, like SCN neurons [247]. 
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1.2.6 Use of primary cells to study individual traits 
After the evidence of the presence of a canonical circadian oscillator in established tissue 
culture lines it has been noticed that these oscillators may not be totally unrelated to the 
mammalian central oscillator but instead they possess several characteristic in common to 
the master clock cells (Fig. 6). Peripheral cells are able to maintain a robust oscillations 
that in vivo occurs with 4 hr phase difference between cycling in the SCN and cycling in 
the periphery [240]. Cycling mRNA undergoes an oscillation in the fibroblasts comparable 
to its in vivo circadian cycle after treatment with a synchronizing agent (serum shock). 
There are evidences of a connection between light-induction in the SCN of a living being 
and serum-induction in culture. A phase-shifting light stimulus is known to stimulate the 
transcription of a set of genes so-called immediate-early genes (IEGs) within the SCN. The 
same genes that are rapidly induced by light in the SCN are also rapidly induced after the 
serum shock in tissue culture. Both SCN and peripheral oscillators have the ability to free-
run in the absence of environmental clues. And even if some damping turns out to be an 
intrinsic feature only of the tissue culture oscillators, the similarities between the two 
systems will almost certainly dwarf the differences. The ability to transfect peripheral 
oscillators such as fibroblasts with overexpression or dominant-negative constructs is 
another important tool that can be used to investigate particular aspects of circadian 
rhythm. In this way it has been possible to ensure that circadian genetic differences are 
reflected in the rhythms of fibroblast gene expression. Circadian rhythm of adult dermal 
fibroblasts was analysed from tail biopsies of mice with a different genome. Parallel to this 
analysis, circadian wheel running behaviour was measured for the same individuals. Mice 
with a period of wheel-running behavior shorter than wild-type yielded fibroblasts whose 
period of circadian Bmal1 expression was also shorter. Similarly, fibroblasts from mice with 
a period of wheel running that was longer than wild-type had correspondingly longer period 
lengths. Mice that were behaviorally arrhythmic produced arrhythmic fibroblasts [248].  
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Fig. 6. Circadian rhythm in 
different models. (A) Core 
body temperature in humans; 
grey bars represent habitual 
sleep period. (B) Locomotor 
activity in hamster. (C) 
Hamster suprachiasmatic 
nucleus neuronal firing rate. 
(D) Human skin fibroblasts 
rhythm from Bmal1::luc 
infected cells. (Adapted from 
[259], [177], [91]). 
 
Primary cells are a good model to study circadian aspects for many reasons. Some 
circadian characteristics, such as the period length (Fig. 7), remain unmodified even 
isolating in vitro the oscillators. However the measurement of the period length of the 
circadian rhythm of isolated cells or tissues is exaggerated compared to the period length 
of the all animal or the period length measured in SCN cells. One hypothesis of this 
phenomenon is the absence of coupling between peripheral oscillators [248, 282]. 
A big advantage in the use of peripheral oscillators is the possibility to manipulate the 
genome. It is possible in fact re-create the genetic mutation of a disease to investigate the 
molecular mechanisms that determine certain behaviour. Vanselow and colleagues 
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introduced a mutation in Per2, believed to be responsible for human familiar ASPD, into 
fibroblasts and were able to recapitulate the phase advance in the behavior of familiar 
ASPD patients as an advanced phase of clock-gene transcription in synchronized familiar 
ASPD fibroblasts. Subsequent molecular analyses allowed them to show effects of this 
mutation upon phosphorylation at multiple sites in the PER2 protein and to further 
demonstrate that these modifications affected both PER2 protein stability and nuclear 
localization [283].  
In vitro studies on isolated peripheral oscillators can be associated to in vivo studies to 
investigate a circadian question from more points of view. A prerequisite for peripheral 
oscillators to be a good model to study circadian rhythm is to be easy to sample. Blood 
cells and skin fibroblast have this characteristic. 
Fig. 7. Circadian rhythms analysed 
using a human in vivo (A) and in vitro 
(B) protocol. (A) Salivary melatonin 
content measured every 20 minutes in a 
constant routine. The following rhythmic 
parameters can be analysed: amplitude 
(A), period length (τ) and phase (φ). (B) 
Similarly, the same parameters can be 
analysed from the light emitted by 
synchronized Bmal1::luc human skin 
fibroblasts. 
 
 
 
1. INTRODUCTION 
  35  
1.2.6.1 Blood cells 
The hematopoietic and the immune systems in all their components are characterized by 
highly reproducible circadian rhythms in cell proliferation and cell function (circadian 
rhythmicity of cytokine production, leukocyte trafficking, proliferation, and apoptosis). 
Manipulating environmental parameters such as activity-rest, light-dark schedule and/or 
the time of food uptake can cause phase alterations in the circadian rhythms of 
hematologic cells. Characteristically these functions do not change their timing 
immediately after a shift in a time cue phase but adapt over several transient cycles [284]. 
The fact that nervous system has been shown to modulate the neuroendocrine system 
strongly suggests that circadian mechanisms modulate the immune response through 
signals ultimately regulated at the hypothalamic level. 
The existence of the molecular machinery of circadian rhythm in blood cells has been 
widely demonstrated. Presence of both negative (Per1 and Per2) and positive (Bmal1 and 
Clock) components of the molecular clock have been observed in natural killer (NK) cells 
in both light-entrained rats [285] and in rats maintained in constant darkness [286]. The 
characteristics of clock transcript oscillations in NK cells are similar to those seen in other 
peripheral tissues.  
Several evidences reveal that the expression of Per2 in peripheral blood mononuclear 
cells (PBMCs) is significantly different in the morning and the evening, with an expression 
peak around dark phase (zeitgeber time (ZT)14) in rat [287] and around 9:00 a.m. in 
humans [288]. Interestingly, mRNA levels of hclock do not exhibit daily variation [288]. 
Further constant routine studies revealed the presence of oscillation of clock genes in 
PBMCs in the absence of external cues [289]. The analyses of circadian gene expression 
in mononuclear (MNC) polymorphonuclear (PMN) cells showed the same acrophase of 
hper1 mRNA expression rhythm. PMNs exhibited an additional smaller peak in hper1 
expression in the subjective evening similar to that reported in human oral mucosa and 
skin cells [290], whereas this second peak was not observed in MNCs [291]. 
One advantage in blood cells as circadian tool comes from their versatile use, the 
feasibility of studying PBMCs as an accessible surrogate for the identification of rhythmic 
clock gene expression in humans and the possibility of performing genome modification. 
Activated human monocytes can be cultivated and infected with Bmal1::luc reporter gene, 
in order to detect real-time clock gene expression [248]. 
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The demonstration of functional circadian machinery in human blood cells and the 
possibility to perform a knock-in cell line suggests that peripheral blood cells may be useful 
for the investigation of human circadian rhythms and their associated disorders. 
1.2.6.2 Skin cells 
The identification of the molecular clock machinery in isolated skin cells has been widely 
demonstrated. Fibroblasts (Fig. 8) are one of the first peripheral cell lines where a cell-
autonomous and self-sustained circadian rhythm has been observed. The cultivation and 
genetic manipulation of fibroblast are easy to perform and these are some of the main 
reasons why fibroblasts are a good model of peripheral oscillator organs (see 6.1 
Appendix 1). 
Skin cells can be easily obtained from a 2-mm skin punch biopsy. At least two cell lines 
can be successfully isolated from skin biopsy: fibroblasts and keratinocytes. Also hair root 
keratinocytes cling to the end of a plucked human hair have been cultivated and used as a 
genetic tool for circadian studies. One of the main difficulties related to the sampling of hair 
root keratinocytes is that most plucked hairs do not contain keratinocytes and so scalp 
biopsy would be necessary to isolate hair root keratinocytes [248]. 
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Fig. 8. Protocol to study the circadian rhythms of human skin fibroblasts. Punch skin biopsy is 
harvested (1) and cultivated under sterile conditions. Fibroblasts that grow around the biopsy are isolated, 
amplified and infected with a circadian reporter (2) coding for firefly luciferase under a clock gene promoter, 
i.e. Bmal1. The infected cells are selected and then, after synchronization of circadian rhythms, the light 
emitted by the cells is measured in the Lumicycle (Actimetrics) or in a home-made device able to detect and 
measure bioluminescence (3). 
1.2.6.3 Signals to synchronize peripheral oscillators in vitro  
One of the main differences between SCN slices and other tissues is the damping 
tendency observed in peripheral oscillators: peripheral cells thus need to be re-
synchronized after few days in culture to be able to continue to detect a circadian 
rhythmicity. The rhythmic damping of peripheral oscillators is predominantly due to phase-
desynchronization of individually oscillating cells [247, 292]. To maintain a good rhythmicity 
(consistent amplitude) it is necessary to resynchronize individually oscillating, but 
asynchronous, cells. Treatments that increase the coherence of the oscillators reflect the 
coordination of a phase-shifting efficacy of the treatment. However, different treatments 
have different strength to activate/inhibit specific signalling pathways, that ultimately result 
in oscillations of “clockwork” genes of varying amplitude [244]. 
During a resetting of the SCN clock machinery after a light pulse the expression of Per 
genes is the first to be affected; Per is a member of the family of the immediate-early 
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genes, as well as the transcription factors c-Fos, FosB, JunB; Per is implicated in light-
mediated phase shifting [293]. The same pattern of Per genes can be observed when 
peripheral oscillators are synchronized for example through serum shock [246]. Several 
signals are capable to restart circadian rhythms coherence, increasing Per and Fos 
expressions with a similar kinetic observed during SCN circadian rhythms resetting after 
light pulse [246]. One of the classical methods used to synchronize peripheral oscillators is 
serum shock, that consists in the incubation of the cells in a high percentage horse serum 
medium for 1-2 hours [246]. 
Not only serum shock is able to induce the expression of the immediate-early gene Per1 
followed by the restoration of circadian rhythmicity, but also single substances and other 
molecules contained in the serum. These substances include: activators of adenylate 
cyclase (forskolin) [294], activator of protein kinase C phorbol-12-myristate-13-acetate 
(PMA) [295], angiotensin II [296], calcium ionophore (calcimycin), fibroblast growth factor, 
the hormone insulin, three activators of receptor tyrosine kinases [220], the activation of 
the protein kinase C-mitogen-activated protein kinase cascade and cyclic adenosine 
monophosphate (cAMP) response element-binding protein (CREB) phosphorylation [297] 
entothelin-1 [298] and prostaglandin E2 [299].  
Another signal that induces the synchronization of cellular circadian rhythms is the 
activation of glucocorticoid receptor, as it is demonstrated by the use of dexamethasone 
(an analog of glucocorticoid receptor) shock [220, 300]. 
Even the simple changing of medium with fresh medium is able to induce coherence on 
cellular circadian rhythms and probably the key step is the restorement of glucose levels 
[230]. The medium change does not induce a rapid increase in Per genes expression, in 
contrast with other synchronising agents, suggesting a quite different manner for the 
induction of the synchronization. The glucose-synchronization is dependent on increasing 
RNA expression and protein synthesis [230] and it is mediated by the specif glucose-
responsive immediate-early genes such as transforming growth factor ß-inducible early 
gene 1 (Tieg1) and vitamin D3 up-regulated protein 1 (Vdup1). Probably the action of 
TIEG1 as synchronizing agent sensitive to glucose levels is due to its binding to Sp1 
sequence [301] present near the transcription initiation sites of Per1 and Bmal1 genes 
[302-303], whereas VDUP1, through its negative regulation of thioredoxin, might inactivate 
CLOCK-BMAL1 [304] and hence reduce the transcription of Per1 and Per2 genes. 
The synchronization of circadian rhythms mediated through different signals can influence 
circadian parameters in different ways: indeed, PMA synchronization lengthens the period 
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length, the synchronization with serum shock and forskolin lead to a later phase of the 
rhythms, while dexamethasone, 0.001% ethanol and 0.1% dimethyl sulfoxide (DMSO) 
treatments lead to an earlier phase of the rhythms. The most effective treatments in 
inducing higher amplitude of the rhythms are dexamethasone, forskolin and serum shock. 
Cellular circadian rhythms can be sensitive to different substances that affect the same 
pathway; for example, forskolin, 8-bromo-cAMP (a potent protein kinase A activator), 
fibroblast growth factor (factors for the receptor tyrosine kinase–mediated mitogen-
activated protein kinase pathway), and endotheli-1 are factors that activate CREB 
phosphorylation, but forskolin is the most efficient in increasing the amplitude of 
mPer2::luc Rat-1 cells [305]. 
Temperature is another factor that is able to entrain the circadian rhythms of peripheral 
oscillators. Indeed, cycles of the environmental temperature of about 4°C are able to 
sustain fibroblast circadian rhythms [223]. Interestingly, a reverse clock genes phase is 
observed between cells that have an opposite temperature cycles (e. g. 33:37 versus 
37:33). Mammals have a CBT range of 1 to 4°C [306] and this cycle is able to sustain 
clock genes circadian rhythms in peripheral oscillators [223].  
Even if synchronizing signals in vitro may play a role as zeitgeber also in vivo, none of the 
time cues controlled by the SCN is exclusive in entraining peripheral oscillators. Rather, 
this task may be accomplished via multiple redundant mechanisms, some of which are 
indirect. 
1.2.6.4 Temperature compensation  
Temperature compensation is one characteristic that defines circadian rhythms that means 
that the cycles run with the same period within a physiological range of temperatures 
[307]. The mechanisms of temperature compensation are still unclear. 
The parameter that defines temperature compensation is Q10, that is (T2/T1)^(10/θ1-θ2) 
where T is circadian period length and θ is temperature. Cells are temperature 
compensated when Q10 is around 1.8 and 1.2, whereas the normal biological reactions 
have a Q10 of 2 or 3, i.e. cell cycle [308]. Temperature compensation was demonstrated in 
several mammals tissues [309], but in nonneuronal tissues the damping was stronger than 
in SCN [243]. Rat-1 cells in a temperature range between 28.5 and 36.5°C have a Q 10 of 
about 0.9 and period length shortens with temperature decrease [244]. NIH 3T3 have a 
Q10 of about 0.9 in a temperature range between 33 and 42°C [308]. Moreover, in this cell 
line the accumulation of clock gene proteins is greater at higher temperatures [308]. 
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On the contrary, temperature over-compensation is the situation when at lower 
temperatures the clock oscillates faster. 
The increase in damping rate at higher temperature is probably due to a damping of the 
cellular pacemaker itself and not due to desynchronization of cells within the population 
[244]. 
1.3 AGEING AND THE CIRCADIAN OSCILLATOR  
As the body ages, the coordination of circadian rhythms deteriorates in universal fashion: 
the circadian organization of the sleep-wake cycle is disrupted and with it most other 
physiological manifestations of the circadian clock become less pronounced [310] (see 
also 6.2 Appendix 2). In situations of pathological ageing such as dementia and 
Huntington’s and Parkinson’s Diseases, initial disease stages are marked by abnormal 
daily behavior and later stages are correlated with almost total loss of circadian function 
[311-312]. An understanding of this deterioration could therefore be of great assistance in 
increasing the quality of life for elderly individuals. Incorrectly, many of these disturbances 
are ascribed simply to “sleep difficulties”: in western countries one in five elderly people 
reports taking a sleep medication regularly [313]. While these may provide a momentary 
alleviation of fatigue, underlying causes remain unaddressed, leading to a chronic 
dependence upon these substances. 
1.3.1 Involvement of circadian system in ageing  
There are several links that connect the impairment circadian system with the reduction of 
life span and cancer and other age-related pathologies [314-315]. The disruption of the 
circadian system, in the arrythmic Bmal1 deficient mice, highly reduced life span of the 
animals; from the adult age, mice lacking Bmal1 have a lower body weight due to a 
reduced mass of adipose and muscle tissue. These mice showed earlier in age symptoms 
of age-related pathologies such as sarcopenia, progressive cornea inflammation and 
cataracts, hair loss. The early ageing phenotype correlated in these mice with increased 
levels of oxidative stress accumulation in kidney, heart and spleen [316]. An imbalance 
between circadian system and oxidative stress production and scavenger system may 
contribute to and/or complicate pathogenesis and aging. 
Recent findings on the redox-sensitive input into the core oscillator via modulation of 
NPAS2/BMAL1 or CLOCK/BMAL1 heterodimer binding to DNA indicate a direct influence 
of cellular redox balance, including oxidative stress, on the circadian clock [317]. An 
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example of the interconnections between the circadian system and cellular redox state is 
the nicotinamide adenine dinucleotide (NAD) ± dependent protein SIRTUIN (SIRT1) [318]. 
SIRT1 is a histone deacetylase required for the circadian transcription of Bmal1, Rorγ, 
Per2, and Cry1 genes; in addition SIRT1 bound to the CLOCK:BMAL1 complex in a 
circadian fashion and promoted the deacetylation and subsequent degradation of PER2 
[319] and the deacetylation of BMAL1 at Lys537 [320]. SIRT1 is regulated in a circadian 
manner and its deregulation leads to significant disturbances in the circadian cycle due to 
acetylation of histone 3 (H3) and BMAL1 [320]. 
In another study CLOCK:SIRT1 complex was shown to regulate the circadian levels of 
NAD+ by regulating the circadian expression of the enzyme nicotinamide 
phophoribosyltransferase (NAMPT), the rate-limiting step in the NAD+ salvage pathway 
[321]; the inhibition of NAMPT promoted the oscillation of the clock gene Per2 by releasing 
CLOCK:BMAL1 from SIRT1 suppression [322].  
Accumulated evidence suggests that SIRTs are involved in promoting longevity [323-326] 
in several organisms. The first evidence of a link between longevity and SIRTs was found 
in C. elegans [327] and yeast [328]; for example in Sir2 mutant yeasts rDNA circles are 
accumulated due to a disregulation in the recombination processes [329-330]. In glucose 
starvation regimen the yeast mother cell longevity is extended in a Sir2-dependent manner 
[331]. 
SIRT1 deacetylates non-histone proteins such as the p53 tumour suppressor protein, 
alpha-tubulin and forkhead transcription factors to mediate diverse biological processes 
including metabolism, cell motility and cancer [325]. In mammalian cells, SIRT1 has been 
shown to down-regulate stress-induced p53 and FoxO pathways for apoptosis, thus 
favoring survival [324, 332]. In the absence of SIRT1 p53 is hyperacetylated [333] and 
when the hyperacetylation of p53 is accompaigned by DNA damage cells undergo 
apoptosis.  
Treatment of yeast cells with resveratrol, an agonist of Sir2 extends yeast mother cell 
longevity in a Sir2-dependent manner [334]. Experiments in C. elegans and Drosophila 
[335-336] suggest that resveratrol (and related polyphenolic compounds) can increase 
longevity in very diverse organisms. In human cell culture treatment of cells with 
resveratrol can increase longevity by modulating SIRT1 activity on p53 and tumor necrosis 
factor (TNF) alpha-induced apoptosis [337]. 
The majority of SIRT1 null animals succumb to developmental defects during early 
postnatal period maybe due to cardiac defects [333]. SIRT1 deficient mice report a failure 
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to thrive, abnormal retinal histology with rosette formation, sporadic exencephaly, and 
cardiac septal and valvular abnormalities [333]; moreover, lung or pancreatic defects were 
reported in these animals [338]. 
1.3.2 Circadian behaviour modifications  
The most common symptom of circadian rhythm disruption during ageing is the 
impairment of the sleep-wake cycle (see also 6.2 Appendix 2). Aged people show a 
reduced amplitude of the activity compared to young people, which is marked during 
evening hours [339], whilst time spent awake during the night increases [340]. Moreover, 
sleep hygiene is serious compromise in elderly: a reduction in the promotion of sleep by 
the circadian pacemaker during the biological night in combination with a reduced 
homeostatic pressure for sleep may be causes for the observed earlier awakening 
compared to the circadian phase, loss of sleep consolidation specially in NREM sleep 
[341] and increased sleep latency [342-343]. Alterations in sleep homeostasis are 
confirmed by the observation of a decreasing in slow-wave sleep across the life span 
[344]. However, the imposition of a regular routine of mealtime and exercise may improve 
sleep hygiene and the amplitude of the sleep-wake cycle [345-346]. 
The phase of entrainment of the activity changes with age: during the first phase of life the 
chronotype is very early and tends to delay, wereas from the puberty the tendency inverts 
for the rest of the life span [347]. Females, that mature earlier, present this trend of 
advanced chronotype compared to males; however, from the menopause females have 
the same chronotype as age-matched males [348]. Moreover the correlation between 
circadian phase and chronotype with circadian period length present in young adults [90] 
are lost analysing older subjects [349]. 
A hypothesis for the sleep-wake cycle and chronotype alterations is a lower sensitivity in 
the entrainment of light during elderly [350-351]. Indeed, in mammals the circadian system 
entrains mainly to the light signals that enter the eyes and are capted and translated into 
biological signal by the retina photoreceptors. Then the retina then sends these signals to 
the SCN [78]. However, within elderly, many changes in the eye physiology occur and may 
be the reason of impaired entraining properties in aged people. Elderly have a lower 
transmittance of the crystalline lens also due to the yellowing of the lens, especially at 
higher visible wavelength, impairing the possibility to stimulate opsins, such as melanopsin 
that peaks around 460 nm [352-353]. Pupil area is decreased in elderly, leading to the 
senile miosis, reducing further the light that enters in eyes [354]. Moreover, a poor light 
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quality and quantity of artificial light [355] for hospitalized elder people may exacerbate the 
lower capacity of entrainment of older people. From the early 1990s during cataract 
surgery the lens were replaced with yellowish blue-blocking intraocular lens [356]. This 
particular lens diminished the possibility for the opsin, in particular melanopsin, to entrain 
circadian rhythms of the SCN. Nowadays, the use of UV-only blocking intraocular lens are 
favoured for the replacing of cataract and the improve of nocturnal sleep and reduction of 
daytime sleepiness suggests an increasing of the amplitude of the patient’s circadian 
rhythms [357].  
To counteract the changes in the entrainment capacity and eyes physiology that occur 
during ageing valid treatments are the combination of melatonin and light treatment; 
whereas light therapy alone attenuated cognitive deterioration, ameliorated depressive 
symptoms, attenuated the increase in functional limitations and melatonin alone shortened 
sleep onset latency, increased sleep duration, the combination of the two therapies 
attenuated aggressive behaviour, increased sleep efficiency and improved nocturnal 
restlessness [358-359]. 
1.3.3 Hormones changes during ageing  
In adult animals the immune system is able to influence circadian rhythms: functional 
receptors for IFN-γ (IFN-γ) are found in the ventral part of the SCN [360-361] and present a 
daily rhythm [362] and the intracerebroventricular injection of the pro-inflammatory 
cytokine IFN-γ affects locomotor activity [363] and sleep [364]. Also the cytokines TNF-α 
and IL-1β are shown to modify some clock genes expression in vitro and in vivo in 
animals; the effect of TNF- α on clock genes is also present in vivo in the SCN and 
probably it is the mechanism that leads to a decrease activity mice during the dark period. 
Moreover, TNF- α is shown to inhibit CLOCK-BMAL1-induced activation of E-box 
regulatory element-dependent clock gene promoters [365]. 
During ageing functions of the immune system change, with an expansion of memory T 
cells [366] and increasing levels of pro-inflammatory cytokines, also in the brain [367] 
which may indicate chronic low-grade inflammation [368]. A correlation between some 
inflammatory mediators, such as IFN-γ, and longevity was found [369-371], and in non-
human primates IFN-γ levels were found to correlate with rhythm parameters of locomotor 
activity and body temperature and are characteristic of aging [369].  
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In addition, altered responsiveness of SCN neurons to i.c.v. injections of cytokines with 
aging indicates an age-dependent dysfunction in the interaction between immune factors 
and biological clock [372-374]. 
Ageing leads also to an impairment of the the hypothalamic-adrenal-pituitary (HPA) axis, 
revealed by a decreased amplitude of cortisol levels especially during the evening [375] 
and a reduced HPA sensitivity to steroid feedback [376-377]. When ageing accompaigned 
dementia, the adrenal production of dehydroepiandrosterone and of its sulfate was even 
stronger [375]. 
Some pathology associated with ageing, such as atherosclerosis and hypertension, may 
be due to a reduced production of endothelium-derived NO that is a critical regulator of 
cardiovascular homeostasis. The reduced NO production may affect also circadian 
rhythmicity, since the presence of NO donor induced Per2 gene expression. In elder 
animals daytime NOS activity is reduced, as well as clock gene expression; this situation is 
mimicked by blocking NO production in young animals. Probably NO increases Per 
expression by acting through cAMP response element-dependent and the E-box enhancer 
element-dependent pathways. Another link between NO presence and the modulation of 
circadian rhythm is given by the finding that NO donors caused the S-nitrosylation of 
BMAL1 protein and thus increased its stability [378]. Bmal1 knock-out mice have a 
disrupted blood pressure variation and heart rate [379], but the blood pressure was 
restored in the presence of NO donor [378]. 
1.3.4 Alterations of circadian parameters and entrainment  
Althout animal studies and SCN slices show a shortening in period of sleep-wake cycle 
during ageing [380-381], human studies revealed no age-related reduction of period length 
considering CBT of sighted and blind subjects [342], melatonin and cortisol rhythms [260]. 
However, an increasing number of data demonstrate an influence of ageing on circadian 
rhythms amplitude. For example, CBT amplitude [138, 342], cortisol and growth hormone 
[382] amplitudes are affected by ageing in human.  
During ageing the amplitude of melatonin production and secretion decreases [312] (Fig. 
9); in rat hypothalamus, this decreasing is paralled by the decreasing of melatonin 
receptors (MTs) [383]; the same finding was shown in human SCN [384]. 
Also in animals a marked decrease of circadian rhythms amplitude is observed [385], such 
as in rodent activity [386] and SCN firing rate [387] (see also 6.2 Appendix 2). 
Interestingly, in addition to a decreased amplitude, the variability in the circadian waveform 
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of dispersed SCN cells is increased in aged animals [388], implying that aging could either 
disrupt coupling between SCN pacemaker cells or their output, or cause deterioration of 
the pacemaking properties of SCN cells [389-390]. 
Another circadian parameter that is influenced by ageing is the phase: ageing leads to a 
phase delay peak of melatonin compared to wake-up time [391] and an advanced time of 
awakening, CBT and plasma cortisol [392-393]. Moreover animal studies revealed an age-
related PVN, pineal gland and kidney cells phase advance [381]. 
Ageing reduces the phase shifting properties of light: in human a reduced phase shifting of 
blue-light was observed [394-395], whereas in animals the reentrainment to a new light-
dark schedule takes more days [386, 396]. Peripheral organs show a stronger impairment 
to the resynchronization to a new light-dark schedule compared to SCN, as it was 
demonstrated in aged rats [397]. 
Fig. 9. Hypothetical example of 
the reduction of a circadian 
marker during ageing. Melatonin 
secretion shows great variability 
within individuals; normally 
melatonin appears in humans from 
the 6th-8th week of life and reaches 
the maximum between the 4th and 
the 7th year of age. However, 
already around 20-40 years of age 
the amplitude of melatonin 
secretion, as well as other 
circadian markers, decreases. At 
around 70 years of age the 
nocturnal peak of melatonin 
secretion is barely detectable. 
Throughout ageing melatonin 
secretion levels can extremely 
change up to 100 fold. Black bar 
represents the night period. (From 
[398]). 
 
1.3.5 SCN influences on age-related circadian disorders  
Many findings indicate that changes in the SCN underlie some of the sleep disturbances 
among elderly people [342-343, 399] (see also 6.2 Appendix 2). In post-mortem analyses 
of human brain, many neuropeptide cycles were impaired during elderly, such in the case 
of vasopressin that is is present with a marked decreased amplitude rhythm in aged 
people [399]. 
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During ageing dramatic changes in SCN electrophysiological activity occur. The period 
length of the SCN cells of aged animals appear to be shorten compared to young animals 
[381]. A long-term, single-cell recording of mouse SCN neurons showed that ageing 
induced a marked decrease in the amplitude of impulse activity and an increase in 
variability in the circadian waveform [388]. Similarly, the measurement of the ventrolateral 
part of the SCN revealed that the the amplitude of the spontaneous neuronal firing rate 
was reduced, due to a higher night activity. This effect is owed to a decreasment in the 
spontaneous GABAergic synaptic activity during both day and night [400], where 
GABAergic activity does not show a rhythm, unlike in the dorsal part [401]. GABAA-α3 
subunit does not show an age different expression in mouse SCN [402], as well as the 
GABA-synthesizing enzyme glutamic acid decarboxylase isoform 67 (GAD67) RNA and 
protein levels [402]; however, the number of GAD67 positive neurons are decreased with 
ageing of the animal in the areas with both dense and sparse retinal afferences [402]. 
Similar results are found also in hamster, where the SCN spontaneous firing rate was 
lower in aged animals in the subjective day [390]. 
The expression of VIP is reduced during ageing in hamsters and rats and this reduction 
may contribute to the alteration in the entrainment and attenuation of phase resetting that 
can be observed during ageing [403-404]. Also the diurnal amount of the receptor VPAC2, 
VIP and PACAP receptor [405-406], are reduced in aged rats [404]. Moreover, levels of 
VIP mRNA in rats have a very narrow rhythm amplitude [407]. As a result, melatonin 
inhibition on CREB-phosphorylation PACAP-induced is impaired, suggesting a loss of 
sensitivity of mouse SCN to melatonin [408]. 
Interestingly, SCN transplant could restore circadian rhythms of aged animals. In hamster 
the age-related alterations on the circadian system, such as the locomotor activity and the 
loss of responsiveness to the phase shifting or entraining substances can be reversed by 
implanting old animals with fetal SCN tissue [409-411]. In another accurate study on SCN 
transplant in aged hamsters, the grafted host behaviour was not completely reversed to 
the donor behaviour, but in most of the cases the older hamsters showed a coordination 
between donor and host rhythmic behaviour [412]. The results suggest that the expression 
of rhythmicity by the grafted SCN may depend on the relative amplitude or strength of 
signals produced by the host and donor SCN. 
In a study conducted on rats, only the half of the grafted animals benefited by the 
transplant, showing improvements of one or more rhythms (locomotor, drinking, 
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temperature); the number of VIP-positive cells correlated with the improvement circadian 
behaviours [413]. 
1.4 MELATONIN  
Melatonin is a hormone synthetised primarily in the central nervous system. The major 
source of melatonin is the pineal gland, a small pine cone shaped endocrine gland located 
near the center of the brain, between the two hemispheres, tucked in a groove where the 
two rounded thalamic bodies join, mainly consisting by pinealocytes, cells that produce 
and secrete melatonin [414]. Melatonin production was demonstrated to occur also in sites 
outside the pineal gland such as: retina [415], Harderian gland [416], gastrointestinal tract 
[417], testes [418], human lymphocytes [419] and melatonin synthesis enzymes are found 
expressed in skin tissues [420]. Melatonin synthesis and secretion occur only during the 
dark period of the day in all the species; moreover, in photoperiodic species, melatonin 
amplitude profile correlates with the lenth of the night [421]. 
1.4.1 Melatonin synthesis and degradation  
Melatonin, a small indoleamine, is synthetised throught a cascade of enzymatic reactions 
from tryptophan (Fig. 10). The rate limiting in melatonin production is the enzyme 
arylalkylamine N-acetyl transferase (AA-NAT), whose levels are 7-150 fold higher in the 
night than in the day. Also serotonin, the substrate of AA-NAT, may play a role in the 
regulation of melatonin production. 
AA-NAT levels in human are regulated primarily at post-transcriptional levels, whereas in 
rodents the regulation appears to be related to a cAMP-dependent phosporylation of a 
transcription factor that binds to the AA-NAT promoter. Rapid decline in activity with light 
treatment at night appears to depend on proteasomal proteolysis. 
The signal that regulates the presence of AA-NAT comes from the retina (Fig. 10); indeed, 
retina photoreceptors convert light and darkness into signals that are sent directly to the 
SCN through the main pathway, the retino-hypothalamic tract (RHT) [422]. From the SCN, 
neuronal projections make synaptic connections in the PVN of the hypothalamus 
descending onward through the medial forebrain bundle to the intermediolateral cell 
column of the spinal cord from where preganglionic fibers reach the superior cervical 
ganglia [423]. Sympathetic postganglionic noradrenergic fibers from the superior cervical 
ganglia innervate the pineal gland through the nervi conarii [424]. Thus, production of 
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pineal melatonin occurs in response to noradrenergic stimulation which produces a 
cascade of biochemical events within the pinealocyte. Noradrenaline release from the 
sympathetic nerves that innervate the pineal gland is normally high at night and low during 
the day [425]. In most species, noradrenaline interacts with both beta1- and alpha1-
adrenergic receptors present in the pineal gland [426]. In the rat pinealocyte, stimulation of 
adrenergic receptors induces a rise in adenylate cyclase and cAMP signaling pathway that 
stimulates AA-NAT expression and phosphorylation via protein kinase A, which also allows 
AA-NAT to be stabilized by binding of 14-3-3 proteins [427-428]. The nocturnal exposure 
to bright light suppresses melatonin production immediately by degradation of pineal 
AANAT [429]. Simultaneous activation of alpha1-receptors potentiates the effects mediated 
through the beta1-receptors [430]. Locally in the pineal gland, the rhythmic melatonin 
synthesis is ensured by the oscillating cAMP-dependent transcriptional control mechanism 
[431]. 
1. INTRODUCTION 
  49  
Fig. 10. Melatonin production and secretion process. Melatonin is synthesised from tryptophan through 
several enzymatic steps. The enzyme N-acetyltransferase (NAT) is the limiting step of the enzymatic 
melatonin synthesis cascade. The major site of melatonin production is the pinealocytes in the pineal gland. 
The pineal NAT is regulated, through a multi-synaptic pathway, by light condition. Light information from the 
retina are sent to the master clock from the retina, then to the paraventricular nucleus (PVN) of the 
hypothalamus, descending onward through the medial forebrain bundle to the intermediolateral cell column 
of the spinal cord from where preganglionic fibers reach the superior cervical ganglia (SCG). Sympathetic 
postganglionic noradrenergic fibers from the SCG innervate the pineal gland through the nervi conarii. 
Through beta1- and alpha1-adrenergic receptors present in the pineal gland nocturnal noradrenerdic stimuli 
activate NAT through a signalling pathway that involves the increasing of cyclic adenosine 3´,5´-
monophosphate production by adenylate cyclase. (From [432]). 
Melatonin half-life is short, between 20 and 60 minutes and is degraded by 6-hydroxylation 
to 6-hydroxymelatonin, which is sulfated to 6-sulfatoxymelatonin and excreted in urine. 
Minor degradation pathways are by O-demethylation to N-acetyl-5-hydroxytryptamine, 
which is further conjugated to its sulfate and its glucuronide and the deacetylation to 5-
methoxytryptamine [433]. The principal enzymes involved in melatonin metabolism are: 
CYP1A1 [434], CYP1A2 [435] and CYP1B1 [436] that is an ubiquitous extrahepatic CYP 
melatonin 6-hydroxylase enzyme, demonstrating that the hepatic metabolism may not be 
the only pathway for melatonin clearance [420]. 
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1.4.2 Melatonin binding sites  
From the discovery of melatonin many efforts were done to unravel the nature of melatonin 
binding sites, their function and signaling pathway [218]. So far, several binding sites were 
discovered. 
Melatonin can bind calmodulin [437], calreticulin [438] or tubulin [439-440] and so 
preventing the calcium ion binding [437]. This action may be the responsible for the 
antiproliferative effects of melatonin on breast cancer [441]. 
Melatonin was reported to be a free radical scavenger by direct chemical reaction to 
oxidative species [20], as well as an increase of the production of enzymes to counteract 
the oxidative species [442]. 
Melatonin has the capability to bind the retinoid related orphan nuclear hormone receptor 
(RZR/ROR) [443]. The function of melatonin binding to the orphan receptor is not totally 
understood, even if melatonin activation of RZR/ROR was shown to induce the repression 
of 5-lipooxygenase mRNA expression in human B cell lines [444] and regulate IL-2 and IL-
6 production by human mononuclear immune cells [445-446]. 
In mammals melatonin act mainly through three types of receptor: MT1, MT2 and MT3. 
MT1 and MT2 are G-coupled 7 transmembrane receptors [447]. MT1 is 350 aminoacid, 
whereas MT2 is 362 aminoacid long; their molecular weight is around 39-40 KDa [448-
449]. Both MT1 and MT2 are high affinity receptors, even if MT2 (Kd = 160 pmol/l) has a 
lower affinity for 125I-melatonin compared to MT1 (Kd = 20-40 pmol/l) [450]. 
MT1 and MT2 melatonin receptors have potential glycosylation sites in their N-terminus 
and phosphorylation sites for several kinases such as protein kinase C, casein kinase 1 
and 2 and protein kinase A [451]; these sites may participate to the regulation of the 
receptor functions. 
In MT1 and MT2 the intracellular loop II is slightly different compared to the other members 
of the G-protein coupled receptor and the DRY or ERY motif is substituted with the NRY 
[452]; this region is involved in the receptor trafficking and cell signalling [453]. The 
disulfide bond between Cys 113 and Cys 190 is essential for the high affinity binding of 
MT2 and possibly of MT1 [454]. 
MT1 and MT2 protein and RNA were reported to have a circadian regulation in their 
expression and well as regulation by light and melatonin concentration. For example, in 
the rodent SCN and pars tuberalis (PT) MT1 expression is circadian, with higher levels 
during daytime; nocturnal light administration increases melatonin levels [455-456], leading 
to a downregulation of the receptor by melatonin [457-458]. Indeed, if melatonin 
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suppression by constant light or pinealectomy is followed by exogenous melatonin 
administration the receptor densities in PT decrease [459].  
However, it should be mentioned that the expression levels of MTs in the murine SCN are 
very low during the day, when melatonin levels are low, and high at night, when melatonin 
concentrations peak [460]. Hence the increases in MT concentration parallels the 
increases in the level of its ligand, suggesting that the regulation of the receptor level and 
sensitivity by melatonin is somewhat more complex than earlier studies had concluded and 
may depend upon the tissue and the species considered. Paradoxically, a light pulse 
delivered during the subjective night (expected to halt melatonin secretion) decreased the 
specific binding of radiolabeled melatonin to MT1 receptors in the rat SCN [456]. 
Estradiol was shown to regulate MT1 mRNA expression in the rat hypothalamus [461], as 
well as ageing [383, 462]. During ageing MT1 levels in human SCN and cortex decrease 
[463], although an increase in MT1 and MT2 protein was also reported in hippocampus 
and retina, and hippocampus and cortex respectively [464]. 
MT3 was later characterized as quinine reductase 2 [465]: this detoxification enzyme 
belongs to a group of reductases that participate in the protection against oxidative stress 
by preventing electron transfer reactions of quinones. 
MT3 shows fast kinetics of association/dissociation and a characteristic peak of melatonin 
binding at 4°C; this peak is not present in the oth er receptors that show higher binding 
rates at rising temperatures [466]. The functions of MT3 are still not clear. Moreover, MT3 
affinity is higher for N-acetylserotonin than melatonin, and melatonin to serotonin, and 
appears to couple to stimulation of phosphoinositide turnover [467]. 
In rats and hamster low affinity binding sites (Kd about 10 nM) were demonstrated in the 
preoptic area of the hypothalamus and in the medulla-pons [383]; however, the proteins 
involved in this activity are still unidentified. 
1.4.3 MT1 and MT2 signal transduction pathway  
MT1 and MT2 were demonstrated to be coupled and to activate different G-proteins, such 
as Gi1-3, possibly Gs and Gq/11/14. A coupling of MT1 and MT2 with the promiscuous G16 
was demonstrated in COS-7 cells [468-469]. In several in vitro studies (NIH, HEK, CHO) 
as well as in recombinant cell lines one of the major pathway that is activated by MT1 and 
MT2 is the inhibition of forskolin-stimulated cAMP accumulation through Gi activation, by 
inhibiting the protein kinase A (PKA) activity and phosphorylation of the transcription factor 
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cAMP-responsive element binding protein (CREB) [470-471]. This is the same pathway 
activated by melatonin that was shown to mediate melatonin phase shifting properties in 
animals [472]. However, the signal transduction pathways for MTs appear to vary among 
different tissues and cell types [473-474]. 
Fig. 11. Schematic representation of melatonin signalling pathway. Melatonin receptors MT1 and MT2 
are coupled to several heterotrimeric G proteins, activating specific downstream pathways. Dashed lines 
indicate that the role of intermediate proteins has not yet been elucidated. AA = Arachidonic acid; AC = 
adenylyl cyclase; CaM = calmodulin; CREB = cAMP-responsive element binding protein; cGMP-PDE = 
cGMP phosphodiesterase; cPLA2 = cytosolic phospholipase A2; ERK = extracellular signal-related kinase; 
GC = guanylyl cyclase; JNK = c-jun NH2-terminal kinase; KCa = Ca2+-dependent K+ channels; KIR = G 
protein-gated inwardly rectifying potassium channels; LOX = lipooxygenase; LT = leukotrienes; NO = nitric 
oxide; NOS = nitric oxide synthase; PKA = protein kinase A; PKC = protein kinase C; PL = phospholipids; 
PLC = phospholipase Cß; QR2 = quinine reductase 2. (From[475]). 
1.4.3.1 MT1  
MT1 receptor can be coupled to several G-proteins such as i, o, q, z, 12, 13, 14, 16 [475-
476]. The coupling with Gi2 and Gi3 proteins mediate adenylyl cyclase (AC) inhibition and 
as a consequence inhibition of forskolin stimulated cAMP formation, PKA activity and 
phosphorylation of CREB [470], while the coupling with Gq/11 protein increases 
phospholipase C (PLC) activity [477-478]. The β and γ subunit of G-protein potentiate ATP 
or Prostaglandin F2α-induced release of arachidonate and hydrolysis of phosphoinosite 
[478-479]. 
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Other pathways may be activated by MT1; in MT1 transfected COS-7 and neuroblastoma 
SH-SY5Y melatonin causes stimulation of cAMP; the mechanism is still not clear but it is 
probably mediated through a calcium-calmodulin signal transduction pathway and c-Jun N-
terminal kinase activation [480-481]. 
The activation of MT1 by melatonin is also able to induce a transient elevation of cytosolic 
Ca2+ and inositol phosphate accumulation [477-478] and activate the mitogen-activated 
protein kinase and ERK kinase 1/2 (MEK172) and extracellular signal-regulated kinases 
1/2 (ERK1/2) probably leading to induction of synthesis of filamentous structures non-
neuronal tissues [482].  
Moreover, it also regulates functional responses of melatonin in ion channels. For 
example, it was shown that vasoconstriction of rat arteries is mediated by melatonin-
induced blockage of calcium activated potassium channels [483] and the activation of the 
inward rectifier potassium channel KIR3, which leads to inhibition of neuronal firing in the 
SCN [484]. 
1.4.3.2 MT2  
Similar to the second messenger pathways of the MT1 receptor, activation of the MT2 
receptor also inhibits forskolin stimulated cAMP formation [471]. Moreover MT2 mediates 
the increase in phosphoinositide production and the inhibition of cGMP formation [485] and 
cGMP pathway [486]. 
 
Another pathway activated by MT2 is the stimulation of phospholipase C and 
diacylglycerol-mediated activation of protein kinase C that was shown linked to the phase 
shifting properties of melatonin in several studies using rat SCN slices [487-488]. 
1.4.3.3 AC 
Apart from the classical inhibition of AC due to melatonin activation of Gi, more 
complicated pathways may involve melatonin in the activation/repression of AC. 
There are 9 different isoforms of AC and every isozyme exhibits different sensibility to Gαi, 
Gβγ and Ca2+/calmodulin. Indeed, type 1-6 AC are inhibited by Gαi1-3 and Gαz, type 1 is 
inhibited by GoA/B and Gβγ. On the other hand Gβγ and activated Gαs or protein kinase C 
(PKC) stimulate AC 2, 4 and 6 [489]. This activation is observed in the VIP stimulated 
cAMP accumulation in human lymphocytes; since human lympocytes express Gαi1–3, Gαz, 
and Gαs [490] and MTs [491], if type 2 or 4 AC is also present in lymphocytes, it is entirely 
possible for MTs to enhance the VIP-induced response via the Gβγ released from Gi or Gz. 
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Ca2+/calmodulin can inhibit AC 5 and 6 isoforms but activates type 1, 3 and 8 [492]; since 
AC 5 and 6 are expressed in human lymphocytes [493] and melatonin antagonizes 
Ca2+/calmodulin function [494], the potentiation of VIP induced cAMP accumulation may 
be due to the attenuation of the inhibition of Ca2+/calmodulin by melatonin. However, the 
binding of melatonin with Ca2+/calmodulin may inhibit the activation of AC types 1, 3 and 8. 
The overall effect on AC activity by the binding of melatonin to calmodulin will be 
determined by the balance of its inhibitory and activatory effects on AC. 
Another way by which melatonin may stimulate AC type 1-8 is through the activation of 
PKC [492]. 
Moreover, melatonin block of the forskolin-stimulated increased levels of c-fos and junB 
mRNA levels [495] may be due to the inhibition of cAMP production by melatonin, that as a 
consequence leads to the block of the activation of PKA [496] and CREB [497]. This effect 
is important especially considering the ovine PT and the seasonal changes which are 
regulated by melatonin [498]. 
1.4.3.4 PLC 
PLC are enzymes that catalize the convertion of phospholipids to diacylglicerol and inositol 
triphosphate. However, only the isoform PLCβ is activated by G protein; in particular 
melatonin activates PLCβ through the activation of MT1 and MT2 that then Gα16 [499] or 
Gβγ subunits, as demonstrated in MT1 and MT2 tranfected CHO cells [500] and rat SCN 
slices [487]. In a study on MT1 transfected HEK cells the activation of PLCβ was possible 
if Gq was coactivated [478]. 
The expression levels of MTs in the SCN and PT vary throughout the light/dark cycle, 
which are in part regulated by melatonin itself [459]. Receptor levels are sensitive to PKC 
[501] and as PKC activity in the SCN is responsive to melatonin [487] it is possible that the 
PLC/PKC pathway is employed to modulate the sensitivity of cells to melatonin. This may 
also occur by melatonin-induced PKC activity being responsible for phosphorylation and 
desensitization of MTs, as demonstrated in human prostate epithelial cells [457]. 
1.4.3.5 Phospholipase A2 (PLA2)  
PLA2 is a cytosolic enzyme that catalazes the production of arachidonic acid (AA) from 
phospholipids. In MT1 transfected NIH3T3 cell lines melatonin activates Gi and PKC 
facilitating the activation of PLA2 stimulated by PGF2α activation of Gq-coupled pathways, 
with no effect on the basal level of AA secretion [479]. 
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Another effect of melatonin on AA is the inhibition of the metabolism by human platelet 
cyclo-oxygenase [502] and downregulation of 5-lipoxigenase in human B lymphocytes via 
the activation of a nuclear melatonin receptor RZR/ROR [444] and of 12-lipoxygenase in 
the rat pineal gland [503], resulting to an increased levels of AA. 
However, melatonin was also shown to inhibit the hormonal-induced AA accumulation and 
oppose AA-induced physiological responses: melatonin inhibits AA-induced platelet 
aggregation [504] and thromboxane-B2 production in pancreatic cells [505] and in the rat 
anterior pituitary melatonin administration downregulates PLA2 expression and AA 
production [506]. 
The composition of effectors in a particular cell type may play a key role in the 
responsiveness of cPLA2 to melatonin. 
1.4.3.6 K+ channels and Ca2+ channels  
Melatonin acutely depresses the in vitro electrical activity of SCN neurons in hypothalamic 
slices [507] indicating that the modulation of the electrophysiology of neurons contributes 
to the propagation of melatonin effects. In particular melatonin regulates potassium and 
calcium channels. 
Potassium channels: Potassium currents play a critical role in maintaining the resting 
membrane potential of cells, the control of neuronal firing rates and the regulation of 
neurotransmitter release [508]. 
In SCN neurons and rat cerebellar granule cells melatonin induces an outward potassium 
current and inhibits an inward cation current and firing rate, through activation of MTs but 
not via cAMP or PLC arthways [484, 509-510]; indeed, members of the Kir3 potassium 
channel subfamily, which are widely expressed in the brain, can be activated by Gβγ2 via 
direct interaction, but the Gαi1 subunit counteracts Gβγ2-stimulated Kir3.1 activity [511-
512]. It would seem that melatonin regulates Kir3 channels in the brain via a balance 
between activation and release of Gα and Gβγ subunits. 
Through its regulation of cAMP and NO/cGMP, melatonin is able to indirectly modulate 
also the Ca2+-dependent potassium channel family (KCa), responsive to these second 
messengers calcium [508]. Melatonin, acting via MT1 and MT2 receptors, was indeed 
been demonstrated to inhibit the large conductance (BKCa) channels through the 
decrease in the cAMP-protein kinase A pathway that phosphorylates channels and this 
inhibition potentiates the constriction of vascular smooth muscle [483, 513], although 
whether this is mediated via Gβγ subunits or a Gα-coupled pathway is not clear. 
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Furthermore, melatonin-induced inhibition of the small conductance (SKCa) channels in rat 
gastric smooth muscle results in the relaxation of pre-induced vasoconstriction [514]. 
Calcium channels: Two groups of Ca2+ channels, voltage-dependent Ca2+ channels 
(VDCCs) and second messenger-operated Ca2+ channels (SMOCs), are putatively 
involved in the melatonin signaling pathways. VDCC channels may be modulated by G 
protein: L-, N- and P/Q-type VDCCs are inhibited by Gi/o family proteins, with Go more 
efficient than Gi [515], while N- and P/Q-type VDCCs can be stimulated by Gs proteins. 
Physiological responses induced by melatonin-mediated inhibition of Ca2+ influx or uptake 
have been found in many mammalian tissues. For example, melatonin inhibits dopamine 
release from the rat hypothalamus [516], inhibition associated with suppression of calcium 
uptake by the stimulated tissue and documented at different times of the day [516-518] 
and causes vasorelaxation in rabbit basilar arteries [519]. It is known that Go and Gi 
proteins are involved in the inhibition of N-, L-, and P/Qtype VDCCs. Moreover, Gβγ 
subunits have been suggested to inhibit N-type channels by a PLC-ß stimulated PKC 
pathway [520]. Thus, it might be expected that stimulation of MTs may lead to the 
inhibition of N-, L-, and P/Q-type VDCCs via Gαi/o- and Gβγ-mediated pathways. On the 
other hand, there is growing evidence that melatonin is able to facilitate opening of L-type 
channels to induce vasoconstriction in the rat [521] and increase the contractility of chick 
myocytes [522]. The induction of Ca2+ influx by melatonin has been reported also in 
hamster retina [523]. 
Melatonin may regulate also the SMOCs: these channels are activated by intracellular 
inositol phosphates [524], so it is possible that melatonin induces the opening of SMOCs 
via a PLC-dependent pathway. For example, in human prostate cells the increase by 
melatonin of cGMP leads to enhanced calcium uptake through cyclic nucleotide gated 
channels [525]. 
1.4.3.7 Guanylyl cyclase (GC) and cGMP-phosphodiesterase (cGMP-PDE)  
It is widely demonstrated that melatonin has an inhibitory function of cGMP production: in 
the cerebral cortex of the chick, rat pituitary, human prostate epithelial cells and murine 
melanoma cells [457, 526-528], resulting in cGMP circadian rhythm. This effect is 
mediated via MT2 and not MT1 [471, 485, 529]. 
cGMP is an important regulator of SCN circadian rhythms [530] and retina, however 
melatonin role in regulating cGMP are still not yet apparent. In the retina the activation of 
the photopigments rhodopsin and opsin by rods and cones activate the rod-specific Gt1 
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and cone-specific Gt2 G proteins that lead to the metabolism of cGMP in 5’GMP by cGMP-
PDE [531]; it is not known whether MTs can utilize Gαt proteins to directly affect cGMP 
levels or whether they employ Gαi family proteins to modulate pre-stimulated cGMP levels. 
Alternatively, melatonin may inhibit GC activity by inhibiting the activity of NO synthase 
(NOS), which produces NO, a known activator of GC [532-533]. The mechanism of 
melatonin inhibition of NOS activity has not been extensively studied but one hypothesis 
may be that melatonin block the Ca2+/calmodulin activation of NOS [534]. 
Melatonin is also able to induce cGMP accumulation in tissues such as human 
lymphocytes [535], chick pineal gland [536] and in rat anterior pituitary, thyroid, liver and 
small intestine [537]. These findings suggest that cGMP may be involved in melatonin 
signalling pathway. The mechanism how melatonin increases cGMP levels are still not 
clear but may involve the inhibition of cGMP-PDE activity [528] as well as the activation of 
GC [536]. 
1.4.3.8 MAPK  
Melatonin was shown to be able to activate several MAPK pathways, such as the 
extracellular signal-regulated kinases (ERKs) and the transcription factor Elk-1, that in 
human granulosa cells may regulate progesterone production, LH receptor, GnRH, GnRH 
receptor gene expression, ovarian function [538], and the c-Jun NH2-terminal kinases 
(JNKs, also referred to as the stress activated protein kinases, SAPKs) in COS-7 cells 
transfected with human MT1 and MT2 that activated through Gs, Gz and G16 [480]. MCF-7 
breast carcinoma cells JNK and ERK were activated by MT1 receptor [480]. 
Melatonin has been proven also in this case to have opposing effects in different cell 
types. In PT cells it was noticed that melatonin inhibit the ability of IGF-1 to activate ERK 
activity probably through its inhibitory effect on cAMP production [539, 540], the same 
effect that mediated the inhibition of the uptake of the promoter of mitogenesis via MAPK 
kinase pathways linoleic acid by rat hepatoma cells [541]. 
1.4.4 MT1 and MT2 melatonin receptor distribution and function 
Melatonin exerts its role mainly through the binding to melatonin receptors MT1 and MT2. 
These receptors were widely demonstrated to be present in the central nervous system, in 
many brain areas. Also MT3 is present in the brain, but its levels are higher in other organs 
such as the kidney and liver [465]. In the brain the effects of melatonin depend on the area 
where the receptors are present: in the SCN melatonin modulates the entrainment of 
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circadian rhythms and may induce sleep [542], in the retina melatonin inhibits the 
stimulation evoked release of dopamine [471], modulates rod phototransduction pathway 
and photoreceptor functions and help the retina for the adaptation to low light intensities 
[543] whereas in the hippocampus melatonin contributes to the memory formation and to 
the excitation and inhibition of neuronal activity [464, 544]. Other functions of melatonin in 
the brain are the modulation of dopamine synthesis and release and activation of 
dopamine receptors [545]. 
1.4.4.1 SCN 
MT1 receptor is demonstrated to be expressed in rodent SCN [217] as well as in human 
SCN [542]. 
As explained above, the SCN takes place in the synthesis and release of melatonin from 
the pineal gland [423, 546]; however, melatonin feedbacks in the SCN and regulates 
neuronal activity and circadian rhythms [211]. 
Models to study melatonin influences on the SCN are cellular (mammalian SCN2.2 that 
express both MT1 and MT2 [448, 488, 529, 547]) and animals (e.i. rodents, whose SCN 
was reported to express MT1 and MT2 proteins with 37 KDa and the glycosylated form) 
[448]. 
One of the classical effects of melatonin was studied in SCN2.2 cells, where melatonin 
inhibits the forskolin-stimulated cAMP accumulation [448]. A similar effect was observed in 
mouse SCN slices, where melatonin inhibits the PACAP–mediated cAMP response 
element binding protein (CREB) phosphorylation, an effect mediated via MT1 [472, 548]. 
From the retinohypothalamic tract two kinds of synapses are connected to the rodent SCN: 
glutamatergic, that induces through n-methyl-D-aspartic acid (NMDA) activation Ca2+ influx 
and PACAP, that through PACAP-R1 increases cAMP production [549-551]. Both 
pathways phopshorylate CREB. However, PACAP is more sensitive during late daytime, 
signalling darkness, whereas glutamate is more sensitive during early night time, signalling 
light. Melatonin, thorugh its inhibition of PKA pathway, is able to counteract PACAP 
signalling [552], but not glutamate signalling [553] and probably this may preserve the 
responsiveness of the SCN to light-induced phase shifts at night. This mechanism is 
mediated via MT1 receptor at low melatonin concentrations, but at higher melatonin levels 
it is also mediated via MT2 [472]. 
The activation of MT2 in rat SCN and cellular model stimulates PKC activity [448, 488]. 
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Melatonin has an effect also in inhibiting neuronal firing rate in SCN slices especially at 
dusk [554] through MT1 activation [507, 555]; this effect is due to an increase in potassium 
conductance and subsequent neuronal hyperpolarization [484] through activation of the 
inward rectifier potassium channel Kir3 [556]. This function of melatonin on alteration of 
clock excitability as it shifts from day to night may promote sleep by inhibition of neuronal 
activity in the SCN and/or other areas of the limbic system. 
Melatonin has a function also in phase advancing circadian rhythms at dusk (fall phase of 
melatonin production) and dawn (rise phase of melatonin production) through activation of 
MT2 and PKC [487-488, 529, 557]. Interestingly, if physiological concentrations of 
melatonin (between 30 and 300 pM) are applied on rat SCN slices or SCN2.2 cells for 8 
hours during the night the phase shifting and PKC stimulation effects of melatonin are 
abolished by desensitization of MT2 but not MT1 that was fully recovered 8 hours after 8 
hours from melatonin administration [558-559]. 
1.4.4.2 Pituitary gland (PT) 
Melatonin is critical for the regulation of seasonal changes in various aspects of physiology 
and neuroendocrine function [560-561]. These actions of melatonin are processed in 
nuclei of the hypothalamus [562] and in the PT of the pituitary [563-564].  
In PT melatonin activates Gi and Go that leads to the inhibition of forskolin-stimulated 
cAMP accumulation [496, 526, 565-566] inducing the inhibition of CREB phopshorylation 
[472, 497, 552-553]. This inhibition influences the expression of the transcriptional inhibitor 
inducible cyclic AMP early repressor (ICER) that is rhythmically expressed in the PT. 
Another implication of melatonin inhibition of cAMP in rodent PT is the Per1 expression 
[567], whose production is repressed by the inhibition of cAMP induced by melatonin [473]. 
However, the repression of AC after several hours super-sensitises the enzyme by 
activators [568], leading to higher Per1 level expression than occur in the absence of 
melatonin [567]. The temporal regulation of the Per1 gene by melatonin is thought to 
contribute to the release of pituitary hormones, such as PRL [569], that regulate circadian 
rhythms [567]. 
In mouse strains melatonin-deficient, such as C57BL mice, mper1 mRNA and mPER1 and 
ICER protein are completely absent from the PT [564, 567]. If MT1 melatonin receptor-
deficient mice are bred with the melatonin-producing C3H genetic background, the 
offsprings show lower levels of mPER1 protein as compared to their wild-type littermates 
[567]. 
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However, no MTs seem expressed in human PT [570]. 
1.4.4.3 Retina 
Melatonin receptors MT1 and MT2 are localized in several structures of birds, rats and 
humans eyes, such as cornea, choroid, sclera, horizontal, amacrine, and ganglion cell 
bodies as well as the inner segments of rod photoreceptor cells, retinal pigment epithelium 
(RPE) and retinal blood vessels [543, 571-573]. The wide-ranging distribution of MT1 
receptors is indicative of melatonin indirect action on vascular smooth muscle [574] the 
presence of MT2 receptors in the apical microvilli of cell membrane, but not in the basal 
membrane of the RPE, suggests that melatonin is involved in photoreceptor outer segment 
disk shedding and phagocytosis [572] 
MT3 is also found expressed in the eyes of rabbits, probably regulating intraocular 
pressure [575] 
The presence of MTs highlight the role of melatonin in the eyes, to regulate rod 
phototransduction pathway [543] differential regulation of the growth and remodelling of 
the fibrous and cartilaginous scleral layers which in turn affect eye size and refraction [573] 
and in the regulation of humor secretion and maintenance of the circadian variations of 
intraocular pressure [576]. Moreover, melatonin was demonstrated to have a role in 
physiological adaptation to low light intensities: in mammalian retina rod photoreceptors 
make synapsis with AII amacrine cells, whose gap junctions modulation by ambient 
illumination forms the basis for visual acuity. Retinal dopamine inhibits retinal melatonin 
synthesis [577-579] through D2/4 receptors; melatonin inhibits dopamine synthesis [579-
580]. 
Dopamine uncouples homologous AII junctions acting through D1 receptor [581] whereas 
melatonin blocks D1 induced accumulation of cAMP via MT1 receptors present in AII cells 
[582]. This inhibition of the light-induced release of dopamine is probably due to the 
enhancement of GABA activity [583].  
1.4.4.4 Hippocampus 
Melatonin receptors MT1 and MT2 were found in the dentate gyrus, CA3, CA1 and in the 
subiculum of the rat hippocampus [584]; however in mice melatonin receptors show a 
different localization profile, since the MT1 receptor is predominantly expressed in neurons 
from the CA1 subfield, which is the main output of the hippocampus, whereas the MT2 
receptor is especially detectable in the CA4 and CA3 pyramidal neurons, which receive 
glutamatergic excitatory inputs from the entorhinal cortex [585]. 
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In the rat CA1 melatonin enhances the neuron firing rate [584] and inhibits the long-term 
potentiation (LTP) in murine hippocampus slices [586] through MT2 dependent pathway, 
that involves PKA inhibition [586]. The same conclusions about the melatonin-dependent 
inhibition of LTP were found in vivo, by the observation that the processes of 
learning/memory are impaired in MT2 knockout mice [587]. Probably the 
excitatory/inhibitory actions of melatonin on the hippocampus are influenced by circadian 
rhythms of melatonin secretion. 
In a human study melatonin was shown to enhance the activation of the left 
parahippocampus in an autobiographic memory task [588]. The activity of this area of the 
hippocampus shows diurnal variation, with an enhancement of the activity in the evening 
[589]. Since the exogenous administration of melatonin could increase the activity only 
when the endogenous melatonin levels were already increasing, this may indicate an 
effect of melatonin and circadian rhythm in human memory processing during the night 
[589] such as memory consolidation [590]. 
In elder and AD subjects, increasing levels of MT1 and decreasing levels of MT2 in 
hippocampal CA1-4 subfields were observed [464, 544]. MT1 level changes are probably 
a compensatory mechanism due to a decreased melatonin secretion, whereas the MT2 
level changes were hypothesised to be related to the memory impairment of the diseases. 
Indeed, administration of melatonin disrupted the inhibitory neuronal functions by reducing 
the GABAA receptor mediated currents in CA1 pyramidal cells through activation of MT2 
receptors [584] so probably the loss of hippocampal MT2 receptors could disturb the 
activity of GABA-ergic transmission which may underlie the pathogenesis of AD. Another 
pathology that melatonin may affect through the influences on GABA transmission is 
epilepsy. In children, pharmacological doses of melatonin lead to a decrease in the 
severity and/or frequency of epileptiform activity [591] and pinealectomy in rats increases 
the probability to develop the processes that follow the long-lasting status epilepticus, 
including increased neuronal loss with a higher number of spontaneous seizures occurring 
during the chronic phase [592]. 
While melatonin does not interact with GABAA receptors, it is interesting to note that it 
potentiates the hypnotic effects of benzodiazepine and non-benzodiazepine drugs that 
enhance GABAA receptors [593-595]. Co-administration of melatonin during the withdrawal 
period has been shown to facilitate discontinuation of hypnotic drugs [596-597].  
 
1. INTRODUCTION 
  62  
1.4.4.5 Other brain areas  
In the murine substantia nigra, ventral tegmental area, nucleus accumbens, caudate-
putamen, and in the human prefrontal cortex, putamen, caudate nucleus, nucleus 
accumbens, substantia nigra, and amygdala MT1 expression was shown [545] 
The dopaminergic system is important for movement and psychological factors, such as 
reward, as well as for producing the reinforcing actions of drugs of abuse, like cocaine. For 
example, it was shown that melatonin cotreatment can block the development of cocaine-
induced behavioral sensitizations, such as anxiety during cocaine withdrawal [598]. 
In distinct human cerebellar cortex cells MT1 and MT2 are expressed [599]. MT1, for 
instance, was localized in cell bodies of granule cells and basket-stellate cells. Moreover, 
MT receptors may have an inhibitory effect by colocalization with the excitatory 
glutamatergic synapses, leading the hypothesis that melatonin has a role in the posture 
control and balance [600]. 
1.4.4.6 Skin  
Most dominantly MT1 is expressed in the human skin [601], including kerotinocytes, 
melanocytes (epidermal and hair follicle), fibroblasts and squamous cell carcinoma and 
melanoma cells. The MT2 receptor was also detected, but transcripts were present only in 
neonatal keratinocytes and in one melanoma cell line. Even if melatonin was shown to 
inhibit cell proliferation in cutaneous melanoma cells and in normal and malignant uveal 
melanocytes [602-603] it has no effects on the proliferation of dermal fibroblasts grown in 
medium containing growth factors [601]. In addition to its receptor mediated effects, 
through its antioxidative mechanism melatonin, has protective effects on UVB-induced 
damage in dermal fibroblasts and epidermal keratinocytes [604]. 
1.4.4.7 Gastrointestinal tracts  
MTs are expressed in several tissues of the gastrointestinal tract of rodents and humans: 
MT1 is expressed in liver, kidney [605] and gallbladder [606], MT2 is expressed in lung 
and duodenum [450] and MT3 is expressed in liver, kidney, lung, muscles, intestine [465]. 
Because of its local synthesis by enterochromaffin cells [607] the gastrointestinal tract and 
the gallbladder contain high concentrations of melatonin [608]. However, the function of 
melatonin in the gallbladder is only speculative. It is known that melatonin can modulate 
gastrointestinal ion transport processes and motility [417]. Furthermore, in rats, melatonin 
alters cholecystokinin-induced changes of ileal motility [609]. Melatonin may also interfere 
with NO signaling [533], possibly influencing gallbladder contraction. 
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In the duodenum melatonin influences HCO3– release from the duodenal mucosa [610-
611] with a mechanism under nervous control [612]: melatonin activates the release of the 
intracellular calcium in the enterocytes which, in turn, activates apical electroneutral HCO3–
/Cl– exchange [613]. 
Many pancreatic cell models, such as pancreatic islets and the insulinoma pancreatic β 
cells INS-1, express MT1 but not MT2 [614-616]. Acute melatonin treatments inhibit 
forskolin-stimulated and glucagon-like peptide insulin secretion through activation of Gi/Go 
pathway and insulin promoter activity and CRE–mediated gene expression [614-616]; 
however, melatonin alone has no effects on insulin secretion. On the contrary, chronic 
melatonin treatments increased basal levels of insulin secretion and potentiated GLP-1- 
and forskolin-induced insulin and cAMP production [614]. Regulation of the circadian 
release of insulin and sensitization of the cAMP system by endogenous melatonin may 
provide a mechanism by which high morning levels of insulin facilitates glucose disposal 
following nutritional stimuli [614]. 
1.4.4.8 Adipose tissue  
All melatonin receptors MT1, MT2 and MT3 were shown to be expressed in adipocytes 
[450, 465, 617]. 
Melatonin is known to play a role in energy expenditure and body mass regulation in 
mammals: melatonin can modulate fat mass activation in several species [618-620]. 
Moreover, classical side effects of the misalignement of circadian rhythm and melatonin 
pattern in human are oversleeping, carbohydrate craving and overall weight gain [621].  
In a cellular model of immortalized adipose tissue MT1 and MT2 were indentified to be 
expressed. 
Long melatonin treatment leads to a decline in cAMP accumulation and inhibition of cGMP 
levels, probably mediated by MT2, that produces a decrease in the insulin-mediated 
glucose transport GLUT4 and glucose levels [485]. 
Inguinal and epididymal rat adipocytes express MT1 and MT2; in inguinal adipocyets 
melatonin inhibits isopropanol-stimulated lypolysis via Gi/Go pathway [622], whereas in 
epididymal adipocytes melatonin in the presence of insulin increases leptin secretion and 
counteracts forskolin-induced inhibition of leptin secretion and mRNA expression. 
However, insulin or melatonin alone did not modify leptin secretion suggesting cross talk 
between these hormones to modulate leptin production from adipocytes via MT1 receptor 
activation [623]. 
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1.4.4.9 Reproductive system and seasonality  
Several tissues in the reproductive system express MT: MT1 was shown to be expressed 
in breast [624] testis [625] ovary [626] and MT2 is expressed in myometrium and 
granulosa cells [450]. 
Some evidences that may connect melatonin with the uterus functions are a circadian 
rhythm of uterine contractility and electrical activities [627] and the evidence that birth rate 
occurs especially during the night [628]. During rat pregnancy oxytocin receptors are 
upregulated and MT receptors are downregulated, probably due to the inhibitory effect of 
melatonin alone on uterus contraction [629]. However, in the presence of noradrenalin, 
melatonin can augment contractile forces in human myometrial strips [630]. 
Administration of exogenous melatonin to women induces a decrease in luteinizing 
hormone (LH) secretion, blocks ovulation, and the luteal phase, increase in progesterone, 
without affecting follicle-stimulating hormone (FSH) or inhibiting estradiol [631] Acute 
suppression of LH levels was also observed in men with a negative correlation between 
inhibin and the LH/testosteron ratio [632]. These effects are thought to be mediated by 
regulating hypothalamic gonadotropin release [633]. However, recent studies suggest that 
melatonin can also exert effects on this axis by directly binding to granulosa cells in the 
ovary [634]. A study in human granulosa cells showed that both types of melatonin-
receptors are present and that melatonin can upregulate LH mRNA receptor [538]. LH is 
essential for the initiation of luteinization. Furthermore, melatonin treatment enhanced the 
hCG stimulated progesteron secretion. An additional important result of this study was an 
inhibition of gonadotrophin-releasing hormone (GnRH) and GnRH-receptor expression. 
GnRH in the ovary is suggested to be an important paracrine and/or autocrine regulator 
and may be involved in the regression of corpus luteum [635]. Therefore these results may 
point to a possible involvement of melatonin in the maintenance of the corpus luteum 
during pregnancy. 
Endogenous released melatonin resulting from changes in day length modulates 
reproduction in seasonal breeders [561, 636-637]. This effect is mediated by modulation of 
the hypothalamic–pituitary–gonadal (HPG) axis function through activation of MTs in 
hypothalamic GnRH releasing neurons, PT of the anterior pituitary, gonadotrophs and 
lactotrophs of pars distalis, as well as testes and ovaries [625, 638-640]. 
In laboratory rodents the effect of melatonin on the HPG axis is predominantly inhibitory. In 
immortalized GnRH releasing cells melatonin decreased the expression of GnRH mRNA in 
a 24 hours cyclical manner through MT1 and MT2 signalling [638]. GnRH in turn controls 
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the secretion of the gonadotrophins, LH and FSH that regulate reproductive functions at 
the level of the gonads. 
Activation of MTs expressed in neonatal rat pituitary gland inhibits GnRH-induced LH 
release, cAMP and cGMP accumulation and the increase in intracellular Ca2+ through 
activation of a pertussis toxin–sensitive G protein–coupled receptor [641-643]. The 
mechanism(s) by which melatonin modulates gonadotrophin secretion from the pituitary 
gland is complex and appears to involve primarily activation of MT1 melatonin receptors 
[631, 644]; however, participation of MT2 receptors[645] cannot be excluded.  
In hamster testicular Leydig cells, melatonin inhibits basal and chorionic gonadotropin-
stimulated cAMP and androgen (testosterone and androstene 3α-diol 17β diol) production 
through activation of MT1 receptors [625]. In this animal model melatonin increases local 
corticotrophin-releasing hormone and downregulates the expression of steroidogenic 
acute regulatory protein and other key steroidogenic enzymes [625].  
1.4.4.10 Cardiovascular system  
A link between melatonin function and cardiovascular functionality was highlighted by the 
observation that patients with coronary heart disease and non-dipper hypertensive patients 
(patients who do not exhibit a normal decline in blood pressure at night) have significantly 
lower nocturnal melatonin secretion than healthy controls [646-649]. 
In the cardiovascular system the three main MTs are found. MT1 is present in the 
peripheral and cerebral arteries [650-651] as well as MT2 [450]; MT2 is also present in the 
aorta [450] and in the heart are present both MT2 [450] and MT3 [465]. Expression of MT1 
receptors in human coronary arteries exhibits 24 hours variation with lowest values 
detected after 02:00 am up to the late morning hours and a progressive increase seen 
after 01:00 pm until midnight [651]. The expression of melatonin MT1 receptor in the 
coronary arteries followed a similar rhythm and amplitude in coronary patients and in 
controls [651]. In contrast, melatonin MT2 receptor expression in coronary arteries, aorta 
and left ventricles of patients with coronary heart disease differed from that of controls 
[652]. 
Although melatonin receptors MT1 and MT2 were found in human left ventricular tissue 
[650, 652] melatonin role in left ventricular function has not been fully clarified. Melatonin 
stimulates high voltage activated calcium currents in chick embryonic heart tissues [522] 
and in isolated rat papillary muscle it possesses anti-adrenergic effect inducing reduction 
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of contractility increase [653]. Furthermore, melatonin can inhibit isoproterenol-stimulated 
cAMP production in primary heart cell cultures [654].  
Better known is melatonin role in vessels: MTs mediate both vasoconstriction and 
vasodilatation through activation of distint MTs, probably by modulating NO and 
noradrenergic effects. 
In porcine coronary arteries melatonin induced vasoconstriction via inhibition of NO effects 
and potentiation of serotonin effects [655]. In rat caudal artery melatonin potentiates the 
adrenergic nerve stimulation and norepinephrine contraction without affecting the vascular 
tone [656]. In this case vasoconstriction is probably mediated by decreases in cAMP-
dependent phosphorylation of calcium-activated potassium channels (BKCa) through Gi/Go 
protein-coupled MT1 melatonin receptors present in the smooth muscle, although 
participation of receptors localized in the endothelium cannot be ruled out [483, 657-658].  
Also the vasoconstriction of the cerebral arteries is mediated via Gi/Go and BKCa channels 
[659-660]. In this way MT1 melatonin receptor may have a role in the regulation of cerebral 
blood flow [661]. It is conceivable that melatonin-mediated vasoconstriction by modulating 
vascular tone may attenuate diurnal fluctuations in blood pressure keeping cerebral flow 
constant [662]. 
From rat studies on arteries, melatonin seems to mediate vasodilatation through MT2 
receptor [657, 663]. Moreover, vasodilation and increase in blood flow induced by 
melatonin in distal skin regions may underlie the concomitant heat loss and hypothermic 
effect of this hormone [664]. Melatonin is involved in the control of intraocular pressure 
during the daily photoperiod probably through MT3 receptor [575]. 
In bigger arteries such as rat and rabbit aorta melatonin was shown to mediate 
vasodilatation [665] through the elevation of NO, potentiation of acetylcholine- and/or 
inhibition of noradrenaline effects [666]. 
In humans, treatment with melatonin is effective for lowering blood pressure in normal men 
[667] and postmenopausal women [668], in the hypertensive type 1 diabetic adolescents 
[669] and in patients with nocturnal hypertension [670] without affecting the heart rate. 
Melatonin effects on thermoregulation are also important in humans: the administration of 
melatonin leads to vasodilatation in distal body regions reducing CBT and inducting 
sleepiness [671-672]. Exactly which MTs are involved in these effects remains to be 
investigated. These studies confirmed the hypothesis that melatonin in humans is involved 
in the circadian variation of body temperature and induction of sleep. 
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1.4.4.11 Immune system and cancer  
Melatonin regulates hematopoiesis, through its action on specific receptors on bone 
marrow cells [673] and has a function in the physiology of the immune system. The first 
strong evidence of a connection between melatonin and the immune system comes from 
the observation that pinealectomy caused thymic involution and suppressed immunity 
[674] and that inhibition of melatonin synthesis suppressed both cellular and humoral 
responses in mice [675]. 
Melatonin is synthesized by human lymphocytes and the evidence that human lymphoid 
cells and mice immune system express MTs (respectively MT1 and RZR/RORα [676] and 
MT1 and MT2) [677] suggests an autocrine and/or paracrine role of melatonin in regulating 
immune responses [419, 678-679] participating in the production of IL-2 and IL-2 receptor 
[419]. Also in other lymphoid organs, such as the thymus and spleen of mice, a significant 
expression of membrane MT1 and MT2 receptors and of nuclear RZR/ROR α, occur [677]. 
Melatonin is an immunomodulator: indeed it stimulates the immune system [678] and 
decreases the acute inflammatory processes. In seasonal animals short day duration, the 
period of maximal melatonin secretion, corresponds to enhancement of the immune 
function [680]; diurnal rhythms of experimental granulomatous inflammation in rodents are 
blocked by pinealectomy and are re-established by nocturnal replacement of melatonin 
[681] and an effect of melatonin as enhancement of mice splenic lymphocyte proliferation 
was measured either during the day or night probably through melatonin receptor MT2 
[682-683].  
Melatonin reduces acute inflammation in rats by inhibiting leukocyte rolling in the 
microvasculature through activation of the MT2 melatonin receptor and leukotriene B4-
induced leukocyte adhesion to endothelial cells through a MT with the pharmacological 
characteristics of the MT3 site [684]. 
One important function of melatonin is mediated through modulating of the 
production/secretion of cytokinese [685]: melatonin enhances human lymphocytes IL-2 
production and monocytes IL-6 production [686] probably mainly through a RZR/ROR α 
receptors dependent mechanism [687]. In human lymphocytes melatonin counteracts the 
inhibitory effect of PG-2 on IL-2 production through its MT1 membrane receptor, but 
nuclear receptor cannot be ruled out [446, 688]. Furthermore, melatonin activates human 
monocytes by inducing cellular cytotoxic agents, such as interleukins and TNF-α [674]. In 
clinical trials carried out in metastatic cancer patients, melatonin and IL-1 were found to 
increase the cluster of differentiation (CD)4/CD8 ratio [680] 
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The activation of lymphocytes and monocytes/macrophages by melatonin is one of the 
principal mechanisms by which melatonin prevents tumor development [689-690]. In many 
studies the co-therapy with IL-2 and melatonin improved the treatment of several tumors, 
such as advanced tumors of the digestive tract [691]. 
In addition to immunostimulation, the melatonin/IL-2 relationship may be particularly 
relevant for immune tolerance. CD4+-CD25+ T regulatory cells represent a critical T cell 
subset that suppresses peripheral autoreactive T cells that escape thymic negative 
selection [692] and melatonin and IL-2 may affect T-cell tolerance by inhibiting 
uncontrolled T cell proliferation and autoimmunity [693]. In fact it has been reported that IL-
6 plays a crucial role in driving the differentiation of T regulatory cells into IL-17 secreting 
T-helper (Th) cells which contribute in Th-1 and autoimmune responses [694]. Thus, in the 
absence of inflammatory stimuli the immunological function of melatonin might be opposite 
to that exerted during inflammation and/or infection.  
Beyond melatonin effects on cytokine secretion, it reveals also an antiproliferative effects 
that is why it can be considered as an oncostatic agent (for review, see refs. [695-696]) 
In animals bearing carcinogen-induced tumors, melatonin treatment reduces tumor 
number and size, increases tumor latency, and lowers tumor incidence. In vitro melatonin 
inhibits tumor cell proliferation through an effect on the cell cycle [697], interaction with sex 
steroid–responsive pathways [696] and/or perhaps in part via its free-radical-scavenging 
potential [698]. Membrane MTs appear to be involved in melatonin oncostatic effect [624, 
699-701]. The concentration of MTs can vary on the basis of the tumor [606, 702]. Other 
mechanisms that involve melatonin in the cell proliferation inhibition are: the inhibitory 
effects on the expression of estrogen-receptor alpha (ERα) and/or inhibition of binding of 
the E2-ER complex to the estrogen responsive element on the DNA, the inhibitory effects 
of melatonin on calmodulin, which can phosphorylate the ERα thus facilitating the binding 
of estrogen and in a phase II study it was shown that the administration of melatonin and 
tamoxifen induced an objective tumor regression compared to tamoxifen alone [703]. 
1.4.4.12 Adrenal gland  
Few studies suggest a link between MT activation and adrenal gland effects. In the 
capuchin monkey MT1 is expressed in the fetal and adult adrenal gland [704-705]. In adult 
adrenal explants and dispersed cells melatonin inhibited the ACTH–induced cortisol 
production, corticotropin releasing hormone–induced cortisol secretion and decreased 
dibutyril cAMP-induced cortisol secretion [704]. 
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Melatonin did not appear to regulate cortisol secretion, although it inhibited ACTH-induced 
increase in 3β hydroxysteroid dehydrogenase mRNA gene expression in fetal adrenal 
gland, suggesting a selective effect of melatonin on the cortisol synthesis pathway [705]. 
Moreover, suppression of melatonin by light treatment in capuchin monkey increased 
blood cortisol in the newborn; this effect was normalised when mothers were treated with 
melatonin [705]. 
1.4.5 Melatonin interactions with the circadian system  
Several studies in humans showed that phase shifts of major physiological parameters, 
such as core temperature, endogenous melatonin onset, and sleep timing occur after 
melatonin administration. Phase delays are observed after morning administration, 
whereas phase advances occur after evening administration [169]. Furthermore, timed 
administration of melatonin facilitates the readjustment after acute phase shifts of the 
light–dark schedule-such as in jet lag and shift work [706]. Finally melatonin 
supplementation results in entrainment of free running circadian rhythms in blind people 
[707]. All of these studies suggest that melatonin, after binding to MT-receptors in the 
SCN, participates in synchronizing circadian rhythms. 
1.4.5.1 Melatonin as zeitgeber in animal mammalian studies 
Physiological concentrations of melatonin significantly phase advanced the peak of 
circadian rhythm of neuronal firing in the SCN brain slice from a melatonin-deficient mouse 
strain, the C57BL/6 [217, 708-709]. Melatonin administered in rat SCN slices at about CT 
10-14 is able to cause 2 or 3 hours of electrical activity peak phase advance, whereas 
treatment at other times had no apparent effect [710]. The effect on the phase shift of SCN 
firing rate is mediated by MT2. 
Another hint that melatonin has chronobiotic properties comes from cellular studies, where 
coculture of chick astrocytes with chick pinealocytes or administration of exogenous 
melatonin cycles could entrain metabolic rhythms of 2-deoxy 14C-glucose (2DG) uptake 
and/or clock gene expression in cultured astrocytes [711].  
Most of the original chronobiotic effects of melatonin were observed in photoperiodic 
seasonal breeders such as hamsters and sheep. Suitably timed treatment over periods of 
weeks was equipotent with artificial changes in daylength in the induction or suppression 
of seasonal events such as reproductive competence. These major physiological changes 
were accompanied by clear changes in the circadian waveform of PRL secretion and in 
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the rhythmic characteristics of LH and FSH secretion, suggesting effects of melatonin on 
central rhythm generator(s). 
In mammals pinealectomy has no a dramatic effect on the locomotor activity, suggesting a 
redundancy of this circadian output [712-713]. However melatonin may play an important 
role in circadian organization: after pinealectomy subtle desynchrony of several 
physiological functions has been described [714] and the reentrainment of rat locomotor 
activity rhythm is modified after a phase-shift of the light/dark (LD) cycle. One week after 
pinealectomy the firing rate rhythm of SCN neurons in vitro is altered, as well as the daily 
rhythm of responsiveness to melatonin [715]. Melatonin is also known to interfere with the 
metabolic activity (glucose utilization and protein synthesis) of the SCN [716] and in the rat 
PT, the MT circadian rhythm density is suppressed after pinealectomy [717]. 
The exogenous administration of melatonin has important effects on mammalian circadian 
rhythms, since melatonin can entrain free-running activity in rodents, if the administration 
is given at the activity onset, although activity arousal per se has a phase advancing effect 
of the locomotor activity [718]. Melatonin administrered in drinking wate, or canulated 
chronic infusion up to 16 hours, was able to entrain Syrian hamsters [719-720]. In 
chronical parfused animals the phase angle difference between the entrained rhythm and 
the zeitgeber (melatonin) depended upon the duration of the infusion period [720]. In 
Syrian hamster the daily infusion for more hours of a lower melatonin dose is more 
effective in entraining than a higher melatonin dose for just one hour; however, the 
majority of animals showed entrainment, whereas another part showed transient 
entrainment and few animals didn’t entrain to melatonin administration [721]. 
When free running animals were entrained with melatonin at different day duration 
(melatonin treatment once a day, with variable day length), a good entrainment was 
obtained only when melatonin administration was given in a stepwise manner; this 
experiment also shows that in rats the limit phase advance value of melatonin entrainment 
is around 35 minutes and entrainment occurred at about CT 12 [722]. 
Infusion of Mel has been reported to entrain hamsters or Arvicanthis ansorgei, a diurnal 
rodent, by inducing phase advances when the free-running period was longer than 24 
hours and phase delays when the period was shorter than 24 hours [723]. All these 
observations strongly suggest that the effects of exogenous melatonin are dependent on 
the period before entrainment. 
In rats, when submitted to a 5 hours phase advance of the dark onset in LD conditions and 
injected daily at the new dark onset, they reentrained with a decreased latency, although 
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some of the animals phase delayed, whereas others phase advanced [718]. Moreover, a 
locomotor activity phase shift effect of melatonin was obtained when the administration 
was at dusk (CT 10) but not at dawn (CT 22–CT2). These results suggest that nocturnally 
released melatonin may functionally desensitize MT2 melatonin receptors in the SCN and 
preclude phase shifts at dawn [724].  
Also in mice melatonin administered at CT 10 phase advanced the onset of circadian 
activity rhythms in vivo and accelerated the rate of re-entrainment of wheel-running activity 
rhythms after an abrupt advance of dark onset, through both MT1 and MT2 function [529, 
557, 709]. 
However, since to obtain entrainment the doses of melatonin have to be high, leading to a 
100 to 1000 fold higher serum levels than the endogenous melatonin at nighttime suggest 
that the chronobiotic effect of Mel appears to be pharmacological rather than physiological 
[716, 719-720]. 
1.4.5.2 Melatonin as zeitgeber in human studies 
Melatonin was shown in several studies to entrain human circadian rhythms. Most of the 
studies were performed to ameliorate the free-running condition of totally blind individuals. 
The majority of these subjects could benefit from melatonin treatment [117, 169, 725-726]. 
The major parameter that is measured in these experiments is the sleep-wake cycle, 
whose entrainment is the major cause of problems of this kind of people. Indeed, 
melatonin could stabilize the sleep-wake cycle, probably through its pro-hypnotic effects. 
Indeed, melatonin is reported to have a role in sleep initiation as the trigger for opening the 
circadian “sleep gate”, acting as a sleep regulator [59, 727-731]. The pro-hypnotic effects 
of melatonin are more evident during daytime, when melatonin levels are low: it lowers 
body temperature and induces fatigue while concomitantly producing a brain activation 
pattern resembling that which occurs during sleep [588-590]. When melatonin (at doses 
ranging from 0.5 mg to 5 mg) was administered to blind people once daily at the normal 
bedtime hour, it entrains free running circadian rhythms of most blind subjects and 
improves nocturnal sleep and daytime alertness [169, 732-733]. 
Melatonin (0.5 mg/day) could entrain DLMO or cortisol rhythms of blind subjects only when 
it was administered in the phase advancing portion of the curve [169, 725], but also when 
other circadian parameters are not entrained, the sleep-wake cycle is more stable [726]. 
In a very well controlled study on sighted subjects in dim light condition for several days 
melatonin entrained the rhythms or at least shortens the CBT period of most of the 
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subjects immediately treated with 5 mg of melatonin whereas if melatonin was 
administered after few days of free-running condition its effects where broader, inducing 
both phase advancing in most subjects, phase delay or entrainment of CBT in few 
subjects, whereas another minor part continued to free-run. These results indicate that 
melatonin was unable to synchronize core temperature consistently, even if in the majority 
of subjects the sleep-wake cycle could be synchronized [261]. 
A reason that may explain the failure of melatonin to entrain may be associated with the 
intrinsic period length of the subjects themselves. A longer period needs a greater daily 
phase shift to maintain entrainment and in some cases this may exceed melatonin phase 
shifting ability (this of course also applies to sighted subjects, suggesting that late 
chronotypes need greater phase shifts than early chronotypes to remain entrained). 
Sleep-wake cycle of aged people becomes more stable after melatonin administration 
when subjects are treated from 0.5 to 2 hours before bedtime [167, 734-738]. 
1.4.5.3 Melatonin PRC  
Melatonin was demonstrated to have chronobiotic properties; indeed it is able to phase 
shift human circadian rhythms. Many PRC experiments attempted to understand the 
correlation between time of melatonin treatment and shift of circadian rhythms [166, 739-
740]. In these experiments melatonin was administered to sighted subjects at the same 
time of the day for few days and DLMO was chosen as circadian marker to determine 
shifting properties of melatonin. In these studies melatonin was demonstrated to phase 
advance sleep, CBT and the endogenous melatonin rhythm when administered at CT of 6 
- 12 hours (with a peak around CT 9), that corresponds to about 6 hours before and 4 
hours after the initial onset of endogenous secretion, while melatonin phase delays the 
clock when administered during CTs around 18-24 hours with a peak around 20 hours 
[166, 739]. Melatonin PRC magnitude and the direction of the shift is different compared to 
the light PRC: light has about the double of the magnitude of shift compared to melatonin 
shift, whith a phase advance maximum around CT 6-12 hours and a phase delay 
maximum around CT 0-6 hours [263, 739]. Moreover, bright light was demonstrated to 
have a type 0 PRC, whereas melatonin has a type 1 PRC. 
Although the PRCs for melatonin have provided to date the template to determine the time 
of melatonin administration needed for an appropriate phase shift (advance or delay), they 
do have some methodological problems. A classic PRC assesses phase shifts following a 
single pulse of the zeitgeber under free-running conditions. The use of repeated doses of 
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melatonin, sighted subjects in entrained conditions, possible light confounds and 
transience following the melatonin dose renders not ideal the current PRCs for melatonin. 
Indeed, in more environmental controlled conditions melatonin oral administration failed to 
demonstrate a phase delay function of a single melatonin administration in the morning 
[724], whereas a single melatonin administration in the evening could lead to a significant 
phase advance [741]. However delays were observed after intravenous infusion of 
physiological night-time melatonin levels [740]. Probably different results are due to 
differences in oral melatonin pharmacokinetics between the individuals. 
A number of studies have addressed the ability of melatonin to hasten circadian adaptation 
to simulated phase shift [742]. Shift workers indeed show a misalignement of internal 
circadian rhythm with the external time, resulting in a multitude of negative symptoms 
including poor performance and reduced alertness during night work and poor daytime 
sleep at home. In environmental isolation, studies using suitably timed melatonin treatment 
(5 mg) and advanced phase shift, rather than delay phase shift, have shown an increase in 
the rate of re-entrainment of temperature, hormonal, and electrolyte rhythms but with 
inconsistent effects on sleep [743-744]. Melatonin is able to improve day-time sleep in shift 
workers, but the alertness during the subsequent night work is unaffected [745-746].  
Many other studies demonstrated the efficacy of melatonin to alleviate eastward perceived 
jet lag (primarily sleep disturbance) [747], but not westward [748], especially if the 
eastward travel is associated o advancing in bedtime starting few days before the shift till 
few days after the shift [749]. 
1.4.5.4 Melatonin and still open questions 
 As mentioned above, melatonin has multiple roles in many organs; however its function in 
the circadian system is still not totally understood. The importance of melatonin in 
chronobiology is documented by many reports in which a decrease in melatonin level is 
associated to pathologies with strong circadian behaviour impairments such as sleep-wake 
cycle disturbances (i.e. Alzheimer’s disease, autism but also ageing). Several blind people 
can benefit from a daily intake of melatonin, to help them to entrain within the 24 hours of 
day length, but melatonin action seems to be “individual” and effectiveness is not granted. 
The reasons for non response as well as the right dosage and application time are still 
under debate. 
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Moreover, the well conserved circadian presence of melatonin in all biological fluids 
suggests that the neurohormone has an important function in periphery, but that fact has 
to be confirmed in further studies. 
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ABSTRACT 
Background: Diurnal behavior in humans is governed by the period length of a circadian 
clock in the suprachiasmatic nuclei of the brain hypothalamus. Nevertheless, the cell 
intrinsic mechanism of this clock is present in most cells of the body. We have shown 
previously that for individuals of extreme chronotype (“larks” and “owls”) clock properties 
measured in human fibroblasts correlated with extreme diurnal behavior. 
Methodology/Principal Findings: In this study, we have measured circadian period in 
human primary fibroblasts taken from normal individuals, and for the first time compared it 
directly with physiological period measured in vivo in the same subjects. Human 
physiological period length was estimated via the secretion pattern of the hormone 
melatonin in two different groups of sighted subjects and one group of totally blind 
subjects, each using different methods. Fibroblast period length was measured via cyclical 
expression of a lentivirally delivered circadian reporter. Within each group a positive linear 
correlation was observed between circadian period length in physiology and in fibroblast 
gene expression. Interestingly, although blind individuals showed on average the same 
fibroblast clock properties as sighted ones, their physiological periods were significantly 
longer. 
Conclusions/Significance: We conclude that the period of human circadian behaviour is 
mostly driven by cellular clock properties in normal individuals, and can be approximated 
by measurement in peripheral cells such as fibroblasts. Based upon differences among 
sighted and blind subjects, we also speculate that period can be modified by prolonged 
unusual conditions such as the total light deprivation of blindness. 
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INTRODUCTION 
Nearly all aspects of human daily behavior and physiology are governed by a master clock 
in the suprachiasmatic nuclei (SCN) of the hypothalamus. This intrinsic oscillator not only 
governs sleep and wake timing, but also rhythms of temperature, the hormones melatonin 
and cortisol, mood and cognitive acuity, cardiac, respiratory, and renal function, and most 
aspects of digestion and detoxification [1]. These rhythms are entrained to 24 hours by the 
environmental light-dark cycle primarily via a subset of photosensitive retinal ganglion cells 
that project directly to the SCN [2]. Using multiple hormonal and neuronal signals, the SCN 
“master” clock in turn entrains peripheral clocks of similar molecular mechanism present in 
most cells of the body [3]. 
In humans and other organisms, the timing of 24-hour behavior is governed by the period 
length of the circadian oscillator. This period is approximately, but not exactly, 24 hours 
long (“circa diem”), and has a reported population range of 23.47 – 24.64 in laboratory 
conditions [4,5,6,7,8,9,10,11] Short periods lead to behavior occurring at an earlier clock 
time in some individuals (so-called “larks”), and long periods to later timing of behaviour in 
others (“owls”) [9,12,13,14], at least in young adults. Mutations in clock genes affect period 
length, and can lead to circadian rhythm sleep disorders such as Advanced Sleep Phase 
Syndrome (ASPS) [15]. Measurement of circadian period length is therefore a useful step 
in assessing circadian clock function, either experimentally or clinically. 
Determination of the period of circadian behavior in sighted subjects requires prolonged 
subject observation under controlled-light laboratory conditions. In humans, these studies 
are expensive and labor-intensive. In one protocol, subjects are kept for multiple days 
under ‘constant routine’ conditions consisting of sustained wakefulness or scheduled sleep 
episodes under continuous dim light with constant posture and frequent isocaloric meals 
[16,17]. Alternatively, circadian period can be measured under constant dim light for 
several weeks [18]. Finally, it can be measured under ‘forced desynchrony’ (FD) conditions 
where the sleep-wake cycle is scheduled to day-lengths that are outside the range of 
entrainment for the circadian pacemaker, conditions which force the clock to exhibit its 
endogenous period. Since it is not ethically possible to keep human subjects in constant 
routine protocols for prolonged periods, FD protocols are thought to offer greater precision. 
[4]. A further special case employs totally blind individuals, whose circadian pacemaker 
cannot be entrained by the environmental light-dark cycle. Although under certain 
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circumstances these individuals can become entrained to the 24-hour day via nonphotic 
cues such as exercise, food, and activity [19,20], in other cases they exhibit ‘non-24-hour’ 
rhythms in melatonin, cortisol or temperature under both laboratory and real-world 
conditions that provide a direct estimate of their physiological period [21]. 
Given the intensive experimental control required to assess human physiological period, 
our laboratories have taken advantage of the duplication of the molecular mechanism of 
the circadian clock in most mammalian tissues to measure period length in human 
fibroblasts. To do this, we infect cells with a lentiviral reporter containing the luciferase 
gene under control of a circadian promoter. Period length in infected cells can then be 
measured via real-time bioluminescence [22]. In mice with mutations in circadian clock 
genes, a qualitative correlation has been observed between behavioral period measured 
by wheel running activity and fibroblast period measured by lentiviral reporter; and in 
humans, extreme early-type individuals had on average shorter fibroblast periods than 
extreme late-types [13]. Although these correlations among mutant animals or extreme 
chronotypes are promising, it remains unclear how well human period length is predicted 
from measurements in peripheral tissues in ordinary individuals, and whether these values 
correlate with sleep-wake timing in vivo. 
In this report, we have for the first time directly compared estimates of human 
physiological circadian period with the period measured in fibroblasts from the same 
subjects. We used three different subject groups whose physiological period was 
estimated via different protocols, and which showed different population averages for 
physiological period. In each trial, the correlations that we observed suggested that this 
easy cellular method could be used as a biomarker for human clock properties. 
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RESULTS 
Human fibroblast circadian period in vitro correlates with estimates of human 
physiological period measured in vivo in normal individuals. 
As described in Methods, we recruited subjects that had participated previously in one of 
five different studies of physiological period in three countries (Basel, Switzerland; 
Novosibirsk, Russia; and Guildford, United Kingdom). Four protocols estimated 
physiological period of sighted subjects under controlled laboratory conditions designed to 
minimize the effects of environmental light, exercise, food, and sleep upon the workings of 
the circadian oscillator. Physiological period was determined by the timing of melatonin, a 
hormone produced at night in circadian fashion and measurable in human saliva. A fifth 
study focused upon totally blind individuals. For such people, freerunning physiological 
period has been shown previously to remain independent of the solar day even in a home 
environment under some circumstances [21]. Hence, subject period could be measured at 
home over several weeks via the periodicity of the melatonin metabolite 6-
sulfatoxymelatonin excreted in urine. 
From each subject, two skin biopsies were taken and fibroblasts were cultivated from 
them. The circadian period length of these fibroblasts was then measured via transduction 
of a lentiviral circadian reporter and subsequent long-term bioluminescent monitoring. 
Figure 1B shows a portion of data from fibroblasts of the same subject whose 
physiological period is shown in Figure 1A. 
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Figure 1. Determination of circadian period in vivo and in vitro. 
A. In vivo period length was obtained from salivary melatonin content profiles of normal sighted subjects 
under a constant routine protocol for three consecutive cycles. Data from one representative subject 
(Start25) are shown. Open circles, melatonin measurement values. B. From the same subject, fibroblast 
cultures were obtained from two separate biopsies and infected with a lentiviral bioluminescent circadian 
reporter. After synchronization with dexamethasone, circadian oscillations in bioluminescence were recorded 
from eight measures over five days. Three cycles of this oscillation are shown aligned with the physiological 
data of part A. Period calculations for both panels were conducted by cosinor fitting and the best-fit curve is 
shown in color, along with its period length and goodness of fit R2. 
For all subjects, estimates of physiological in vivo period were compared to fibroblast 
period measured via transduction of a lentiviral circadian reporter and subsequent 
longterm bioluminescent monitoring. The results from 9 subjects measured from two 
studies in Basel are shown in Figure 2A. Results from a further 11 subjects participating in 
two studies in Novosibirsk are shown in Figure 2B. Finally, results from 8 totally blind 
individuals measured in Guildford are shown in Figure 2C. All data are graphed together in 
Figure 2D. In all groups, positive correlations were observed between fibroblast period and 
physiological period measured in the same subjects, and Bland-Altman statistics among all 
subjects show an absence of systematic error between measurements in vitro and in vivo 
(Supplementary Figure 1). Table 1 shows the specific values and correlation coefficients 
obtained from each subject population. 
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Figure 2. Relationship between physiological period length and fibroblast period length. 
A. In vitro period length was obtained from skin fibroblasts from nine sighted human subjects of normal 
chronotype and compared to physiological period in the same individuals measured in two constant routine 
studies (Basel Start and Likri). The solid line shows the best-fit linear regression (1st polynomial order) 
represented by the data, and the dashed lines represent 95% confidence intervals to the indicated 
regression line, with goodness-of-fit R2 shown at lower right. The overall p-value (vs. null-hypothesis slope of 
0) is shown at upper-left. For this panel and also panels B and C, identical statistical measures are depicted. 
In addition, the range and average for each group of subjects are shown in Table 1, and data for individual 
subjects are listed in Supplementary Table 1. B. The same comparison was performed for 11 sighted 
subjects whose physiological period was measured in controlled laboratory conditions in two studies 
(Novosibirsk). C. A further comparison was performed for 8 totally blind subjects whose physiological period 
was measured at home (Guildford). Fibroblasts from the asterisked subject showed abnormal clock 
properties in vitro at different temperatures and were excluded from statistical analysis. D. The results of all 
five studies are graphed on the same axes: Yellow, Basel; Red, Novosibirsk; Blue, Guildford. 
 
Table 1. Period lengths in vivo and from fibroblasts. 
 
Subject location  N  τ in vivo  τ in vitro  r2 
 
Basel     9   24.00 ±0.33  24.71 ±0.38   0.46 
(23.60-24.50)  (24.15-25.29) 
 
Novosibirsk   11   24.07 ±0.20   24.77 ±0.42   0.68 
(23.71-24.31)  (24.10-25.45) 
 
Guildford    8   24.52 ±0.27  24.46 ±0.48   0.66 
(24.13-24.92) (23.80-25.23) 
Table 1. Period lengths obtained from subjects by physiological measurements and from fibroblast 
molecular analyses. 
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Blind individuals showed longer physiological period but equivalent fibroblast 
period. 
Average physiological period lengths were significantly longer for the blind subjects than 
for the sighted subjects (Figure 3A), as reported previously [4,21]. Surprisingly, average 
fibroblast period was the same for these three populations when measured under identical 
conditions (Figure 3B). In other words, cellular fibroblast periods were similar among the 
groups of subjects even though physiological periods varied. Therefore, fibroblast 
measurements succeeded in capturing inter-individual differences in period among 
members of each group (whether they were blind or sighted), but were insensitive to 
apparent differences between blind and sighted individuals. 
Figure 3. Relationship 
between population 
averages of human 
physiological period 
length and fibroblast 
period length. 
A. The average in vivo 
period lengths obtained 
from both protocols 
with sighted individuals 
were significantly 
different from that of 
blind subjects (p<0.01, 
0.05). B. Nevertheless, the fibroblast-derived values were not significantly different among all three 
populations. (1-way Anova). Data are presented as a standard boxplot, with bars showing the smallest and 
largest observed values and box dimensions and midline reflecting lower quartile (Q1), median (Q2) and 
upper quartile (Q3) values. 
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DISCUSSION 
The fundamental mechanism of the mammalian circadian clock is cell-autonomous, and is 
based upon feedback loops of transcription and translation that use identical components 
in most cells of the body [23]. In fact, long-term recordings suggest that the intrinsic clocks 
in peripheral cells like fibroblasts are probably as robust as those in the “master clock” of 
the brain SCN [24]. Probably because of these mechanistic similarities, our laboratory has 
been able to show previously that clock properties of fibroblasts taken from subjects of 
extreme chronotype (i.e. “larks” and “owls”) generally correlate with the results of 
questionnaires about subject daily behavior. Many of these extreme subjects, however, 
showed normal fibroblast period length. We ascribed their behavior to alterations in other 
clock properties like amplitude [13]. 
Thus, it remains unclear to what degree the genetically encoded period length of the 
human circadian clock, as reflected in peripheral tissues like fibroblasts, controls daily 
behavior in normal individuals whose period lengths vary relatively little. Herein, we have 
rigorously examined this matter by comparing directly circadian period length measured 
from human fibroblasts and that estimated physiologically in the same individuals, under 
different experimental conditions. In the five studies from three laboratories that we have 
analyzed, we have observed good correlations between period lengths of the circadian 
oscillator in vivo and in vitro, even among individuals whose clock properties vary very little 
(Figure 2). 
In vivo, circadian period length under free-running conditions has been shown previously 
to correlate well with circadian phase under entrained conditions. This circadian phase is 
best reflected in outputs of the circadian oscillator, such as sleep-wake timing [9,14]. In 
retrospect, we were interested to know to what extent fibroblast period could predict sleep-
wake timing, but our studies were not designed to test this hypothesis and in most cases 
the rigorous routines of our subjects also controlled sleep-wake. Nevertheless, for the six 
subjects participating in a constant routine protocol in Basel, physiological circadian phase 
was measured on the first night of in-patient study via dim-light melatonin onset, and 
spontaneous wakeup time the next day by EEG. By comparing these two times, we could 
estimate a “phase angle” of sleep timing with respect to melatonin, which from previous 
studies should correlate with period [14]. In our case, we could directly compare this phase 
angle with subject circadian period length measured both in vitro and in vivo. A trend was 
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observed between sleep timing and circadian period length in fibroblasts (Figure 4A) and 
in vivo (Figure 4B), but limited subject number prevented it from reaching significance. A 
larger study would be needed to answer this question more rigorously. 
Figure 4. Circadian period and wake 
timing. 
A. Period length measured in fibroblasts is 
plotted against the circadian phase angle 
of sleep, calculated as the difference 
between the measured time of dim-light 
melatonin onset on the first day of the 
protocol and the time of subject 
spontaneous waking that morning. This 
value could only be determined in one of 
the five studies presented (Basel constant 
routine). Linear regression and statistical 
analyses were as in Figure 2. B. Period 
length in vivo is plotted versus the same 
sleep phase angle. 
 
Approximation of human circadian period by cellular assays could present important 
advantages. The measurement of human circadian period in vivo, either via constant 
routine or forced desynchrony protocols, is expensive and labor-intensive. An in-vitro 
measure of human circadian period, if validated in vivo, could provide an attractive lower-
budget alternative. Nevertheless, it should be noted that fibroblast period measures are 
not a direct proxy for measures of physiological period: for some subjects, considerable 
differences between the two were observed, and physiological period differences between 
sighted and blind subjects were absent entirely in fibroblasts.  
While it is too soon to be able to draw firm conclusions, it is possible that fibroblast period 
might prove more useful than physiological period in certain applications. For example, 
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determination of period length in fibroblasts under carefully controlled conditions might 
permit separation of genetic effects upon basic clock mechanism from environmental 
influences present in more complex physiological measurements. Such influences are 
vividly illustrated by the measurement of sighted and blind subjects included in the present 
paper. In ours and other published studies of sighted subjects, various protocols have all 
given period values close to 24 hours [4,6], whereas period length measured in blind 
subjects at home are longer, and average 24.5 hours [21] (See also Figure 3A,B). This 
discrepancy is unlikely to result from differences in methodology: recent data illustrates 
that period assessments in field studies of blind individuals are comparable to period 
assessment under forced desynchrony in the same subjects (Hull et al., in press). In 
reverse, two groups of sighted subjects in our study were measured in near total darkness 
(<0.2lux, Novosibirsk), and showed the same shorter period of the sighted subjects that we 
estimated with constant routine (Basel), or that others have estimated in forced-
desynchrony protocols [4]. 
If the difference is not due to methodology, a basic question arises: are the shorter periods 
of sighted subjects “aftereffects” of entrainment to light, or is there a fundamental genetic 
difference between these groups? Our measurements suggest that it is unlikely that this 
difference is genetic: average fibroblast period was the same in all groups that we 
investigated, blind and sighted (Figure 3), but still reflected accurately genetic differences 
causing short and long physiological periods within each group. It is possible, of course, 
that fibroblast clocks are sensitive to some types of genetic variation but insensitive to 
others. Nevertheless, in our study we favor the hypothesis that circadian properties 
between blind and sighted groups differed for physiological reasons rather than genetic 
ones: for example, human physiological period length might be modified by prior light 
history and/or retinal function [25]. In support of this idea, individuals recently entrained to 
a simulated Martian day length showed a longer period length afterward [26]. 
It should be mentioned that the period of fibroblasts is not invariant, either: their circadian 
clocks are temperature-overcompensated [27,28]. Thus, whereas normal biochemical 
reactions slow as temperature decreases, circadian clocks increase in speed. As a result, 
period length measured from fibroblast cells in vitro varies with the temperature at which 
the measurement is conducted. Not surprisingly, the best correlations with period length in 
vivo are seen at physiological temperatures. In addition, measurements conducted at 
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different temperatures are correlated, preserving inter-subject differences (Suppl. Fig. 2A). 
Interesting exceptions exist, however. For example, one subject showed almost perfect 
temperature compensation at multiple temperatures, in stark contrast to the temperature 
overcompensation seen in all other subjects (Suppl. Figure 2B). This subject also showed 
a significant difference between period in vivo and period in vitro (asterisked subject in 
Figure 2C). Although the meaning of this difference is uncertain, we suggest that inter-
individual genetic variations also exist in the (thus far unknown) loci implicated in 
temperature compensation by the human circadian oscillator. 
In the extreme case, our experiments suggest that a measurement of “true” circadian 
period emanating from the suprachiasmatic nucleus may be unrealistic. Both in vivo and in 
vitro, the observed period appears to be altered by environmental factors. Fibroblast 
period can be altered by temperature, and physiological period might be sensitive to prior 
light history and/or retinal function. Nevertheless, measurement of fibroblast period at 
precise physiological temperatures offers a reasonable approximation of physiological 
period determined by more rigorous measures. Both values, in spite of their variance, 
show strong inter-individual differences independent of environment or method, and will 
likely provide exciting clues to understand the genetic basis of human daily behavior and 
its influence upon health. 
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METHODS 
Ethical Permission. The study protocol, screening questionnaires, and consent forms 
were approved by the relevant ethical committee (the Ethical Committee of Basel, 
Switzerland; the Ethical committee of the Institute of Internal Medicine, SB RAMS, 
Novosibirsk, Russia; the University of Surrey Advisory Committee on Ethics; and the 
Moorfields Eye Hospital Ethics Committee) and conform to the Declaration of Helsinki. 
Informed consent was obtained from all subjects. 
Subject selection. Subjects for this study were individuals who have previously or 
concurrently participated in chronobiological studies of the authors in Basel, Novosibirsk, 
or Guildford, and were additionally recruited to donate skin biopsies for this study. In two 
studies (Basel, Novosibirsk), extreme chronotypes were specifically excluded. Where 
noted, physiological measurements have been reported previously in other contexts. In 
brief, study participants consisted of nine sighted subjects (6 men, 3 women, mean age ± 
S.D. 48.3 ± 21.9 years) recruited in Basel, eleven sighted subjects (2 men, 9 women, 
mean age ± S.D. 25.5 ± 7.8 years ) recruited in Novosibirsk, and eight subjects with no 
perception of light (7 men, 1 woman, mean age ± S.D. 54.6 ± 7.4 years) recruited in 
Guildford. Further information is cited in Supplementary Methods and in a subject 
information table included with it, Supplementary Table 1. 
Circadian period determination in vivo. In order to ensure that the correlations 
presented herein were not dependent upon a particular method of determining circadian 
period, each subject group described above participated in a different protocol for the 
measurement of physiological period in vivo. Detailed descriptions of each protocol are 
listed in Supplementary Methods. In brief, sighted subjects (Basel and Novosibirsk subject 
groups) were required to adhere to a regular sleep-wake schedule for 5-14 days prior to 
admission to the laboratory. Subsequently, subjects were maintained under various sets of 
“constant” conditions designed to eliminate environmental influences upon the circadian 
oscillator: a 60-hour multiple nap protocol or a 40-hour sleep deprivation protocol (Basel) 
under constant dimlight (<8 lux) conditions with constrained posture and frequent 
scheduled meals; or a 4 to 9-day protocol under near-total darkness (<0.1 or 0.2 lux) with 
normal scheduled sleep episodes (Novosibirsk). Saliva samples were collected at intervals 
of 0.3-3 hours and analysed for melatonin content through a direct double-antibody 
radioimmunoassay (Bühlmann Laboratories, Schönenbuch, Switzerland). Blind subjects 
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(all with no perception of light, Guildford), were studied in their own homes for 3-5 
consecutive weeks. No attempt was made to alter the lifestyles of the individuals during 
the study. For such people, free-running physiological period has been shown previously 
to remain independent of the solar day even in a home environment [21]. For 48 hours 
each week, subjects collected sequential ~4-hourly urine samples during the day plus an 
~8-hour overnight sample. Urinary 6-sulphatoxymelatonin (aMT6s) concentrations were 
measured as described previously [29]. Period lengths were determined by the timing of 
intervals between melatonin rise, either by regression analysis in longer protocols 
(Novosibirsk, Guildford), or by cosinor analysis for shorter ones (Basel). 
Measurement of fibroblast circadian period length. Subjects from each of the studies 
presented above were recontacted to participate in the present investigation by donating 
skin biopsies. The time elapsed between measurements in vivo and fibroblast donation is 
indicated in Supplementary Table 1. Detailed methods are presented in Supplementary 
Methods. Briefly, two cylindrical 2-mm diameter cutaneous biopsies were taken from the 
buttocks or upper arms of each subject. Fibroblasts were isolated from biopsies and 
infected using Bmal1::luciferase lentivirus as described previously [22]. Five days or more 
after human fibroblast infection, circadian rhythms were synchronised by 100nM 
dexamethasone (Sigma), and light output was measured (3 measurements per biopsy; 
total of 6 measurements per subject) in the presence of 0.1nM luciferin in specially built 
light-tight atmosphere-controlled boxes for at least 5 days. Period determination was 
accomplished by cosinor analysis of data between the second and the fifth day of 
measurement. Values are presented as mean plus or minus standard error from four to 
eight measurements. 
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Supplementary information 
Supplementary methods 
Subject selection and ethical permission. The study protocol, screening questionnaires, 
and consent forms were approved by the relevant ethical committee (the Ethical 
Committee of Basel, Switzerland; the Ethical committee of the Institute of Internal 
Medicine, SB RAMS, Novosibirsk, Russia; the University of Surrey Advisory Committee on 
Ethics; and the Moorfields Eye Hospital Ethics Committee) and conform to the Declaration 
of Helsinki. Informed consent was obtained from all subjects. Subjects are described in 
detail in Supplementary Table 1. At the time of in-vivo period measurement, all subjects 
had not taken melatonin or prescribed medications. At the time of skin biopsy, some blind 
subjects were currently taking melatonin (see Supplementary Table 1). With the exception 
of one subject (Basel) for whom stable in-vitro measurements could not be obtained 
(Subject Start05), all biopsied subjects were included in our analysis. 
Circadian period determination in sighted subjects (Basel). One week prior to the 
study (baseline week), participants were requested to abstain from excessive caffeine and 
alcohol consumption (one caffeine-containing beverage per day at most and less than five 
alcoholic beverages per week). They were instructed to keep a regular sleep-wake 
schedule during the baseline week at home (bedtimes and wake times within ± 30 minutes 
of a self-selected target time between 22:00 h and 2:00 h) prior to admission to the 
laboratory. Compliance was checked by sleep logs and ambulatory activity measurements 
(wrist activity monitor, Cambridge Neurotechnology Ltd®, UK). Timing of the sleep-wake 
schedule during the protocol was adjusted to individual average habitual bedtimes. For 
each participant, habitual bedtime was calculated by centering the approximately 8-hour 
sleep episodes during the baseline week at their midpoint. The inpatient part of the 
protocol comprised two baseline 8-hour sleep episodes in darkness in the laboratory, 
followed by a 40-h sleep deprivation (Start study) or a 60-h multiple nap protocol with the 
interplay of 16 alternating sleep:wake cycles of 75:150 minutes duration (Likri study). 
Participants remained under constant conditions (constant dim light levels <8 lux during 
scheduled wakefulness, semi-recumbent posture in bed, food and liquid intake at regular 
intervals, no access to time cues) [1,2]. During scheduled sleep episodes a 45 degree shift 
to a supine posture was allowed, and the lights were turned off (0 lux). Saliva samples 
were collected every 20 minutes and analysed for melatonin content through a direct 
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double-antibody radioimmunoassay (validated by gas chromatography–mass 
spectroscopy with an analytical least detectable dose of 0.65 pm/ml; Bühlmann 
Laboratories, Schönenbuch, Switzerland). The in vivo period length of the sighted subjects 
was determined via the temporal profile of melatonin content in saliva, using CosinorTM 
software (SEPTMR) to fit a hypothetical sinusoidal wave to the collected melatonin data. 
For the Start study, the temporal profile included the nights before, during, and after the 
constant routine; for the Likri study, the temporal profiles of the nights before and during 
the nap protocol were used. Data for one representative subject is shown in Figure 1A. 
Suppl. Figure. Protocol for measurement of physiological period in sighted subjects 
(Basel). 
Protocol for two different groups of subjects 
maintained in either a constant routine 
(START) or nap protocol (LIKRI). 
Crosshatched areas are scheduled sleep 
episodes; stippled areas reflect recumbent 
awake or nap periods. 
 
Circadian period determination in sighted subjects (Novosibirsk). For the current 
paper, subjects were recruited that participated in two chronobiological studies during 
which they adhered to 24-hour days with fixed sleep times in near darkness. The protocols 
of these studies have been described elsewhere [3, 4]. Generally, the participants were 
required to go to bed at 23:00-23:30 for 5-14 days prior to admission to the isolation 
facility. Compliance was checked by wrist actimetry (GähwilerTM, Zurich) and/or sleep 
logs. The laboratory parts included 24-h days: 9 days under <0.2 lux light ("Sleep-
advance" study, #1), or 4 days under <0.1 lux red light ("ERG in DD" study, #2). The saliva 
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for melatonin assay was collected every 0.5–3 hours on days 2, 5, and 9 during a constant 
routine protocol in study #1, and on days 1 and 4 in study #2. In the latter study, subjects 
were additionally awakened to collect night saliva samples three times during both initial 
and final days of measurements. (These protocols are illustrated in the Supplementary 
Figure below.) The melatonin content was assayed using the same kits and methods as 
described for Basel above. All samples from an individual were measured in a single 
assay. Circadian period in study #1 was obtained by linear regression across times of 
melatonin evening rise at each of the three days measured. Evening rise was defined as 
time when melatonin concentration attained 3-pg/ml threshold (by linear interpolation 
between two 0.5-h-apart values). In the second study, the comparison was made between 
two times of evening rise (on days 1 and 4) that was computed as the time of the ¼ 
amplitude crossing after fitting the 24 h melatonin curves with a skewed bimodal baseline 
cosine function [5]. 
Suppl. Figure. Protocol for measurement of physiological period in sighted subjects 
(Novosibirsk). Protocol for two different groups of subjects from Novosibirsk maintained in 
near-complete darkness (<0.2 lux). Crosshatched areas are scheduled sleep episodes; 
stippled areas reflect recumbent awake periods. 
1
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23:30 8:00
(before lab: target bedtime 23:30 ± 10’
for 14 days at home)
23:00 8:00
12:00
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at home)
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<30 lx
<0.2 lx
<8 lx
 
Circadian period determination in blind subjects (Guildford). The protocols used here 
to determine physiological period length of blind subjects have been reported elsewhere 
[6,7,8,9]. Briefly, subjects with no conscious perception of light (NPL) were studied in their 
own homes for 3-5 consecutive weeks. One had both eyes intact, one had one eye and 6 
had no eyes (see Supplementary Table 1). All but one of the blind subjects (#S33) 
2. THE PHYSIOLOGICAL PERIOD LENGTH OF THE HUMAN CIRCADIAN CLOCK IN VIVO IS 
DIRECTLY PROPORTIONAL TO PERIOD IN HUMAN FIBROBLASTS. 
  134  
complained of a sleep disorder as assessed by the Pittsburgh Sleep Quality Index (PSQI; 
≥ 5) [10]. No attempt was made to alter the lifestyles of the individuals during the study. 
For 48 hours each week, subjects collected sequential ~4-hourly urine samples during the 
day plus an ~8-hour overnight sample. After each collection period, the subjects measured 
and recorded the volume or weight of the sample and the time of the urine collection 
period. Urinary 6-sulphatoxymelatonin (aMT6s) concentrations were measured by 
radioimmunoassay using the method of Arendt et al., [11] adapted by Aldhous and Arendt 
[12]. Antiserum was supplied by Stockgrand Ltd., University of Surrey. Urinary data (ng/h) 
from each 48-hour assessment were subjected to cosinor analysis (software provided by 
Dr. D. S. Minors, University of Manchester, UK) to determine the acrophase, or fitted peak 
time, of the aMT6s rhythm. The acrophase times were subjected to regression analysis to 
determine the period (τ = 24 h + slope) [6].  
Measurement of fibroblast circadian period length. Subjects from each of the studies 
presented above were recontacted to participate in the present investigation by donating 
skin biopsies as described below. The time elapsed between measurements in vivo and 
fibroblast donation is indicated in Supplementary Table 1. During measurements of 
physiological period length, no subject used medications known to alter circadian phase. 
At the time of skin biopsy, four blind subjects were concurrently taking melatonin (2-6 
mg/day in the evening), one blind participant had recently taken melatonin, and 3 blind 
subjects reported not taking melatonin. To ensure that this medication did not interfere with 
measurements in vitro, cells from all studies were identically cultivated for at least six 
weeks prior to measurement, using medium that did not contain melatonin.  
Two cylindrical 2-mm diameter cutaneous biopsies were taken from the buttocks or upper 
arms of each subject. The time of day at which biopsies were taken varied from 10:00 to 
14:00, but we have shown previously that time of biopsy does not affect measured period 
length. [13]. Immediately after removal, biopsies were placed in Dulbecco's Modified 
Eagle's Medium high glucose (DMEM)/1% Penicillin-Streptomycin solution 
(Sigma)/1%Glutamax (Sigma), hereafter designated as DMEMc, supplemented with 50% 
Foetal Bovine Serum (FBS) (Sigma), and shipped on ice to Basel, where cell isolations 
were conducted. Fibroblasts were isolated from biopsies by digestion of tissue for 4 hours 
in DMEMc supplemented with 20% Foetal Bovine Serum (FBS) (Sigma) and 87.5 ng/ml 
liberase (Roche). After digestion, cells were cultured in DMEMc/20%FBS. Confluent cells 
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were infected using Bmal1::luciferase lentivirus as described previously [13]. Five days or 
more after human fibroblast infection circadian rhythms were synchronized by 100nM 
dexamethasone (Sigma) in DMEMc + 20% FBS [14]. DMEMc without phenol red was 
supplemented with 0.1 mM luciferin (Molecular Probes, USA) and light output was 
measured (3 measurements per biopsy; total of 6 measurements per subject) in specially 
built light-tight atmosphere-controlled boxes for at least 5 days. For each luciferase 
measurement, the period of oscillation was calculated by analyzing the period between the 
second and the fifth day of measurement, fitting hypothetical sine curves with period and 
phase as free variables using the software Lumicycle Analysis (Actimetrics, USA). The 
period of the sine wave with the best least-squares fit to the data was assumed to be the 
true period of oscillation. Values are presented as mean plus or minus standard error from 
four to eight measurements. A portion of the measures from a representative subject is 
shown in Figure 1B (the same subject whose in-vivo data are plotted in Figure 1A). 
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Supplementary tables 
Supplementary Table 1 – Subject Information  
 
Study 
acronym 
Dura-
tion 
Subject 
code 
Sex Age at 
biopsy  
Year of 
study 
Year of 
biopsy 
Tau in 
vivo 
Tau in 
vitro 
Eyes 
intact 
Basel       (cosinor)   
Start 21 m 63 2002 2006 24.45 25.29 2 
Start 23 f 73 2002 2006 24.13 25.01 2 
Start 24 m 64 2002 2006 23.80 23.99 2 
Start 25 m 66 2003 2006 24.10 25.18 2 
Start 31 f 68 2003 2006 24.50 25.26 2 
Start 
(Cajochen 
et al., 
2001; 
Munch et 
al., 2005) Start 34 f 63 2003 2006 23.90 25.04 2 
Likri03 m 21 2007 2007 23.90 24.38 2 
Likri04 m 21 2007 2007 23.60 24.65 2 Likri 
 
 
 
 
 
3 
days 
Likri06 m 21 2007 2008 24.10 24.58 2 
Novosibir
sk       
(regres-
sion)   
cC m 29 2001 2009 24.08 24.55 2 
Dd f 32 2001 2009 23.96 24.75 2 
Ee f 31 2001 2009 24.23 24.60 2 
Gg m 34 2001 2009 24.00 24.63 2 
Ll f 42 2001 2009 23.98 24.70 2 
Sleep-adv 
(Danilenko 
et al., 
2003) 
8 days 
Mm f 29 2001 2009 23.77 23.90 2 
2b f 50 2004 2009 24.12 25.00 2 
4d f 22 2005 2009 24.17 24.90 2 
5e f 22 2005 2009 24.31 25.45 2 
6f f 22 2005 2009 23.71 24.10 2 
ERG in DD 
(Danilenko 
et al., 
2009) 
4 days 
7g f 23 2005 2009 23.82 23.90 2 
Guildford       (regres-
sion)   
 
S23 m 53 1995 2007 24.39 23.80 0 
(MT) S43 m 47 1995 2007 24.13 24.13 0 
(MT) S17 m 57 1994 2007 24.27 24.10 2 
 
S33 m 67 1995 2007 24.6 24.61 0 
 
S48 f 66 1995 2007 24.41 24.71 0 
(MT) S45 m 54 1995 2007 24.82 24.17 0 
(MT) S76 m 50 2000 2007 24.6 24.91 1 
(MT) 
3-5 
weeks 
S62 m 49 1996 2007 24.78 25.23  0 
 
MT – melatonin intake at time of biopsy 
Supplementary Table 1 – Subject Information. 
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Supplementary figures 
Suppl. Figure 1. Bland-Altman 
statistics for period 
measurements. 
For each subject, average period 
length (in vivo and in vitro) is plotted 
against the difference between the 
two measurements, expressed in 
standard deviations from the mean. 
 
 
Suppl. Figure 2. Comparison of 
fibroblast period length measured 
at 36.5 degrees C and at 37.0 
degrees C incubator temperature. 
A. Period length was measured from 
skin fibroblasts of blind and sighted 
subjects (from Guildford and 
Novosibirsk) at two different 
incubator temperatures, and plotted 
in comparison. Most subjects 
showed a similar augmentation in 
period at the higher temperature 
(1.1 ± 0.3 hours). B. Extreme 
temperature compensation 
properties in one subject – this 
individual (S45) is asterisked in 
Figure 2. Fibroblast period lengths 
at 36.5, 37.0, and 37.5 degrees C 
are shown for this subject (left) 
versus another representative 
subject (S43) (right). 
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Abstract: 
Human ageing is accompanied by dramatic changes in daily sleep-wake behaviour: 
activity shifts to an earlier phase, and the consolidation of sleep and wake is 
disturbedAlthough this daily circadian rhythm is brain-controlled, its mechanism is encoded 
by cell-autonomous circadian clocks functioning in nearly every cell of the body. Therefore, 
to better understand molecular mechanisms by which human ageing affects circadian 
clocks, we characterised the clock properties of skin fibroblasts from young and older 
subjects. Fibroblast period length, amplitude and phase were identical in the two groups, 
but incubation of these cells with human serum from older donors shortened period length 
and advanced the phase of cellular circadian rhythms compared to treatment with serum 
from young subjects. Further experiments demonstrated that this effect is likely to be due 
to a thermolabile factor present in serum of older individuals. Our results suggest that the 
molecular machinery of peripheral circadian clocks does not change with age, but some 
age-related circadian changes observed in vivo might be caused by circulating factors. 
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Introduction 
Circadian clocks possess an endogenous periodicity of about 24 hours and play a key role 
in physiological adaptation to the solar day for all living organisms -- from cyanobacteria 
and fungi (1) to insects (2) and mammals (3). They influence nearly all aspects of 
physiology and behaviour, including sleep-wake cycles, body temperature, and the 
function of many organs (3). During normal ageing, clock function is attenuated, with 
consequences both for health and quality of life. Older individuals have an earlier phase of 
everyday activity compared to the young (4). Not only is the consolidation of sleep and 
wake dramatically reduced (5-6), but overall circadian amplitude of hormones and body 
temperature is lower (7-8), and many ageing-associated sleep-wake pathologies have 
been reported (9-11). As a result, one in five healthy older individuals reports taking sleep 
medications regularly (9). In cases of pathological ageing, chronobiological disturbance is 
even more acute: Huntington’s Disease, Parkinson’s Disease, and Alzheimer’s Disease 
are all associated with profound alterations in sleeping patterns (10-12). These effects of 
ageing on circadian rhythms - diminished circadian amplitude, shorter circadian period, 
and desynchronisation of rhythms in peripheral organs - have been observed widely in 
several species of mammals (7, 13-14). 
Mammalian circadian clocks are organized in a hierarchical fashion: the suprachiasmatic 
nuclei (SCN) of the anterior hypothalamus serve as a master clock, receiving light signals 
from the external environment via the retina and retino-hypothalamic tract, and elaborating 
these stimuli into signals that are sent all over the body to synchronise clocks in peripheral 
organs (3). Interestingly, the clock mechanism itself is cell-autonomous, and involves 
interlocked feedback loops of transcription and translation. These loops are encoded by 
dedicated clock genes: for example, in one loop the heterodimer formed by the two 
transcription factors CLOCK and BMAL1 binds cis-acting E-box sequences present in per 
and cry gene promoters to activate their transcription. Subsequently, PER and CRY 
protein complexes inhibit the activity of CLOCK-BMAL1. As a consequence, cry and per 
mRNAs decrease in concentration, and a new cycle can start (15). 
At a cellular level, both the SCN and peripheral oscillators share the same molecular 
mechanism (16). Thus, cellular reporters composed of clock gene promoters driving 
expression of luciferase or green fluorescent protein have proven to be very useful tools 
for the study of circadian rhythms in the SCN as well as in peripheral oscillators (17-18). 
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Using such reporters, we have shown previously that many differences in human circadian 
behaviour can also be seen at a molecular level in peripheral cells. For example, the 
cellular clocks of early chronotypes (i.e. “larks”) have shorter circadian periods than those 
of later chronotypes (“owls”) (19), and circadian period length in vitro is proportional to 
physiological period in vivo (Pagani et al., PLoS ONE, accepted). Under entrained 
conditions in which cellular clocks are constrained to 24 hours, fibroblasts even show the 
early or late circadian phases of their owners (19).  
In this paper we have addressed the effects of ageing on molecular circadian clock 
properties using a fibroblast-based assay. In principle, alterations in circadian behaviour 
due to ageing could arise by a variety of mechanisms. Changing neural networks might 
perturb sleep-wake timing or alter the communication between the SCN clock and other 
brain regions. Hormonal signals critical for maintaining physiological homeostasis might be 
perturbed. On a cellular level, molecular changes associated with ageing (e.g. oxidative 
damage, telomere attrition) might alter basic clock function. Our results are consistent with 
the hypothesis that the molecular machinery of circadian rhythms in peripheral oscillators 
is not altered by age, but that molecule/s present in serum might be responsible for some 
of the circadian changes that occur in the elderly. 
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Results 
Ageing changes human circadian behaviour in vivo, but does not alter fibroblast 
circadian clocks in vitro. 
To try to understand the molecular changes that might underlie modifications in daily 
behaviour in elderly individuals, we characterized the circadian rhythms of dermal skin 
fibroblasts obtained from young and older donors. Subjects were recruited based upon 
age, but were also asked to give information about daytime preference (their preferred 
waking time and bedtime both on workdays and during leisure) by completing the Munich 
Chronotype Questionnaire (MCTQ) (20). The 18 young and 18 older sex-matched subjects 
participating in our study are described in Table S1.  
From the completed MCTQ, older subjects in our study displayed a significantly earlier 
sleep phase compared to young subjects (Fig.1A; Unpaired t-test P < 0.01). This 
difference reflected well the epidemiological trend that is observed in the general 
population, e.g. as reported by Roenneberg and colleagues (21). To characterise possible 
cellular origins of these differences, two 2-mm dermal punch biopsies were taken from 
every subject. Primary fibroblast cultures were isolated from the biopsies and infected with 
a lentivirus that harboured a circadian reporter construct (the Bmal1 promoter driving 
expression of the firefly luciferase gene (22)). Circadian clocks in infected fibroblast 
cultures were synchronised with dexamethasone (23), and circadian bioluminescence 
corresponding to Bmal1 promoter activity was measured for at least 5 days under constant 
conditions in a cell culture incubator. The circadian oscillations from fibroblasts from young 
and elderly subjects were then systematically examined for differences in period length, 
amplitude and phase. It has been shown previously that chronotype negatively correlates 
with period length in vivo (24) and in vitro (19). Hence, if the origins of ageing-related 
differences were cell-intrinsic, we hoped to see correlations between clock properties in 
vitro and subject age. 
The period length for each individual is shown in Fig. 1B. As we have reported for other 
subject populations (22), fibroblast period differed significantly among different individuals 
but not between different biopsies from the same individual (Fig. S1). No differences were 
observed between the groups (Fig. 1B Inset: Unpaired t-test P > 0.05; Table S1). 
Additionally, no correlation was seen between period length and MCTQ sleep phase either 
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in older or younger subjects (Fig. 1C; Linear regression P > 0.05). (N.B. Previous studies 
showing correlations between questionnaire-based sleep-wake behaviour and period 
length were based upon comparisons of early vs. late chronotypes. (19, 24)). 
 
Fig. 1. Influence of age on period length and chronotype. (A) Chronotype of young and old subjects, as 
measured by the Munich Chronotype Questionnaire. The X axis indicates the time of subjects’ mid-sleep 
phase on non-workdays. Dataset variation is shown as a standard boxplot.. N = 18; unpaired t-test **P < 
0.01. (B) Period length of the primary fibroblasts of each subject participating in this study. For ease of 
display, data are sorted on the basis of the period length. Data are mean of 6 independent measurements of 
the period length for every subject ± SEM. (Inset) Population average of period lengths of skin fibroblasts 
from young (Y) and older (O) subjects, shown as a standard boxplot. No statistical difference was observed. 
N = 18; unpaired t-test P > 0.05. (C) Comparison between chronotype and in vitro circadian period length for 
the two groups of subjects (Pall subjects = 0.3707; PY = 0.3785; PO = 0.9229). Period length values are 
shown as mean of 6 independent measurements ± SEM. 
To measure circadian phase in fibroblasts in vitro, we entrained fibroblast clocks to a 24-
hour daily cycle using periodic oscillations of incubator temperature between 34 and 37 
degrees C. After six days, fibroblast daily rhythms entrained well to these cycles in both 
young and old subjects regardless of their period lengths. On the seventh day, we then 
measured the phase of reporter gene expression relative to the temperature cycle. An 
earlier phase was not observed in older vs. younger subjects (Fig. S2A; Unpaired t-test P 
> 0.05).  
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Finally, we also studied the circadian amplitude of the oscillations that we observed in vitro 
by measuring the difference between peak and nadir expression values of the second and 
third cycles, normalized to overall magnitude (Fig. S2B). No correlation to ageing was 
observed, nor did amplitude correlate with fibroblast cell passage number – i.e. a longer or 
shorter time in cultivation (Fig. S2C, D; Unpaired t-test P > 0.05). Thus, none of the 
physiological signs of human circadian ageing could be detected or duplicated in cultured 
fibroblasts from elder subjects. 
Human sera influence fibroblast circadian period length and phase.  
If cellular circadian properties per se do not change with ageing, but nevertheless these 
changes are still observed in peripheral organs, hormone levels, or explanted tissues (7, 
13-14, 25-26), we reasoned that the age-related alterations might be caused by a 
circulating factor. To test this possibility, we replaced the normal standardized foetal 
bovine serum used in our cell cultures with human serum harvested from donors of 
different ages. The circadian rhythms of 4 young (Y) and 2 old (O) cell lines were 
measured in the presence of 8 different human serum-containing media from young male 
donors (YS) and 5 different human serum-containing media from 2 post-menopause 
female and 3 male older donors (OS). Data regarding these blood donors are listed in 
Table S2. Fig. 2A and 2B show data of the period length of circadian rhythms from one Y 
and one O fibroblast cell line, respectively, when measured with each serum, and Fig. 2C 
and 2D show averages from four different Y lines and two different O lines. Irrespective of 
whether the treated fibroblasts were from young or older subjects, cells measured in 
serum from older donors had a significantly shorter circadian period than those in young 
donors’ serum (Fig. 2C-D; Unpaired t-test: PY < 0.001; PO < 0.001). In the presence of 
YS, cells from young and older subjects showed a period length of 24.61 ± 0.18 (mean ± 
SD) and 24.35 ± 0.18 hours respectively, while treating cells from young and older 
subjects in the presence of OS showed a period length of 23.79 ± 0.16 and 23.60 ± 0.33 
hours respectively. 
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Fig. 2. Circadian period 
length of skin fibroblasts 
treated with human serum-
containing media. (A) 
Circadian period lengths 
obtained from one 
representative cell line taken 
from a young subject (Y) 
measured in FBS-containing 
medium (white), and media 
containing human serum 
from 8 young (YS; grey) and 
5 older (OS; black) donors. 
Bars represent the mean of 3 
independent measurements 
± SEM. (B) Equivalent 
measurements from a 
representative cell line taken 
from an older subject (O). (C) 
Graph showing the average 
period length differences 
from 4 Y cell lines treated with YS and OS. Left axis, percentage difference; right axis, absolute difference. 
Results are expressed as average ± SEM. (D) Equivalent average for 2 O cell lines. In both cases, treatment 
of YS gave a highly different period length (Unpaired t-test: ***P < 0.001) compared to the treatment with OS 
in Y cell lines. 
Both in vivo and in vitro, significant differences in period length have been correlated 
previously with differences in phase: shorter period lengths lead to earlier phases, both in 
behaviour and in circadian gene expression (19, 24). To see if the period length 
differences that we observe between YS and OS could provoke differences in phase, we 
measured the circadian phase after temperature entrainment of two Y cell lines and two O 
cell lines in the presence of two YS and two OS. Serum from older subjects indeed phase-
advanced the circadian rhythms of cells from both young (Fig. 3A) and older (Fig. 3B) 
subjects, as compared to the same cells in young serum (Unpaired t-test: P < 0.05). 
Specifically, fibroblasts belonging to young or older volunteers measured in the presence 
of OS showed a phase advance of 1.96 ± 1.18 hours (mean ± SD) or 2.48 ± 0.46 hours, 
respectively, compared to the same cell lines measured in the presence of YS. 
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Fig. 3. Circadian phase of fibroblasts in the 
presence of serum from young and older subjects. 
(A) Phase of cell lines from young subjects (Y) 
was determined after temperature entrainment in 
the presence of serum from younger subjects (YS) 
or from older subjects (OS). Results are expressed 
as phase difference (in hours) between the two 
treatments. Each bar results from the average of 
two different cell lines, each treated with two 
different sera, ± SEM. (B) Equivalent data using 
cell lines from older subjects. In both cases, there 
was a significant advance in the phase of cells treated with OS compared to the same cell lines treated with 
YS (Unpaired t-test: *P < 0.05).  
The influence of sera from older subjects on period length is due to heat-sensitive 
substance/s.  
Our results above suggest that one or more substances in human serum can recapitulate 
at a cellular level the differences in circadian phase seen between younger and older 
subjects. Such effects could in principle arise from substances either in YS or in OS. To 
investigate further the nature of the substance/s responsible for the ageing effects, we 
heat-inactivated 4 YS (YSHI) and 4 OS (OSHI). In this way the secondary structure of 
proteins and unstable metabolites would be destroyed. The circadian period length from 2 
Y and 2 O cell lines were analysed in the presence of medium containing each of these 
sera (Fig. 4 A-B and Suppl. Fig. 3A-B; average values in Fig. 4C-D). Although 
measurements from cells with YSHI were not different compared to measurements with 
YS (period Y = 24.61 ± 0.18 hours (with YS, mean ± SD) versus 24.63 ± 0.27 hours (with 
YSHI); period O = 24.35 ± 0.18 (with YS) versus 24.50 ± 0.45 (with YSHI); PY > 0.05; PO 
> 0.05), measurements with OSHI were significantly longer than with OS, and not 
significantly different from those with YS. (period Y = 23.79 ± 0.16 (with OS, mean ± SD) 
versus 24.60 ± 0.14 (with OSHI); period O = 23.60 ± 0.33 (with OS) versus 24.32 ± 0.28 
(with OSHI); one-way ANOVA Tukey’s Multiple Comparison test: PY < 0.001; PO < 0.01). 
Thus, longer period was rescued by the heat-inactivation of OS, suggesting that the 
substance(s) responsible for the effects that we observe are heat-sensitive circulating 
factors present in serum from older individuals.  
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Fig. 4. Circadian period length of skin fibroblasts treated with normal and heat-inactivated human serum-
containing media. (A) Circadian period length obtained from one representative cell line belonging to a 
young subject (Y) measured in media containing normal or heat-inactivated human serum from 4 young and 
4 older donors. Every bar is the mean of 3 independent measurements ± SEM. (B) Equivalent measures 
from a representative cell line from an older subject (O). (C) Graph showing the average period length from Y 
cell lines treated with normal and heat-inactivated serum from both young (respectively YS and YSHI) and 
old subjects (respectively OS and OSHI). Each bar represents the average of 2 different cell lines, each 
treated with 4 different sera, ± SEM. Left axis, percentage difference; right axis, absolute difference in hours. 
(D) Equivalent graph for cell lines from older subjects. In both cases, YSHI did not modify the period length 
compared to YS (One-way ANOVA Tukey’s Multiple Comparision Test: P > 0.05), whereas OSHI increased 
the period length compared to OS (One-way ANOVA Tukey’s Multiple Comparision Test: *P < 0.05; **P < 
0.01; ***P < 0.001) to a length equivalent to that obtained with YS (One-way ANOVA Tukey’s Multiple 
Comparision Test: P > 0.05). 
Theoretically, either a diurnal factor or one constantly present could achieve the effects 
that we observe. Multiple phase-shifting activities are known to be present in serum, no 
matter what time of day it is drawn (23). Two obvious labile circadian candidates would be 
melatonin and cortisol, hormones widely used as circadian markers and known to phase-
shift the circadian clock. Therefore, we tested the levels of these two substances explicitly 
in our sera: they were not significantly different between young and older blood donors at 
the time that these sera were taken (ca. 2 p.m.) (Fig. S4A-B; Unpaired t-test: P > 0.05). 
Melatonin is barely present in serum at these times. Although a trend toward elevated 
cortisol is visible in older subjects, fibroblasts treated with different amounts of cortisol at 
levels found in the blood of these donors did not show differences in period length 
compared to untreated cells (Fig. S4C). 
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Discussion 
In this study, we have shown that whereas skin fibroblasts taken from young and older 
subjects do not differ per se in their circadian properties, incubation of both cells in serum 
from older subjects results in a shortening of circadian period and a shift to earlier phase 
compared to incubation with serum from younger subjects. Moreover, the effects that we 
observe are due to a thermolabile activity in older serum. 
Although circadian and sleep-wake disruptions have been documented extensively in 
elderly individuals, the causes of these changes are not well understood. According to one 
theory, fragmentation of the sleep-wake cycle coupled with increased daytime napping 
results in less nighttime sleep and a shift to an earlier activity phase (26-27). Thus, age-
related reduction in the evening circadian signal that opposes homeostatic sleep pressure 
modifies sleep structure and sleep consolidation (28-29). Moreover, changes in eye 
physiology with age (lens yellowing and senile miosis, cataracts, etc.) and behaviourally, 
more time indoors are thought to reduce the entraining effects of solar light, further 
exacerbating the problem (30). Recent studies corroborate these hypotheses, and 
demonstrate clearly that the circadian system is less sensitive to light in the elderly (31-
32). 
The results that we present provide an additional cellular explanation for the shift toward 
earlier chronotype occurring in elderly individuals: a hormonal factor might both shorten 
period and advance phase. Indeed, at a behavioural level, both period shortening and 
phase-shifting have been observed in older animals (33-34). Problematically, however, in 
human studies of circadian period in vivo under “forced desychrony” laboratory conditions 
that permit the measurement of circadian period independent of sleep-related input, no 
changes in period have been observed (26, 35). In these same studies, a shift in relative 
sleep phase is still present. Thus, these human studies have documented a change in 
phase without a corresponding change in period. 
We think that this apparent contradiction can be explained in light of the hierarchical 
structure of the mammalian circadian system. If a circulating clock-entraining substance 
that shortened period were unable to entrain the master pacemaker in the SCN, but 
affected other oscillators, the result would be a shift in phase of many clock-controlled 
functions without a change in SCN-controlled period. The observed effect would be 
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mechanistically akin to the way that individuals of shorter and longer intrinsic period 
entrain to the 24-hour solar day by showing earlier and later phases of behaviour. The 
putative causal factor could be constantly present in serum, and use asymmetry in phase 
response curves to shift overall phase. Alternatively, it could be secreted at a particular 
time of day. This factor might be present uniquely in elderly, or it might be a factor present 
in both older and younger individuals, but phase-shifted in its expression.  
Our results suggesting the existence of such a factor are based purely upon in vitro 
assays. Further studies are clearly needed to identify the substance or substances that are 
responsible for the period and phase differences that we observed, as well as how ageing 
alters their production and whether antagonists of their effects might provide real benefits 
to aged individuals. The findings open the possibility that circadian difficulties associated 
with ageing might be pharmacologically treatable without recourse to potentially addictive 
sleep aids, and this would represent a major benefit to health.  
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Materials and methods 
Subject recruitment criteria. Eighteen healthy young (ages 21-30 years old) and 
eighteen healthy older subjects (ages 60-88 years old) were chosen for participation based 
upon age alone, and were asked to fill out the Munich Chronotype Questionnaire (MCTQ) 
to determine their sleep phase (20). Subject statistics are shown in Supplementary Table 
1. Prior ethical consent for the use of human skin tissues was given by the Ethical 
Committee of Basel, and informed written consent for participation in this study was 
obtained from all human subjects. 
Tissue isolation, Fibroblast Culture and Viral Infection. Two cylindrical 2-mm diameter 
cutaneous biopsies were taken from the buttocks of each recruited healthy subjects. 
Fibroblasts were isolated from biopsies by 4 hours digestion of tissue in Dulbecco's 
Modified Eagle's Medium high glucose (DMEM)/1% Penicillin Streptomycin (Sigma, 
USA)/1% Glutamax (Sigma, USA) (DMEMc)/20% Foetal Bovine Serum (FBS) (Sigma, 
USA)/87.5 ng/ml liberase (Roche, USA), and cultured in DMEMc/20% FBS. Confluent cells 
were infected using Bmal1::luciferase lentivirus. Three days after infection transfected cells 
were positively selected (22). 
Harvesting of sera. At 2 p.m. 45 ml of blood were collected from 8 healthy young (8 male; 
age 25.5 ± 4.6 years) and 5 healthy older (3 male and 2 post-menopause female; age 74.4 
± 9.8 years) subjects in clot activator vacutainers (BD Vacutainer System, UK). Whole 
blood was incubated 30 minutes at room temperature and the centrifuged 10 minutes at 
2000 g. Serum was harvested and stored at -20° C. W hen specified, human serum was 
heat-inactivated by treatment for 30 minutes at 56° C.  
Synchronisation and measurement of circadian period and phase. Five days or more 
after human fibroblast infection circadian rhythms were synchronised by 100 nM 
dexamethasone (Sigma, USA) in DMEMc + 20% FBS (36). DMEMc without phenol red 
was supplemented with 0.1 mM luciferin (Molecular Probes, USA) to obtain the counting 
medium (CM) and light output was measured in homemade light-tight atmosphere-
controlled boxes for at least 5 days. For the measurements of fibroblast basal circadian 
rhythms CM was supplemented with 10% FBS; for the influence of human serum on 
circadian period length CM was supplemented with 10% human serum; for determination 
of the influence of cortisol on period length CM was supplemented with 10% sFBS, or 10% 
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sFBS and 25 ng/ml cortisol (Sigma, USA) or 10% sFBS and 75 ng/ml cortisol; for 
determination of the influence of heat-inactivated human serum on period length CM was 
supplemented with 10% heat-inactivated human serum. For phase determination 
experiments, cells in luciferin-supplemented medium were synchronised by incubation for 
6 days in a temperature-controlled incubator under a 16h : 8h 35° C : 37° C daily 
temperature cycle. On day seven, cells were transferred to the Lumicycle device at 37° C 
and bioluminescence was measured for an additional 16 h. Cellular phase was determined 
by measuring the time of the transcriptional maximum of reporter gene expression in the 
smoothed and normalized dataset during this interval (19). 
Melatonin determination in sera. A direct double-antibody RIA was used for the 
melatonin assay, validated by gas-chromatography-mass spectroscopy (Buehlmann 
Laboratories, Schoenenbuch, Switzerland). The minimum detectable dose of melatonin 
(analytical sensitivity) was determined to be 0.2 pg/ml. The functional least-detectable 
dose using the less than 20% coefficient of interassay variation criterion was less than 
0.65 pg/ml. Melatonin concentrations in the sera were expressed as pg/ml of serum. 
Cortisol determination in sera. Quantification of cortisol in sera was performed using a 
Cortisol ELISA Kit (R&D, UK) following the manufacturer's instruction. Cortisol 
concentration in the sera was expressed as ng/ml of serum and the assays were 
performed in duplicate. 
Statistical methods (period). For each luciferase measurement, the period of oscillation 
was calculated by fitting the curve to sine waves of known period using a macro program 
for Microsoft Excel written by SAB. The maxima and minima of each oscillation were 
identified, and the timing of these points was used to fit hypothetical sine curves with 
period and phase as free variables. The period of the sine wave with the best least-
squares fit to the data was assumed to be the true period of oscillation. Because the 
period length of the first day after synchronisation varied according to the conditions of 
synchronisation, it was not included in these calculations; rather, period was determined 
by analyzing only days 2–5. To determine the period length of a particular biopsy three 
separate experimental measurements were done for each fibroblast culture. To determine 
the period length of a particular individual, at least two separate biopsies were analyzed in 
this manner. Values are presented as mean plus or minus the standard error. 
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Statistical methods (relative amplitude). The amplitudes of the second and third cycles 
of circadian expression were obtained as the difference between the peak and nadir 
expression values; these measurements were then normalized using the magnitude of the 
first peak, to eliminate the bias due to the fact that the magnitude of the bioluminescent 
signal measured is proportional to the reporter virus infection efficiency in our fibroblasts. 
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Supplementary information 
Supplementary tables 
Table S1. Subject Characterization 
 
  N Age   Chronotype  Fibroblast period length  
   (years ± S.D.) (MSF-Sc ± S.D.) (hrs ± S.D.)  
 
Young 18 25.44 ± 3.58  4.98 ± 0.84  24.73 ± 0.32 
  YF  7 25.86 ± 2.48  4.86 ± 0.78  24.80 ± 0.38 
  YM  11 25.18 ± 4.24  5.06 ± 0.91  24.69 ± 0.29 
Older  18 67.89 ± 7.32  3.88 ± 1.12  24.94 ± 0.37 
  OF  7 65.43 ± 4.12  4.01 ± 1.22  24.96 ± 0.35 
  OM  11 69.45 ± 8.61  3.79 ± 1.10  24.92 ± 0.40 
 
Table S2. Blood Donor Characterization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood donors Gender Age Medicaments
YS-1 M 21 No
YS-2 M 20 No
YS-3 M 32 citalopram (120 mg/day)
YS-4 M 21 No
YS-5 M 26 No
YS-6 M 27 No
YS-7 M 31 No
YS-8 M 26 No
OS-1 M 81 diosmine (450 mg/day)/Esperidine (50 mg/day)
OS-2 F 83 Aspirine cardio (100 mg/day); Metoprolol (50 mg/day); Perindopril/indapamin (4 mg/day/1.25 mg/day)
OS-3 F 67 No
OS-4 M 80 Aspirine cardio (100 mg/day); Amlodipine maleate (2.5 mg/day); Chlorthalidone (12.5 mg/day)
OS-5 M 61 Aspirine cardio (100 mg/day); Simvastatine (40 mg/day)
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Supplementary figures 
 
Fig. S1. Period lengths obtained from two different biopsies taken from 3 young females, 3 young males, 3 
older females and 3 older males. Each bar represents the mean of 3 independent measurements per biopsy 
± SEM. 
Fig. S2. Influ-
ence of age on 
amplitude and 
phase of entrain-
ment. (A) Graph 
showing chrono-
type vs. phase of 
entrainment of 
reporter expres-
sion for fibro-
blasts from 5 
young and 6 old-
er subjects. 
Statistical an-
alyses revealed 
no significant cor-
relation between 
phase of entrain-
ment, chronotype 
and ageing (PAll 
subjects = 0.3699; 
PY = 0.9462; PO = 
0.0698). (B) Schematic representation of the amplitude measurement. Amplitude of the first three peaks (first 
peak = A1; second peak = A2; third peak = A3) was measured. Damping was approximated as the ratio 
A2/A1 or A3/A1, which produced equivalent results. (See description in Materials and Methods.) (C) Diagram 
showing the correlation between A2/A1 and A3/A1 for young and old subjects. Age did not influence either of 
these ratios (Unpaired t-test: P > 0.05). (D) Graph reporting the influence of cellular senescence on the 
damping rate of peripheral oscillators. Abscissa, passage number of the measured cells; ordinate, damping 
rate A2/A1, normalized to the highest value obtained from each subject. There was no difference in amplitude 
of fibroblasts between young and old subjects with increasing passage number (Unpaired t-test: P > 0.05).  
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Fig. S3. Details of the 
circadian period length 
of skin fibroblasts 
treated with normal and 
heat-inactivated human 
serum-containing 
media. (A) Circadian 
period length obtained 
from cell lines belonging 
to 2 young subjects (Y) 
measured in media 
containing normal or 
heat-inactivated human 
serum from 4 young and 
4 older donors. Every 
bar is the mean of 3-6 
independent mea-
surements ± SEM 
(exceptions: for Y1-
OSHI5 and Y2-OS2, 
n=2). (B) Equivalent 
measures from 2 lines 
from older subjects (O). 
Bars are the mean of 3 
independent mea-
surements ± SEM.        
(exception: for O1-
OSHI2, n=2). 
 
Fig. S4. Levels of 
melatonin and 
cortisol in 4 sera 
from young donors 
(YS) and 4 sera from 
older donors (OS). 
(A) Melatonin levels 
(pg/ml) in 4 YS and 4 
OS. There was no 
statistical difference 
in melatonin con-
centration between 
the two groups of 
sera (Unpaired t-test: P > 0.05). (B) Cortisol levels (ng/ml) in 4 YS and 4 OS. There was no statistical 
difference of cortisol concentration between YS and OS (Unpaired t-test: P > 0.05). Since a (non significant) 
trend was visible, the effects of cortisol upon period length were studied in more detail in the next panel. (C) 
Period lengths of one cell line in serum supplemented with 0 ng/ml, 25 ng/ml, or 75 ng/ml cortisol. Every 
point represents the mean of 3 independent measurements ± SEM . No significant differences were 
observed (Unpaired t-test: P > 0.05). 
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Abstract: 
Melatonin affects SCN activity and synchronizes most of the animal and human sleep-
wake cycle. Here we used human skin fibroblasts as model to investigate the zeitgeber 
properties of melatonin on peripheral oscillators. Melatonin could not restore the rhythms 
of damped fibroblasts, rather it reduced the bioluminescence emitted by newly 
synchronized cells, excluding a direct effect of melatonin as peripheral oscillator zeitgeber. 
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Manuscript: 
During the dark period of the day, the pineal gland produces melatonin in response to a 
multisynaptic signal involving several areas in the central nervous system including the 
circadian master clock suprachiasmatic nucleus. Melatonin pathways are propagated 
mainly through high affinity G-coupled receptors MTNR1A and MTNR1B1; these receptors 
are expressed in skin2 as well as in other tissues (for a review see 3). Several studies 
indicate that melatonin has synchronizing properties on human activity rhythms4 and 
rodents sleep-wake cycles5 likely by modulating SCN firing rate6. Moreover, the circadian 
presence of melatonin in peripheral biological fluids (blood, saliva and urine) suggests that 
melatonin could be an important signal that the SCN might use to synchronize non-
neuronal peripheral oscillators.  
In this experiment we investigated this hypothesis by using skin fibroblasts isolated from 
punch biopsies as a cellular model of peripheral oscillators.  
We first confirmed the expression of melatonin receptors mRNA and protein expression in 
human fibroblasts (Fig. 1a,b). 
Fig. 1. Human skin fibroblasts express G-coupled melatonin 
receptors. (a) Picture of PCR products on an agarose gel: 
DNA ladder, 100 pb, 1; MTNR1A 570 bp, 2; MTNR1B 118 
bp, 3; CDK4 64 bp, 4. (b) Expression of melatonin receptors 
protein MTNR1A (about 60 kDa) and MTNR1B (about 60 
kDa) and the internal control GAPDH (about 40 kDa) in skin 
fibroblasts. 
 
Subsequently, cells were transfected with the reporter gene Bmal1::luciferase for the real-
time detection of circadian rhythms7. We wished to investigate whether melatonin might 
resynchronize the circadian rhythms of damped fibroblasts, as dexamethasone or 
changing medium. After the pre-synchronization of circadian rhythms and 3 complete daily 
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cycles of Bmal1 expression, cells were treated with vehicle (V), positive control (PC) 
(dexamethasone 0.1*10-6M), or melatonin at increasing concentrations (from 2*10-11 M to 
5*10-4 M) at different time-points (at CT 6, CT, 12 and CT 24, considering CT 0 the 
maximum activity of luciferase after 3 days) to test the time-dependent synchronizing 
effects of the drugs (Fig. 2a inset). In case of a re-synchronization of the rhythms either a 
phase change or an increasing of the amplitude of bioluminescence may be observed. No 
difference in the amplitude of the cycle before the treatments (A3) were found (data not 
shown; One-way ANOVA over all data: CT 6 P = 0.9399; CT 12 P = 0.4907; CT 24 P = 
0.6262). A good re-synchronization was obtained after the PC application (Fig. 2a) (mean 
± SD: CT 6 PC = 434.60 ± 104.80; CT 6 V = 100.00 ± 46.04; P CT 6 < 0.01; CT 12 PC = 
461.00 ± 324.50; CT 12 V = 100.0 ± 25.47; P CT 12 < 0.01; CT 24 PC = 364.80 ± 153.60; CT 
24 V = 100.00 ± 66.90; P CT 24 < 0.001; two-way ANOVA P treatment < 0.0001, P CT = 0.0574, 
Bonferroni post hoc test to compare replicate means by row, versus V treatment; α = 
0.05), whereas the treatments with melatonin did not synchronize human fibroblasts at any 
time points and concentrations (P > 0.05: two-way ANOVA, Bonferroni post hoc test to 
compare replicate means by row, versus V treatment) (Fig. 2a-d). Similar results of 
melatonin were found using another cell line (Fig. 2e, inset) (One-way ANOVA P = 
0.0507, Bonferroni post hoc test to compare all pairs of columns, versus V: P > 0.05; α = 
0.05).  
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Fig. 2. Effect of a single dose of melatonin administration on the amplitude of the reporter gene luciferase 
under Bmal1 promoter in human skin fibroblasts. (Inset) Experimental design. For details see supplementary 
methods. (a) At the tested concentrations melatonin did not induce synchronization, unlike positive control 
(PC) treatment, compared to vehicle (V) treatment. Data are plotted as the mean of 3 independent 
measurements ± SE. ** P < 0.01; *** P < 0.001. (b-d) Representative bioluminescence measurement 
diagrams using V (in grey), PC (in violet) or melatonin (5*10-4 M, in blue) treatment at CT 6 (b), CT 12 (c) and 
CT 24 (d). (e) Lack of synchronizing effect of a single melatonin administration on human skin fibroblasts 
from a second subject. Each bar represents the mean of 3 independent treatments ± S.E.. (Inset) 
Representative bioluminescence measurement diagram using V (in grey), dexamethasone (in violet) or 
melatonin (5*10-4 M, in blue) treatments at CT 12.  
The analyses of the phase of entrainment revealed that only PC administered at CT 12 
phase delayed the rhythms (mean ± SD: CT 12 PC = -6.130 ± 0.7071; CT 12 V = 1.987*10-
8 ± 1.260; P CT 12 < 0.01; two-way ANOVA P treatment = 0.0011; P CT = 0.2299, Bonferroni 
post hoc test to compare replicate means by row, versus V; α = 0.05), although a tendency 
of PC and melatonin 5*10-4 M administered at CT 24 to respectively phase delay and 
phase advance the rhythms was observed (unpaired t-test: respectively P = 0.0585; P = 
0.0623; α = 0.05) (Fig. 3a). 
To confirm the absence of zeitgeber properties of melatonin on peripheral oscillators, 
human fibroblasts were washed once and then treated with medium containing luciferine 
alone (L0) or luciferine and 5*10-4 M melatonin (ML0). Measurements of the 
bioluminescence at the zenith peak at nadir peak of the first 3 cycles revealed that 
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fibroblasts treated with ML0 emitted less bioluminescence compared to cells treated with 
L0 (Fig. 3b) (1 zenith peak P < 0.001; 2 zenith peak P < 0.05; two-way ANOVA P treatment < 
0.0001; P peaks < 0.0001, Bonferroni post hoc test to compare replicate means by row. 1 
nadir peak p = 0.0389, unpaired t-test; α = 0.05). To exclude that the previous result was 
due a decreased viability of luciferine caused by a chemical reaction with melatonin8, 
fibroblasts were washed once and then treated with a medium containing luciferine alone 
(L6) or luciferine and 5*10-4 M melatonin (ML6) previously incubated for 6 days at 37°C 
and 7.5% CO2. The analyses of the light emitted by the cells revealed that fibroblasts 
treated with L0 and L6 emitted the same amount of light, as well as cells treated with ML0 
and ML6 (Fig. 3b,inset) (mean ± SD: L0 = 145.80 ± 10.12; L6 = 161.00 ± 32.99; ML0 = 
103.10 ± 6.71; ML6 = 124.00 ± 30.26; unpaired t-test: P L0-L6 = 0.4874; P ML0-ML6 = 0.3066; 
P L0-ML0 = 0.0037; α = 0.05). 
 
Fig. 3. Melatonin does not phase shift but affects the bioluminescence emitted by fibroblasts. (a) Magnitude 
of phase shift (y axis) of A6 upon the treatments at a given time (x axis). Every point represents the mean of 
3 independent treatments ± S.E. ** P < 0.01. (b) Bioluminescence emitted by fibroblasts incubated with 
medium containing luciferine (L0), luciferine and melatonin 5*10-4 M (ML0), or 6 days at 37°C and 7.5% CO 2 
incubated medium containing luciferine (L6) and luciferine and melatonin 5*10-4 M (ML6). z = zenith; n = 
nadir. Data are plotted as mean of 3 independent measurements ± SE. # P < 0.05; ### P < 0.001. + P < 
0.05. (Inset) Light emission at the first zenith. Data are plotted as mean ± SE. Unpaired t-test: ** P < 0.01; * 
P < 0.05.  
To further confirm that melatonin does not interact with luciferine we estimated the effects 
of melatonin 5*10-4 M or V upon solutions of ATP at a variety of concentrations (ranged 
from 0.1 to 5 µM). Luciferase and luciferine were added to the ATP standard samples. The 
chemoluminescence emitted by the reaction seem to not differ in the presence or absence 
of melatonin (Suppl. Fig. 1). These data demonstrate that melatonin at a concentration of 
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5*10-4 M did not exhibit an interaction with luciferine, but interfered with the amplitude of 
circadian rhythms peripheral oscillators. 
The effects of melatonin on the amplitude and synchronization of peripheral oscillators 
reported in this study can be caused by several factors: a block of the coherence of 
cellular circadian rhythms due to a counteraction of the synchronization pathway by 
inhibiting cAMP and PKC-dependent Per1 and c-Fos expression9 by activation of Gαi 
(inhibitor of cAMP signal transduction cascade) (for review see10), a reduction of the 
amplitude of the rhythm in every single oscillator, a decreasing of the protein expression, 
e.g. Bmal1 and luciferase, due for example to the interference of melatonin on the mRNA 
stability, or a combination of the two hypothesis. 
Melatonin was shown to possess synchronizing properties on rat SCN slices6, rodent 
behavior5 and on the circadian rhythm of some totally blind people 11-12. The direct effects 
of melatonin in animals and humans are not easy to unravel due to the complexity of the 
systems; hence melatonin may act directly and/or indirectly on the master clock and on 
neuronal oscillators. Here we describe that in a simple and very controlled system 
melatonin failed to directly entrain non-neuronal peripheral oscillators such as human skin 
fibroblasts and impaired their circadian rhythms amplitude. However, the present study 
cannot exclude that this effect may be relevant for peripheral oscillators synchronization in 
complex systems, since the decreasing of the circadian amplitude may render the cellular 
rhythms more tensile, increasing their sensitivity to other synchronizing signals13; in this 
case melatonin may exert an indirect action as peripheral organs synchronizator. 
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Supplementary information 
Supplementary methods 
Subject. For this study two healthy subjects (S1 female 27 years old; S2 male, 65 years 
old) were recruited to donate skin biopsies. Prior ethical consent for the use of human skin 
biopsies was given by the Ethical Committee of Basel, Switzerland, informed consent was 
obtained from the subjects participating to the study. 
Skin biopsies sampling, fibroblasts culture, viral infection. Three cylindrical 
cutaneous biopsies were taken from the buttock of the subjects. Biopsies were cultivated 
separately and fibroblasts were isolated by 4-hrs digestion of the tissues in Dulbecco's 
modified Eagle's medium (DMEM; Sigma-Aldrich, USA)/2 mM L-glutamine (Invitrogen, 
USA)/100 U/l penicillin/100 µg/l streptomycin (Invitrogen, USA), hereafter designated as 
DMEMc, supplemented with 20 % Foetal bovine serum (FBS; Sigma-Aldrich, USA)/3.5 
WU/ml Liberase Blendzyme 3 (Roche Applied Science, USA). After digestion biopsies and 
fibroblasts were cultivated in DMEMc supplemented with 20 % FBS. One separate plate of 
fibroblasts from each biopsy was infected using Bmal1::luciferase lentivirus as described 
previously 1. Infected cells were selected via resistance to DMEMc/20 % FBS/5 µg/ml 
puromycin (Sigma-Aldrich, USA). After amplification fibroblasts were synchronized and 
circadian rhythm was measured as described below. 
Polymerase chain reaction (PCR). The expression of transmembrane melatonin receptor 
hMTNR1A and hMNTR1B was evaluated using PCR protocol. Total RNA was extracted 
from human fibroblasts using RNeasy Mini Kit (Qiagen, USA). Complementary DNA 
(cDNA) was synthesized from 1 µg of total RNA using Ready-To-Go You-Prime First-
Strand Beads (Amersham, USA) and 0.5 µg of Oligo(dT)15 Primer (Promega, Italia) 
following the manufacturer's instruction. PCR amplification was carried out using a 25 µl 
reaction mixture containing: cDNA, 2 µl in 10× buffer, 0.2 mM dNTPs, 0.1 U/µl U of Taq 
DNA Polymerase (Promega, Italia), 40 pmol of hMTNR1A (5‘-agtcagtgggttcctgatg-3’; 5’-
cattgaggcagctgttgaaatacg-3’), 40 pmol of hMTNR1B (5’-caacttctttgtggggtccctg-3’; 5’-
gatagggaggaggaagtggatgac-3’), 1 pmol of hCDK4 (frw5’-ATCCCAATGTTGTCCGGCTG-
3’; rev5’-TGATCTCCCGGTCAGTTCGG-3’). A sample containing all the reaction reagents 
except cDNA was used as PCR-negative control in any amplification. Mixtures were 
incubated at 95 °C for 11 min, for 35 cycles of amp lification (1 min at 95 °C, 1 min at 57 °C 
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and 2 min at 72 °C), and then at 72 °C for 5 min, u sing a Robocycler Gradient 40 
(Stratagen, USA). PCR products were electrophorized in 1.5 % agarose gel together with 
a DNA ladder of 100 base pairs (Promega, Italia) and visualized by ethidium bromide. 
Western blot. Human fibroblasts were homogenized by sonication in lysis buffer (150 mM 
Tris-HCl, 150 mM NaCl, 1 % NP-40, 0.1 % SDS, 2mM EDTA supplemented with 
phosphatase and protease inhibitors (Roche Applied Science, USA)) and centrifuged 1000 
g for 5 minutes at 4°C. The supernatant was used fo r Western blotting. Ten micrograms of 
total proteins were dissolved in a loading buffer (0.1 M Tris–HCl buffer, pH 6.8, containing 
0.2 M DTT, 4 % SDS, 20 % glycerol, and 0.1 % bromophenol blue) and separated by 10 % 
SDS-PAGE, and electrophoretically transferred to a PVDF membrane (Amersham, 
Germany). Equal protein loading was confirmed by Ponceau Red staining (Sigma, 
Germany). Membranes were saturated with 5 % non-fat dry milk for 1 h and incubated with 
the primary antibodies goat anti-MTNR1A (Santa Cruz, USA) or goat anti-MTNR1B (Santa 
Cruz, USA), overnight at 4°C. PVDF membranes were i ncubated with rabbit anti-goat 
biotin conjugated IgG (DAKO, USA) 1h at room temperature and then with Streptravidin 
horseradish peroxidase conjugated (Sigma, USA) for another hour at room temperature. 
As internal control, the membranes were stained for hGAPDH using a rabbit anti-GAPDH 
antibody (AbCam) 1 h at room temperature and then subsequently an antibody anti-rabbit 
horseradish peroxidase conjugated (Sigma, USA) 1 h at room temperature. Blots were 
developed with an enhanced chemiluminescent (ECL) assay (Amersham, Germany). 
Stripped FBS. To remove steroid hormones and other organic substances from a certain 
volume of FBS, the same volume of a solution of 0.25 % activated charcoal (Sigma-
Aldrich, USA) and 0.0025 % dextran T-70 (Sigma-Aldrich, USA), 0.25 M sucrose, 1.5 mM 
MgCl2, 10 mM Hepes, pH 7.4 was incubated overnight. After centrifugation at 500 g 10 
minutes and removal of the supernatant the serum to be stripped was added to the 
charcoal pellet and the solution was incubated 12 hours at 4°C in agitation. The stripped 
serum was then centrifuged 500 g 10 minutes and the supernatant was filtered through 
0.22 µm diameters pores. 
Pre-synchronization and measurement of circadian rhythms. Circadian rhythms of 
infected fibroblasts were pre-synchronized either via dexamethasone treatment or via one 
wash using phosphate buffer solution (PBS) and replacement with the counting medium. 
For dexamethasone synchronization 100 nM dexamethasone (Sigma, USA) were added to 
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DMEMc/20 % FBS and cells were incubated for 15 min with this medium. After 3 washes 
using PBS counting medium containing DMEMc without phenol red/10 % stripped FBS/0.1 
mM luciferine (Molecular Probe, USA) was replaced to the cells and light output was 
measured (3 measurements per condition) in Lumicycle (Actimetrics, USA). For each 
luciferase measurement, circadian parameters such as amplitude of oscillations and phase 
were calculated using the software Lumicycle Analysis (Actimetrics, USA). 
Synchronization experiment. To the cover of the dishes a small hole of the dimension of 
23–25 gauge, 5/8" needle was digged to allow the treatments to occur without perturbing 
CO2 levels, temperature or light to the dishes. Cells were pre-synchronized using 
dexamethasone incubation for 15 minutes. Circadian time (CT) 0 corresponds to the peak 
phase of hBmal1::luciferase rhythms. Starting from the fourth cycle, cells were treated with 
100 µl at CT 6, CT 12 and CT 24 (Fig. 1 inset) with positive control (dexamethasone 100 
nM), vehicle (DMEMc without phenol red), melatonin at different final concentrations (2*10-
11
 M, 2*10-8 M, 10-6 M, 5*10-6 M, 5*10-4 M). Measurements were conducted for a total of 8 
days. The concentrations of melatonin used in this experiment were chosen on the basis 
of the melatonin binding curve2 to range from concentrations were no receptor bound 
melatonin to concentrations were the 100 % of the receptors bound by melatonin. The 
synchronization was quantified as the percentage of the amplitude of the cycle after the 
treatments (A6) compared to the cycle before the treatments (A3) versus vehicle (100%). 
Phase shift was determined as the difference between the phase of the peak after and 
before the treatment versus vehicle phase. 
ATP standard curve. In a white 96-wells plate an ATP standard curve was performed in 
duplicate using the following concentrations: 5 µM, 4 µM, 3 µM, 2.5 µM, 2 µM, 1 µM, 0.5 
µM, 0.1 µM. Luciferine and luciferase were added as it is described in ViaLight MDA Plus 
manual (Cambrex, USA) in the presence of melatonin 5*10-4 M or vehicle. Luminescence 
was measured using Fluoroscan Ascent (Thermo Fisher Scientific, USA). 
Bioluminescence measurement. The counting medium DMEMc without phenol red/10 % 
stripped FBS/0.1 mM luciferine was supplemented with melatonin 5*10-4 M (ML6 ) or 
vehicle (L6) and was incubated at 37°C and 7.5 % CO 2 for 6 days. Counting medium was 
then prepared fresh and supplemented with melatonin 5*10-4 M (ML0) or vehicle (L0). To 
synchronize the oscillators, cells were washed once with PBS and then the media were 
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added to the fibroblasts. Measurements of the bioluminescence were started in the 
Lumicycle. The quantification of bioluminescence was performed with the software 
Lumicycle Analysis. 
Data analyses. Statistical analyses were done using two-way ANOVA, Bonferroni post 
hoc test to compare replicate means by row, one-way ANOVA, Bonferroni post hoc test to 
compare all pairs of columns, unpaired t-test. α = 0.05 for all the analyses. Results are 
expressed as mean ± standard error. 
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Supplementary figure 
Suppl. Fig. 1. Melatonin does not interact with luciferine. 
Melatonin (5*10-4 M; blue filled dots, blue line) seems to 
not influence the light emitted by the reaction of ATP, 
luciferine and luciferase compared to vehicle treated 
reactions (empty dots, grey line). Data are plotted as 
mean of 2 independent measurements ± SE. 
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5. CONCLUSIONS 
Circadian rhythms control many human physiological processes, such as hepatic, 
metabolic and circulatory system function [1-3], mood and alertness (for review see [4]). 
An increasing number of evidences highlight the role of circadian rhythms disruption or 
misalignment in human pathologies; in diseases like depression, Alzheimer’s disease but 
also ageing circadian disregulations are very well described [5-7] and circadian re-
alignment and chronotherapies can be successful treatments [8] (for a review see [9-10]). 
The comprehension of the mechanisms and function of circadian rhythms can be of crucial 
importance for the circadian manipulation and treatment of several pathologies. However, 
human studies of circadian rhythms have several disadvantages: they are very labour 
intensive and extremely expensive, the number of subjects is limited, exclusion criteria are 
limiting factors (age, gender, life-style habits, etc...) and some patients have difficulties to 
participate due to the low compliance caused by the use of relatively invading devices. The 
aim of the present thesis was to validate human skin fibroblasts as a model to study 
human circadian rhythms in vitro, to use this model to investigating age-related changes 
and to explore the role of melatonin in the human circadian system. 
In our experiments we demonstrated that human skin fibroblasts are able to parallel 
characteristics of human circadian physiology. Previous studies in animals suggested that 
cell lines, cells of the master clock suprachiasmatic nucleus (SCN) or tail fibroblasts, 
isolated from animals possessed a similar period length as the animal locomotor activity 
period [11-12]. However, the present study gives the first direct evidence about the 
existence of a correlation between in vivo period length and in vitro human fibroblasts 
period length. Moreover, fibroblasts are insensible to the effects of light as masking agent, 
effects that are still present in the in vivo protocols, suggesting that these cells are a very 
reliable model for the study of human circadian properties. Our results suggest that human 
fibroblasts may be a predictor of more than one human physiological parameter. Prior 
studies evidenced that extreme chronotype scores correlated with human skin fibroblasts 
period length [13], similarly to the correlation between chronotype and in vivo period length 
[14]. Here we show that, although the number of subjects was small, fibroblasts period 
tended to correlate with in vivo phase of entrainment between melatonin onset and sleep 
and wake time during the first night of constant routine. Our data demonstrate the potency 
5. CONCLUSIONS 
  175  
of human skin fibroblasts as cellular model to unravel the mechanisms of human circadian 
rhythms. 
On the basis of these results, the circadian parameters of skin fibroblasts, isolated 
from a group of young and a group of older subjects, were characterized, to investigate the 
molecular mechanisms by which human ageing affects circadian clocks. During ageing the 
amplitude of circadian rhythms decreases, as it is reported by human melatonin or activity 
cycles [15] (for a review see [16]). Although a difference in chronotype between young and 
older biopsies donors was found, confirming published data [15], no correlation between 
the chronotype and the period length was detected; this apparent contrast with previous 
results [13] can be explained by the absence of extreme chronotypes in our study. Results 
about circadian parameters indicate that the molecular components of peripheral 
oscillators are not affected by ageing: period length, amplitude and phase are not different 
between the cells from the two groups of subjects. However, measuring fibroblast 
circadian rhythms in the presence of sera from older subjects, a shorter period and earlier 
phase were observed compared to the same cell lines measured in the presence of sera 
from young donors. Interestingly, a shorter period [17] and earlier phase [18] were also 
observed in studies on aged animals, although in humans only an earlier phase was 
reported [19]. A hypothesis that might explain these discrepancies is that circulating 
factors present in aged people are not able to entrain the period of the clock pacemaker, 
although peripheral oscillators, that are sensitive to many signals for their nature of 
peripheral oscillators, may respond to that substance by period shortening and phase 
advancing; this process could result in an earlier phase of human circadian parameters, 
with no effects on the period. Results about the nature of the substance responsible for the 
circadian changes observed in our experiments revealed that the only effect of heat-
inactivation was the lengthening of the period of cells treated with sera from older donors; 
we could conclude that probably the circadian disturbances that affect older persons are 
caused by one or more heat-sensitive substances present in the blood of older subjects.  
The importance of fibroblasts as cellular model in circadian rhythm studies is 
highlighted in functional studies. Melatonin is able to regulate SCN firing rate and entrain 
locomotor activity of animals and humans [20-22]. The mechanisms that underlie the 
entrainment of rodent and human activity may be different due to the opposite nature of 
the models: rodents are nocturnal and produce melatonin during their active period, 
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whereas humans are diurnal and produce melatonin during their rest period. Moreover, in 
humans melatonin was shown to facilitate sleep onset, probably by influencing the body 
temperature [23-24], suggesting a circadian role of melatonin prevalently in the central 
nervous system; however, the presence of the hormone in all the biological fluids may 
underlie other functions of the hormone on peripheral organs. Our studies on human skin 
fibroblasts revealed that melatonin was not able to re-synchronize damping fibroblasts; 
however, an effect in decreasing the circadian output was observed after melatonin 
treatment. This amplitude decrease is not caused by the reaction of melatonin with 
luciferine, the fibroblast output substrate. Our experiments indicate that melatonin does not 
directly synchronize the peripheral oscillators; however, our data cannot exclude that the 
effect of melatonin on the amplitude of fibroblasts may render their circadian rhythms more 
sensitive to other stimuli, favouring the entrainment of the clocks by other signals present 
in the periphery [13].  
Taken together our results highlight human skin fibroblasts as important tool for 
human circadian rhythms studies. Fibroblast circadian rhythms parallel the donor circadian 
parameter, such as period length, without the problems related to in vivo studies. Skin 
cells revealed that the molecular components of every oscillator are unchanged during 
ageing, but probably one or more heat-sensitive substances are the factors determining 
the age-related circadian impairments. Moreover, fibroblasts could exclude a direct 
synchronizing role of melatonin in peripheral oscillators. Fibroblasts are easily isolated 
from a punch biopsy, a cheap, relatively invading and not time consuming technique. Many 
kinds of persons may be considered qualified to donate biopsies, including people 
suffering from physical or psychiatric diseases, subjects difficult to recruit for in vivo 
protocols. Genetic manipulation on fibroblasts is easy to perform. Moreover, fibroblasts 
result to be a simple model, where many variables may be easily controlled and tested. In 
conclusion, studies on human skin fibroblasts may be preparatory or complementary to in 
vivo studies and in some cases they may completely substitute human protocols. 
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ABBREVIATIONS 
AA  Arachidonic acid 
AA-NAT Arylalkylamine N-acetyl transferase  
AC  Adenylyl cyclase 
ACTH  Adrenocorticotropic hormone 
AD  Alzheimer’s disease 
ASPD  Advanced sleep phase disorders 
ATP  Adenosine-5'-triphosphate 
AVP  Arginine vasopressin 
BD  Bipolar disorder  
BKCa  Calcium-activated potassium channels 
Bmal1  Brain and muscle ARNT-like protein 1  
CA  Cornu Ammonis of the hippocampus 
cAMP  Cyclic adenosine monophosphate 
CBT  Core body temperature 
CD  Cluster of differentiation 
cGMP  Cyclic guanosine monophosphate 
CK1  Cyclin kinase 1 
Cl–  Chloride ion 
CLOCK Circadian locomoter output cycles protein kaput  
CO2  Carbon dioxide 
CREB  cAMP response element-binding protein 
CRH  Corticotropin-releasing hormone  
CRY  Cryptochrome  
CT  Circadian time 
CYP  Cytochrome P 450 
DBT  Double-time 
DD  Dark/dark 
DLMO Dim-light melatonin onset 
DMSO Dimethyl sulfoxide  
DSPD  Delayed sleep phase disorders 
EEG  Electroencephalography 
ER  Estrogen-receptor 
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ERK  Extracellular signal-regulated kinases 
FEO  Food entrainable oscillator 
FRH  FRQ-interacting RNA helicase 
FRQ  Frequency 
FSH  Follicle-stimulating hormone 
FWD-1 F-box/WD-40 repeat-containing protein-1  
GABA  γ-aminobutyric acid 
GH  Growth hormone  
GLUT  Glucose transporter 
GnRH  Gonadotrophin-releasing hormone 
hCG  Human chorionic gonadotropin 
HCO3– Hydrogencarbonate ion  
HPA  Hypothalamic-adrenal-pituitary 
HPG  Hypothalamic–pituitary–gonadal 
IEG  Immediate-early genes 
IFN  Interferone 
IGF  Insulin growth factor 
IL  Interleukin 
ISWR  Irregular sleep-wake rhythm 
JNK   Jun NH2-terminal kinases 
KIR3  Inwardly rectifying potassium channel 
LD  Light/dark 
LH  Luteinizing hormone 
LTP  Long-term potentiation 
MAPK  Mitogene-activated protein-kinase  
MDD  Major depressive disorder  
MEK  Erk kinase 
MNC  Mononuclear 
mRNA Messenger ribonucleic acid 
MT  Melatonin receptor 
NAD  Nicotinamide adenine dinucleotide 
NAMPT Nicotinamide phosphoribosyltransferase  
NK  Natural killer cells 
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NMDA N-methyl-D-aspartic acid 
NO  Nitric oxide 
Npas2 Neuronal PAS domain-containing protein 2 
NREM Non rapid eye movement 
NSAIDs Nonsteroidal anti-inflammatory drugs  
PACAP Pituitary adelylate cyclase–activating polypeptide  
PAS  PER-ARNT-SIM domain 
PDE   Phosphodiesterase 
Per  Period 
PGO   Ponto-geniculo-occipital  
PKA  Protein kinase A 
PKC  Protein kinase C 
PLC  Phopsholipase C 
PMA  Phorbol-12-Myristate-13-Acetate 
PMN  Polymorphonuclear 
PRC  Phase response curve 
PRL  Prolactin 
PT  Pars tuberalis 
PVN  Paraventricular nucleus 
REM  Rapid eye movement 
RHT  Retina-hypotalamic tract 
RPE  Retinal pigment epithelium 
RZR/ROR α Potential retinoic-acid binding receptor/RAR-related orphan receptor 
SAD  Seasonal affective disorder  
SCN  Suprachiasmatic nucleus 
SIRT  Sirtuin 
SKCa  Small conductance channels 
SMOC Second messenger-operated Ca2+ channel  
SS  Somatostatin 
Th  T-helper lymphocyte 
TIEG1 Transforming growth factor ß-inducible early gene 1 
TNF  Tumor necrosis factor 
VDCC  Voltage-dependent Ca2+ channel 
VDUP1 Vitamin D3 up-regulated protein 1  
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VIP  Vasoactive intestinal peptide  
WC  White collar 
WCC  White collar complex  
ZT  Zeitgeber time 
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ABSTRACT 
Complex behaviors are the product of intercellular signalling events, but their intracellular 
effectors are present in most cell types. The best-studied example of such architecture is 
the circadian clock, which directs all diurnal behaviour and physiology, and whose central 
mechanism is present in most body cells. We present below a method to look at its 
properties via transcriptional reporters virally delivered to primary cells. By studying 
primary fibroblasts cultivated from skin biopsies in different human subjects, we have been 
able to analyze the molecular underpinnings of variance in human daily behaviour. Similar 
methodologies could be applied to other signalling pathways. 
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INTRODUCTION 
Human behavior is influenced by many genetic and environmental factors, and is the 
product of complex inter-neuron interactions; it is therefore often difficult to study by 
reductionist approaches. Nevertheless, it is increasingly clear that fundamental 
intracellular pathways are critical to behavior, and that these same pathways are 
conserved in non-neuronal cell types. The premise of this chapter is that inter-individual 
genetic differences that create changes in behaviour do so at least in part by modifying 
conserved intracellular signalling pathways, and that these changes are paralleled by 
changes in non-neuronal cell types. Hence, they can be studied in peripheral cells 
obtained from human subjects. 
The most clearly illustrated example of this approach can be found in recent studies of the 
circadian clock, which is the molecular basis for human diurnal rhythms. This clock, which 
has a period of about 24 hours -- “circa diem” -- is present in most cells of the body, and 
plays a key physiological role in the adaptation of living organisms to the alternation of day 
and night. In mammals circadian rhythms influence nearly all aspects of physiology and 
behaviour, including sleep-wake cycles, cardiovascular activity, endocrinology, body 
temperature, renal activity, physiology of the gastro-intestinal tract, and hepatic 
metabolism (Gachon et al., 2004). As we discuss in detail below, although specific 
mutations in circadian clock components have profound effects upon behaviour, these 
effects are paralleled by changes in circadian gene expression in easily accessible tissues 
such as skin fibroblasts, and hence these cells can be used as both diagnostic and 
analytical tools in the study of circadian behaviour. 
This chapter is divided into three parts. In the first part, a general introduction to circadian 
clocks and their influence upon human behaviour is provided. The second part contains 
the protocols used by our laboratory to study circadian clock function in primary human 
cells. The chapter then closes with a discussion of future applications. 
Basic mechanisms of the circadian clock 
The idea that genes control diurnal behaviour in higher organisms was first established in 
the fruit fly by the demonstration that certain mutations cause altered circadian rhythms 
(Konopka and Benzer, 1971). The responsible gene, period (per), was subsequently 
isolated (Bargiello et al., 1984) and was found to be expressed in a circadian pattern 
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(Hardin et al., 1990). This finding, and similar data from bacteria, fungi, and plants, has led 
to the general idea that periodically expressed genes constitute the physiological basis of 
circadian clocks in all living organisms (Dunlap, 1996; Hall and Rosbash, 1993; Takahashi, 
1995). Moreover, because clocks exist in virtually all light-sensitive organisms, both multi-
cellular and unicellular, it is not surprising that they are cell-autonomous. Their mechanism 
is based upon feedback loops of transcription, translation, and phosphorylation. In the 
simplest organism known to possess circadian rhythms, the cyanobacterium 
Synechococcus crassa, three genes -- kaiA, kaiB, and kaiC -- play essential roles in a 
central phosphorylation feedback loop, coupled to a transcriptional one (Ishiura et al., 
1998; Nakajima et al., 2005). In Neurospora crassa, the hierarchy is reversed, with a 
transcription/translation feedback loop of Frequency and White Collar proteins (Froehlich 
et al., 2003) probably playing a central role that is fine-tuned by phosphorylation by casein 
kinases 1 and 2 (He et al., 2003). Starting with metazoans, the proteins of the clock are 
highly conserved in sequence and in function. The same protein families that control the 
circadian clock in flies control the circadian clock in mammals, and polymorphisms in the 
genes that encode these proteins affect daily behaviour in human beings. 
Many reviews have been written about the molecular workings of the mammalian circadian 
oscillator (Ko and Takahashi, 2006), and we outline these mechanisms only briefly here. 
As in simpler organisms, the key mechanism is interconnected feedback loops of 
transcription and translation. It is conventional to divide clock components into a positive 
limb (consisting of transcriptional activators of clock genes) and a negative limb (inhibitors 
of these transcription factors). In mammals, the negative key components of the genetic 
circuitry are the four genes encoding cryptochrome 1 (Cry1) and cryptochrome 2 (Cry2) 
(Fig.1, green rhombus), period 1 (Per1) and period 2 (Per2) (Fig.1 violet ellipse). These 
genes are regulated by the two PAS domain basic helix-loop-helix transcription factors 
BMAL1 (Fig.1, red octagon) and CLOCK (or in some tissues NPAS2) (Fig.1, blue 
hexagon), the key positive components of the circadian oscillator. CLOCK and BMAL1 
form a heterodimer that binds specific sequences present in Per and Cry promoters, the E-
boxes, and activates the transcription of Per and Cry genes. Their gene products, PER 
and CRY proteins, in turn form heteropolymeric complexes of unknown stoichiometry that 
interact with the CLOCK-BMAL1 heterodimer, leading to a block of Per and Cry 
expression. As a consequence Cry and Per mRNAs and proteins decrease in 
concentration, and once the nuclear levels of the CRY–PER complexes are insufficient for 
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auto-repression, a new cycle of Per and Cry transcription can start (Albrecht and Eichele, 
2003; Reppert and Weaver, 2002).  
 
FIGURE 1. Schematic diagram of fibroblast synchronization and period measurement. In each cell on 
a plate of cultured cells, a separate circadian clock ticks. The heterodimer of CLOCK (C, blue hexagon) and 
BMAL1 (B, red octagon) activates the transcription of period genes Per1-2 (P, violet ellipse), cryptochrome 
genes Cry1-2 (C, green rhombus) and Rev-Erbα (R,yellow ellipse) through E-box enhancers. As the 
translated PER1-2 protein levels rise in the cytoplasm they multimerize with CRY1-2 protein and casein 
kinase ε/δ (CK ε/δ) (ε/δ, organge ellipse) and are phosphorylated (p, pink circle). The complex re-enters in 
the nucleus where it binds the dimer CLOCK-BMAL1, inhibiting its transcription activity. Meanwhile, REV-
ERBα binds the Rev-Erb/ROR responsive elements present in the Bmal1 promoter, repressing Bmal1 
transcription. Since each cellular mechanism is unsynchronized with that of its neighbour, the population 
average of clock gene expression is constant (dashed line). The addition of dexamethasone results in 
synchronous activation of period genes (a), whose protein products multimerize with the more abundant 
cryptochrome proteins CRY1-2 (b) and are translocated to the nucleus (c). These complexes then inhibit the 
activation of circadian genes by CLOCK and BMAL1 heterodimers (d). The resultant repression of clock 
genes “resets” the clockwork and synchronizes the oscillators of independent cells, allowing precise 
measurement of circadian period from population cultures. (Adapted from Balsalobre et al., 1998). 
Additional interlocked feedback loops contribute to the robustness of this molecular 
clockwork circuitry. For example, the orphan nuclear receptor and repressor REV-ERBα 
(Fig.1, yellow ellipse) interconnects circadian transcription of the positive and negative 
“limbs” of the oscillator. Rev-Erbα transcription is activated by the CLOCK-BMAL1 
complex through the binding to E-box sequences present in its promoter, resulting in a 
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circadian accumulation of REV-ERBα. REV-ERBα leads to periodic repression of Bmal1 
transcription. In turn, this leads to a rhythmic expression of Bmal1 mRNA that is antiphasic 
to Rev-Erbα expression (Preitner et al., 2002). Thus, indirectly, Bmal1 is positively 
regulated by PER and CRY proteins. 
Posttranslational mechanisms such as protein phosphorylation also play important roles. 
For example, casein kinase 1ε (CK1 ε) (Fig.1, orange ellipse), initially identified as an 
essential Drosophila clock component (Price et al., 1998), phosphorylates PER, CRY, and 
BMAL1 proteins (Eide et al., 2002; Eide and Virshup, 2001; Lee et al., 2004). CK1δ (Fig.1, 
orange ellipse), a close paralog of CK1 ε, has also been found to be associated with PER–
CRY complexes and may therefore perform a similar function as CK1 ε (Lee et al., 2001). 
While some phosphorylations of PER proteins stabilize it, others destabilize it, leading to a 
complex balance of post-transcriptional regulation that helps to determine period length 
(Vanselow et al., 2006). 
Central and peripheral oscillators 
Ablation and transplantation studies have firmly established that the suprachiasmatic 
nuclei (SCN) of the brain anterior hypothalamus are the site of the master circadian clock 
in mammals (Ralph et al., 1990). Surprisingly, recording of spontaneous action potentials 
from individual SCN neurons showed that the oscillatory machinery of the SCN is cell-
autonomous as in simpler organisms (Welsh et al., 1995), and many laboratories therefore 
began looking for clock genes and other clock tissues. 
It was soon noted that these “clock genes” are expressed rhythmically outside the SCN 
(Sun et al., 1997), and even outside the brain (Zylka et al., 1998) in many peripheral 
tissues. The use of transgenic Drosophila that express green fluorescent protein under the 
control of the promoter of the clock gene period permitted researchers to follow in real-time 
the oscillation of the circadian rhythm in dissected peripheral tissues such as head, thorax, 
and abdominal tissues, demonstrating that autonomous circadian oscillators are present 
throughout the body of a fly (Plautz et al., 1997). The same result was rapidly shown to be 
true for zebrafish and mammals, and even for immortalized fibroblasts (Balsalobre et al., 
1998; Whitmore et al., 1998; Yamazaki et al., 2000).  
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Communication between the SCN and Periphery 
The SCN uses humoral signals, neural efferents, and indirect physiological cues (neural 
control of body temperature and feeding time) to convey timing information to other parts 
of the brain and the periphery. On an anatomical level, many hypothalamic nuclei receive 
SCN projections that mediate the circadian control of multiple systemic cues. For example, 
both direct and indirect projections from the SCN make synaptic contact with CRH 
(corticotropin-releasing hormone) neurons of the paraventricular nucleus (PVN). These 
neurons in turn impose rhythmic ACTH (adrenocorticotropic hormone) release from the 
pituitary and subsequent circadian corticosterone secretion from the adrenal glands. The 
sleep/arousal, reproductive, and endocrine systems are also regulated by the SCN in part 
through neuroanatomic connections. In addition, there exist SCN connections to all major 
organs via both sympathetic and parasympathetic pathways, and recent evidence 
suggests a critical role of the ANS (autonomic nervous system) in synchronizing peripheral 
physiology (Buijs et al., 2003). Interestingly, though, a transplanted SCN encapsulated in 
porous plastic is still able to direct circadian locomotor activity (Silver et al., 1996), so at 
least this fundamental output of the circadian clock does not depend upon synaptic 
transmission directly from the SCN. 
Hormonal signals probably also play an important role in communication between the SCN 
and peripheral clocks. Glucocorticoids agonists can effectively shift peripheral clock gene 
expression in mice (Balsalobre et al., 2000a). The precise role of other cyclically secreted 
hormones such as GH (growth hormone) and PRL (prolactin) in peripheral phase 
entrainment is yet to be examined. The SCN can also indirectly entrain peripheral 
oscillators by controlling daily activity/rest cycles, and consequently, feeding time (Damiola 
et al., 2000; Stokkan et al., 2001). Hormones and metabolites related to feeding, such as 
insulin and glucose, might be involved in this phase setting (Hirota et al., 2002). Rhythmic 
body temperature -- controlled by the SCN via the preoptic anterior hypothalamus -- is also 
sufficient to entrain peripheral circadian oscillators in vivo and in vitro (Brown et al., 2002). 
Finally, activity rhythms as well as circadian outputs from other tissues can feed back on 
the SCN and on other peripheral oscillators. For example, melatonin released from the 
pineal gland, which is itself under SCN control through autonomic pathways, functions as a 
circadian input signal for both the SCN and the anterior pituitary (Stehle et al., 2003). 
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Mutations in clock genes affect human circadian behavior  
In organisms from mice to cyanobacteria, mutations in clock genes have furnished an 
excellent tool for studying circadian clocks. In human beings, polymorphisms located in 
known clock genes result in circadian pathologies. One of the most studied syndromes is 
familial advanced sleep-phase syndrome (FASPS). Individuals with this syndrome can 
wake up and go to sleep hours earlier than normal people. This phase change is believed 
to be related to a change in the endogenous free-running period of the human circadian 
oscillator. Normally around 24 hours, it has been measured to be only 20 hours in an 
individual from an extensively studied FASPS lineage (Jones et al., 1999). The source of 
the difference has been mapped to a change from serine to glycine at residue 662 of the 
Per2 gene. This mutation leads to a reduction in kinase activity of CK1 ε, resulting in a 
shortening of period length of the circadian rhythm (Toh et al., 2001). An unlinked mutation 
in casein kinase 1δ also results in FASPS (Xu et al., 2005). 
Other polymorphisms in clock genes have been shown to be associated with a delayed 
sleep phase syndrome (DSPS) (Archer et al., 2003; Ebisawa et al., 2001; Katzenberg et 
al., 1998; Pereira et al., 2005), though specific molecular mechanisms have not yet been 
identified. On a more general note, basic heritability studies of twins suggest that human 
daytime preference (“chronotype”) is 50% heritable (Koskenvuo et al., 2007). Studies 
relating chronotype to circadian clock period length suggest that morning chronotype can 
result from a shorter period of the endogenous circadian oscillator, and evening 
chronotype from a longer clock period (Duffy et al., 2001). Altogether, it appears that clock 
workings at a cellular and molecular level in different individuals can provide mechanistic 
explanations for differences observed at a behavioural level. 
Interaction between the circadian clock and mood disorders 
Many other diseases are also linked to sleep and circadian disturbances, For example, 
one striking feature of circadian rhythm sleep disorders is that they are often associated 
with other mood disorders. A part of this association is by definition: an established clinical 
symptom of diseases like major depressive disorder (MDD) and bipolar disorder (BD) is 
abnormal sleep/wake, appetite, and social rhythms (Boivin, 2000; Bunney and Bunney, 
2000) which are also hallmarks of circadian rhythm disorders. Nevertheless, an increasing 
body of evidence suggests that there exists an interesting genetic basis for this correlation. 
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Several circadian markers show abnormalities in depression (Avery et al., 1982; Duncan, 
1996; Souetre et al., 1989; Souetre et al., 1988; Szuba et al., 1997). One hypothesis for 
the involvement of circadian rhythm disturbances and development of depression is that, 
perhaps, depression may involve a weaker coupling process between internal pacemakers 
and involve abnormal sensitivity to environmental cues such as light (Souetre et al., 1989). 
This could be a result of mutant clock genes or allelic variations leading to abnormal clock 
cycles or altered photosensitivity. In BD, a single nucleotide polymorphism in the 3' 
flanking region of the Clock-gene associates with a higher recurrence rate of bipolar 
episodes (Benedetti et al., 2003). This mutation is specific to bipolar depression: a similar 
association is not found in MDD (or unipolar depression) (Bailer et al., 2005). Another 
mutation, this time linked to the onset of illness in BD, has been localized to the glycogen 
synthase kinase 3β promoter (Benedetti et al., 2005). This enzyme is the target of lithium, 
a common treatment for BD, and can phosphorylate the clock component REV ERBα (Yin 
et al., 2006).  
Seasonal affective disorder (winter depression, or SAD), is a syndrome characterized by 
recurrent depressions that occur at the same time every year (Rosenthal et al., 1984). 
Depressive phases are associated with hypersomnia, overeating, and carbohydrate 
craving. Abnormalities in circadian rhythms in SAD include sleep disturbances (Rosenthal 
et al., 1984), and alteration of many circadian markers (Avery et al., 1997; Dahl et al., 
1993; Lewy et al., 1998; Lewy et al., 1987; Schwartz et al., 1997). Light therapy, sleep 
deprivation and phase-advance treatment have been used either separately or in 
combination to treat SAD and depressive illness. (Lewy et al., 1998). Here, too, an 
understanding of the molecular workings of the circadian clock in affected individuals could 
furnish valuable insight into the causes of these disorders. 
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MEASUREMENT OF HUMAN CIRCADIAN CLOCKS 
Many physiological and biochemical parameters such as body temperature, melatonin, 
cortisol, heart rate, and blood pressure exhibit circadian rhythms. In principle, 
measurement of circadian parameters such as period length (the time of one complete 
clock cycle) or phase (the time of an organism’s clock within a given cycle) could be 
accomplished by measurement of any of these properties. However, endogenous 
circadian clocks in humans are masked by environmental factors. To dissect endogenous 
and exogenous components of a circadian rhythm, several protocols have been 
developed. These protocols include “constant routine”, in which subjects remain supine 
under constant environmental conditions, with small isocaloric meals and short naps at 
regular intervals (Duffy and Dijk, 2002), and “forced desynchrony”, in which subjects are in 
a dark-light environment so short or so long (e.g. 20h period length or 28h period length) 
that their endogenous clocks cannot adjust and instead run freely (Blatter and Cajochen, 
2007). Both of these methods employ extensive subject observation under controlled 
laboratory conditions; hence, they are very expensive and labour-intensive. In addition, the 
significant time commitment required by subjects makes their recruitment problematic. 
Reporter assays in peripheral cells 
To circumvent the difficulties of direct measurement of circadian behaviour in humans, our 
laboratory has tried instead ex vivo analysis of clocks in tissues that can be obtained easily 
– skin, blood, or hair root cells. Evidence from rodent models suggests that clocks in 
peripheral tissues utilise similar or identical complements of basic clock proteins, and that 
mutations in clock genes that affect SCN function and locomotor behaviour also affect 
molecular oscillations in peripheral cells (Pando et al., 2002; Yagita et al., 2001). 
To measure clock function in peripheral human cells in high-throughput fashion, we have 
employed lentivirally-delivered circadian luciferase reporter vectors. By virtue of their easy 
preparation, wide host tropism, and stable integration into host DNA, lentiviral vectors are 
an excellent system to deliver reporters to hard-to-transfect primary cells (Salmon and 
Trono, 2007). Firefly luciferase is commonly used for the analysis of promoter function in 
eukaryotic systems (Alam and Cook, 1990). The enzyme catalyzes the oxidative 
decarboxylation of beetle luciferin using O2, Mg2 and ATP as substrates. A photon is 
released at 560 nm in 90% of catalytic cycles: this light emission can be quantified in a 
luminometer. In mammalian cell cultures, the half-life of luciferase activity is approximately 
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3 hr (Thompson et al., 1991), making it a convenient choice as a circadian reporter. 
Studies with transgenic mice containing the luciferase gene under control of clock 
promoters have shown that the molecular oscillations of clock gene expression reported in 
this fashion accurately recapitulate circadian transcription measured by conventional 
means in these tissues. Hence, clock gene::luciferase reporter systems have been widely 
used to measure expression of clock genes in prokaryotes, plants, Drosophila, and 
mammals (Brandes et al., 1996; Kondo et al., 1993; Millar et al., 1995; Millar et al., 1992). 
Cell type considerations 
In principle, circadian reporter constructs could be introduced into any cell type. Practically, 
though, a limited range of primary tissues are available from human hosts. These include 
hair root cells, blood cells, and skin cells. Hair root cells include melanocytes and 
keratinocytes. Melanocytes are deep cells that seldom cling to the end of plucked hair. 
Since keratinocytes are present in the hair sheath, they are more easily obtained, but do 
not proliferate to high levels. Highly proliferative pre-keratinocytes are also present in 
sheath, but are more difficult to cultivate. Blood monocytes are easily cultivated but have 
little amplificatory potential; and B- and T-cells can be amplified, but have very weak 
endogenous clocks and are difficult to infect with lentiviral vectors. 
Because of their ease of manipulation, cultivation, and storage, our laboratory has mostly 
used adult dermal fibroblasts. Individual fibroblast cells are capable of functioning as 
independently phased circadian oscillators that are self-sustained for many days in vitro. 
They are also sensitive to a wide range of phase-shifting stimuli, including serum shock, 
glucocorticoids, and even medium changes (Balsalobre et al., 2000b). From these cells, a 
variety of properties can be measured: 
Period length: By synchronizing cultivated cells chemically (e.g. with dexamethasone) and 
then measuring their period under constant conditions, one can obtain a measure of the 
free-running period length of the circadian oscillator (τ). (Figure 1) A strong correlation has 
been found between in vivo free-running behaviour from different mouse strains and 
period length of primary adult dermal fibroblasts from mouse tail. (Brown et al., 2005). 
Hence, it appears possible to use peripheral oscillators as proxies for the clocks of the 
SCN. Recently, similar studies have been performed in humans, and fibroblasts from 
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humans of extreme early chronotype show period lengths on average shorter than those 
from subjects of extreme late chronotype (Brown et al., 2008). 
Phase response: To entrain to the daily light/dark cycle and respond optimally to changes 
in it, the circadian oscillator responds differently to light at different phases of its cycle. 
(Indeed, at some times of day – the so-called “dead zone” – the oscillator is completely 
insensitive to light.) This differential effect is most easily visualized as a phase-response 
curve (PRC), which plots the change in phase of the circadian clock as a function of the 
time that a stimulus is given. Under normal circumstances, fibroblasts do not respond to 
light. Nevertheless, the same signalling pathways that light uses to communicate to the 
clock in other cells – cAMP and CREB – are present. Thus, one can measure a PRC in 
response to an activator of cAMP (forskolin, which increases adenyl cyclise activity). 
Interestingly, the shape of the curve so obtained resembles the PRC of the human light 
response in vivo (Brown et al., 2008; Khalsa et al., 2003). (Figure 2) By reintroducing a 
photopigment into fibroblast cells, one can even measure the sensitivity of the fibroblast 
clock directly to light (Pulivarthy et al., 2007). 
Phase: After a few days of cultivation, fibroblast cells lose synchrony and phase is 
randomly distributed (Welsh et al., 2004). Since the methods described here involve 
amplification of cells for several days, timing information is therefore lost. For all 
experiments described here, a prior resynchronization, usually with dexamethasone, is 
employed. Absolute phase information – i.e. the time at which the biopsy was taken, 
according to the biological clock – is thereby lost, but one can still measure the phase 
angle of normal entrainment for fibroblasts from any subject. In this case, fibroblasts are 
incubated in a shallow circadian temperature gradient (usually 12 hours at 34°C and 12 
hours at 37°C) to mimic the daily entraining signal s of the SCN. Cells will now adopt a 
period of 24 hours, but the peak of reporter gene expression within this 24-hour cycle will 
vary according to the period and amplitude of the underlying circadian oscillator (Brown et 
al., 2008). For example, the phase of fibroblasts carrying the FASPS mutation in Per2 
have a phase of bioluminescence six hours earlier than otherwise isogenic wildtype 
fibroblasts (Vanselow et al., 2006) in this protocol. 
Amplitude: Because the magnitude of the reporter signals measured here is dependent 
upon the titer of virus used, amplitude is a property that cannot be directly measured at 
this time. It is possible, however, to cultivate identical plates of fibroblasts from the same 
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subject, synchronize circadian oscillations with dexamethasone, and then harvest plates 
sequentially over a period of 24 hours. From these cells, RNA or protein can be prepared 
to give a direct measure of the circadian amplitude of any gene or protein. 
 
FIGURE 2. Diagram of a phase-shifting experiment. Identical plates of cells are synchronized 
with dexamethasone. After one day, a phase-shifting agent (in this case, forskolin) is added to 
each plate at a different time of day. The phase of the next circadian cycle is measured with 
respect to a control plate to which vehicle alone has been added. After all plates have been 
measured, the data can be plotted as a PRC (phase response curve) in which the magnitude of 
phase shift is shown for each addition time. The shape of this curve is very similar to that of a 
PRC of human physiology in response to bright light pulses (inset). (Adapted from Khalsa et al., 
2003 and Brown et al., 2008). 
 
6. APPENDICES 
  203  
PROTOCOLS 
Overview of requirements 
These protocols can be conducted by any laboratory comfortable with mammalian cell 
culture. Some special permissions, as well as the collaboration of a medical doctor, are 
usually required. Moreover, a real-time luminometry device capable of measuring 
bioluminescence in constant-temperature cell culture conditions is necessary to visualize 
results. Several commercial models exist (e.g. from Actimetrics, Hamamatsu, or Perkin-
Elmer). Home-made devices are also feasible, and work equally well. 
Ethical considerations 
Collection of human fibroblasts by dermal punch biopsy is considered an invasive 
procedure in most countries, and therefore requires a medical doctor and prior approval of 
the Ethical Committee or Institute Review Board for the hospital or university in question. 
Typically, this permission is easily obtained for adults, but not necessarily for children. 
Use of viruses 
The self-inactivating lentiviral vectors used here are considered to be Biohazard Level II, 
which typically requires institutional notification and a separate cell culture facility. This 
classification applies only to the viral supernatants. Cell lines, once infected with virus, are 
considered to be only Biohazard Level I and may be cultivated normally. 
Storage of samples 
Fibroblast cells may be stored cryogenically as for any other immortalized cell line. We find 
that a storage medium consisting of 50% fetal bovine serum (FBS)/ Dulbecco’s Modified 
Eagle’s Medium supplemented with 4500mg/l glucose (DMEM)/7%DMSO works optimally. 
Viral supernatant at neutral pH may be stored indefinitely at -70°C, but has a half life of 
only a few hours at 37°C or room temperature, and a  week at 4°C or on ice. Tissue 
biopsies may be stored in DMEM/50%FBS on ice for up to five days prior to fibroblast 
cultivation.  
Producing the reporter virus 
The circadian measurement system described here relies upon lentiviral delivery of a 
bioluminescent reporter construct. We have equally used adenoviruses and adeno-
6. APPENDICES 
  204  
associated vectors, but favour the lentivirus for its stable integration into the host genome, 
allowing permanent storage of infected cells as stable lines. Since lentiviruses are 
amphotropic vectors (i.e. they infect most mammalian cell types including human ones), all 
production systems employ some strategy to prevent the generation of actively replicating 
virus and thereby minimize danger to the researcher. Our vectors are a so-called “second 
generation” system obtained from the laboratory of Didier Trono (http://tronolab.epfl.ch/ ). 
One plasmid containing the vector itself is the only genetic material transferred to the 
target cells. It typically comprises the transgene cassette flanked by cis-acting elements 
necessary for its transcription, encapsidation, and integration. A second plasmid supplies 
all the genes necessary for packaging the virus, and a third supplies the coat protein, in 
our case the VSV-G coat protein for maximum host spectrum. All of these plasmids are 
cotransfected into human embryonic kidney cells immortalized by large T antigen (293T 
cells). Note that all human embryonic kidney (HEK) cells are not 293T cells, but can be 
immortalized by other means. The viral production plasmids contain an SV40 origin of 
replication, and will therefore amplify to high levels in 293T cells (but not in other HEK cells 
such as 293E) after transfection.  
Calcium phosphate transfection in 293T cells: Typically, the transient transfection for viral 
production is done using calcium phosphate. In these cells, it is as efficient as lipophilic 
reagents, and certainly much cheaper. The procedure of virus production is 5 days long. 
The first day, amplified 293T cells must be at about 30-50% confluence in 10 cm Petri 
plates with 8 ml of medium. This medium is DMEM, pennicillin-streptomycin-glutamine 
solution as recommended by the manufacturer, and 10% FBS. For each ten-centimeter 
dish, the following quantities of plasmids are transfected: 15 µg of viral reporter plasmid 
(e.g. pBluFpuro), 10 µg of packaging plasmid (e.g. psPAX2), and 6 µg of coat plasmid 
(e.g. pMD2G). This DNA is assembled in a total volume of 400µl weakly buffered water 
(2mM HEPES pH 7.05). 100 µl of 2.5M CaCl2, tissue culture grade, filter-sterilized, is then 
added, and the mixture is allowed to equilibrate to room temperature. A second tube 
containing 500 µl of a solution of 2x HeBS (NaCl 0.283M, HEPES 0.023M, 
Na2HPO41.5mM, pH 7.05) is also equilibrated to room temperature. The pH of HeBS is 
fundamental for high transfection efficiency: pH 7.05 is ideal, and pH outside the range 
7.0-7.1 will result in significantly reduced efficiency.  
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The plasmid and CaCl2 mix is dropwise added to the 2xHeBS under agitation. The 
combined solution is vortexed for 5 seconds, incubated for 30 minutes at room 
temperature, and added dropwise to 293T cells. The medium is mixed by rocking the plate 
back and forth, and cells are incubated overnight at 37°C, 5-7% CO 2. The day after the 
transfection, 293T cells are washed with 5 ml of 1x PBS and then 10 ml of fresh medium 
enriched with 20mM Hepes 7.8 is added to the cells to stabilize the pH-labile virus. Over 
the next two days, virus will be released into the culture medium. The following day the 
virus-containing medium is harvested and stored on ice, and replaced with 10 ml of fresh 
medium enriched as before. The following day medium is harvested again from the cells. 
293T plates are now discarded. Virus-containing medium is pooled and spun at 2G for 5 
minutes to pellet debris, and then filtered through 0.4 µm filters to remove residual 293T 
cells.  
Virus can be concentrated through ultracentrifugation at 80,000 G 4°C for 90 minutes, 
ideally in conical-bottom tubes. The resulting very small, compact, whitish-translucent virus 
pellet is resuspended overnight by medium-speed vortexing at 4°C. The virus is stored at – 
80°C. A concentration of virus between 7 and 10 x i s ideal for a good cell infection. Higher 
titers can be toxic for primary cell cultures. 
Optimising virus production: Typically, we perform two tests to quantify virus production. In 
the first, we routinely transfect a plate of GFP-expressing vector in a duplicate plate in 
parallel with our larger preparations of virus. After two days, the efficiency of transient 
transfection can be analyzed directly by fluorescence microscopy. About 50% is expected. 
The same plate can be left to produce virus, which is concentrated as usual. One aliquot of 
concentrated virus is then rediluted with medium to its original volume. Both of these 
aliquots are tested by infection of 293T cells (see below). 100% infection is expected in 
both cases. If desired, exact titers can be determined by serial dilution. 
Processing of skin biopsies 
The punch biopsy is a fast, easy, inexpensive method to produce a cylinder of tissue from 
the skin surface to the underlying subcutaneous fat. A two-millimiter round dermal punch is 
sufficient, and disposable needles for this purpose are commercially available. Typically, 
the punch biopsy is taken from the buttocks or upper arm of a subject. The area chosen for 
the sampling is an area that normally is not exposed to sunlight. The reasons for this 
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choice are a reduced risk of mutagenesis caused by light rays to healing wounds and 
reduced aesthetical problems caused by the healing lesion for a few weeks after the 
sampling. No permanent scarring results. 
Preparation of the skin: The skin should be prepared with chlorhexidine (Hibiclens), or 
povidone iodine (Betadine, Isodine), or alcohol. This is performed as a clean procedure, 
and full sterile technique with sterile drapes is unnecessary. Local anesthesia with 
lidocaine can be used at patient request. One percent lidocaine with epinephrine is 
injected via a 30 gauge needle and Luer-Lok syringe, about 50µl on each side of the 
planned biopsy site if desired.  
Punch: With the skin held taut at right angles to skin tension lines, the cutting edge of the 
biopsy needle is pressed down firmly, and simultaneously twisted one way and then the 
other in quick succession. As the punch traverses the dermis, resistance is lost, and there 
is a slight “give”. Typically, the punch will remain in the needle as it is removed. Sterile 
tweezers or a 26 g needle should be available to remove it. Occasionally, the biopsy may 
remain in the wound, and the same removal procedure applies. Bleeding is resolved with 
pressure, and no sutures are necessary for a 2mm biopsy punch. A bandage is applied for 
a few days after the procedure. For every biopsy a collection tube filled with medium must 
be prepared and kept on ice. The medium used to collect the biopsy is DMEM containing 
50% FBS, plus a suitable concentration of penicillin, streptomycin, and fungicide such as 
Amphotericin B as recommended by the manufacturer. Tubes should be almost filled to 
facilitate immersion of biopsy, which adheres easily to dry surfaces. Biopsies in this ice 
cold solution can be kept for up to 5 days. Shipping of the biopsy can occur at this stage. 
Biopsy processing: Biopsies are transferred in a 3.5 cm Petri dish for processing. Pour 2 
ml of DMEM, 20%FBS, Amphotericin B, 200 µl of liberase in the dish with the biopsy. 
Liberase (Roche) is an enzyme blend of collagenase isoforms I and II from clostridium 
histoliticum and thermolysin from bacillus thermoproteolyticus; its action is to destroy 
partially the extracellular matrix, to allow the growth of fibroblasts outside the biopsy. 
Incubate the biopsy with the liberase-containing medium at 37°C, 5-7% CO 2 for 4-10 
hours. At the end of digestion multiple clumps containing tens to hundreds of cells are 
present, though the original biopsy has not entirely dissolved. The biopsy is transferred to 
10 ml of PBS 1x and centrifuged for 5 minutes at 200 g. The biopsy pellet is resuspended 
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in 200 µl of DMEM, 20% FBS, penicillin-streptomycin+Amphotericin B and transferred 
back in the middle of the surface of the 3.5 cm Petri dish. To maintain the biopsy attached 
to the bottom of the plate a home-modified Millicell CM membrane disc (Millipore) from 
which spacer feet have been removed is placed on the biopsy. The membrane disc is 
covered with 1.5-1.8 ml of the same medium and incubated overnight. The following day 
the medium is changed. After a few days the first fibroblasts start to grow around the 
biopsy. After one week of cultivation of the biopsy it is not necessary to add amphotericin 
B to the medium. 7-10 days after the biopsy processing the biopsy is attached to the 
bottom of the plate and the membrane disc can be carefully removed. The biopsy requires 
changing of medium every 3-4 days. Length of culture before the first harvest of fibroblasts 
will vary with the number of viable fibroblast foci. Cells are ready to be harvested when the 
combined volume of their foci is about ½ the volume of the plate to which they will be 
amplified. Trypsinize and replate cells normally. It should be noted that biopsy cultivation 
can lead initially to the growth of more than one kind of cells. Keratinocytes can grow from 
the biopsy; however, they will be overrun by the faster-growing fibroblasts. 
Splitting procedure: To split the cells medium is removed and cells are washed once with 
PBS1x. About 0.4 ml of trypsin is enough to detach fibroblasts that grow in a 3.5 cm Petri 
plate. The detachment of the cells can be followed under the microscope. The trypsin 
reaction should not be prolonged because human primary fibroblasts can be damaged. 
Normally trypsinisation of fibroblasts takes about 1 minute. After this time the plate is 
vigorously shaken to promote the detachment of the cells. 2 ml of serum-containing 
medium are then added to block the reaction of trypsin. Cells are usually split 1:2 during 
each amplification passage.  
Freezing procedure: Trypsinise fibroblasts as described in the splitting procedure. For 
every plate of fibroblasts a 15 ml polypropylene tube filled with 10 ml of PBS1x is 
prepared. Cells are detached from the bottom of the plate and transferred in the tube. 
Centrifugation for 5 minutes at 200 g is necessary to pellet fibroblasts. The supernatant is 
removed and cells are suspended in 1.5 ml of DMEM, 50% FBS, 7% DMSO. Cells are 
transferred into an ice-cold cryovial. The vial is left at least 20 minutes at -20°C and then 
placed at -80°C overnight. The following day cells can be definitively stored in liquid 
nitrogen. Human primary fibroblasts can be stored in liquid nitrogen for years. 
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Thawing process: For every vial of cells to be thawed, a 15 ml polypropylene tube with 10 
ml of 37°C warmed medium must be prepared. Unfreeze  fibroblasts quickly, placing 0.5 ml 
of 37°C warmed medium in the cryovial and transferr ing the medium into the prepared 
tube. Repeat this operation until all the cells have been thawed and moved into the tube. 
Centrifuge the tube 5 minutes at 200 g to pellet the cells. Remove the supernatant and 
resuspend the cells in 2 ml growth medium (as above) and plate into the same size of 
plate as originally used for freezing. 
Measurement of circadian oscillations from skin biopsies 
Fibroblast infection: Even though lentivirus can infect non-replicating cells, the infection 
efficiency is increased when the cells are in mitosis. On the day of the infection, fibroblasts 
should be about 30-50 % confluent. For a 3.5 cm Petri plate it is enough to use about 750 
µl of warmed concentrated virus prepared as above. To increase the transfection 
efficiency, 8 ug/ml protamine sulfate is added to the virus aliquot as a polycation to block 
non-specific virus binding to the cell surface. Fibroblasts can be incubated overnight, 
though the infection is complete in about 6 hours. The following day the virus-containing 
medium is removed from the cells. Fibroblasts are rinsed with PBS 1x and standard 
DMEM high-glucose medium containing 20% FBS and penicillin-streptomycin is added to 
the cells. Three days after the viral transfection antibiotic selection of transfected cells can 
be started, if desired. 
Measurement of circadian period length: When transfected fibroblasts have reached 90-
100% confluence the measurement of the circadian rhythm can be started. It is necessary 
to synchronize fibroblast rhythms. Commonly used methods are serum shock or a pulse of 
the glucocorticoid agonist dexamethasone. To induce synchronization with serum shock, 
cells are incubated with DMEM and 50% FBS for one hour. In the case of synchronization 
through dexamethasone, fibroblasts are treated for 15 minutes with DMEM, 20% FBS, 100 
nM dexamethasone. Cells are washed with PBS 1x to remove the presence of 
synchronization agents and medium is replaced. The medium that is used to measure the 
circadian rhythm is DMEM without phenol red, 10% FBS, penicillin-streptomycin, and 0.1 
mM luciferin. If evaporation is a problem, plates can be sealed with parafilm prior to 
placement in the measurement machine. In this case, medium should be buffered with 
20mM HEPES pH 7.6. Normally, circadian oscillations can be observed for 5-6 days. (The 
induced circadian oscillations are diagrammed in Figure 1.)  
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Phase response experiments: For these experiments, duplicate plates – one for each 
timepoint desired in the phase response curve – are synchronized with dexamethasone as 
above. Plates are measured together for 1 day, and then the phase shifting agent is added 
at the desired time to one plate (experiment) and vehicle to the other (control). It is 
important that all reagents be prewarmed and that the procedure be done quickly, because 
temperature is also a phase shifting agent. (Figure 2) 
Phase entrainment experiments: For these experiments, it is necessary to change 
incubator temperature between 34 and 37°C every 12 hours for six days. (One can 
purchase cell culture incubators that will do this automatically.) Fibroblast cells are placed 
into this regime, and on the seventh day, temperature is kept constant at 37°C and 
bioluminescence is measured. (Figure 3) Because the electrical noise and quantum 
efficiency of the photomultiplier tube is itself temperature-sensitive, the temperature of the 
incubator should not be varied during the day of measurement unless a special insulating 
measurement device is constructed. 
Data analyses: To analyse the circadian rhythm of human primary fibroblasts, either 
commercial software (e.g. Lumicycle Analysis, from Actimetrics), or Matlab routines 
(available from Hanspeter Herzel, Humboldt University Berlin) can be used. Both programs 
begin by normalizing data to a 24-hour running average. To determine period, the 
programs then find the period and time constant that best fit the data to a sine wave 
multiplied by an exponential decay 
 
Empirically, we generally discard the first 18 hours of data because noncircadian 
fluctuations associated with the synchronization protocol make automatic sine fitting more 
problematic. To determine phase shifts during a PRC experiment, the timing of the peak of 
reporter expression after substance addition in experiment and control samples are 
manually determined and compared to each other. The phase response curve contains the 
magnitude of these differences on one axis, and the time of substance addition (relative to 
dexamethasone synchronization) on the other axis. For phase entrainment experiments, 
the peak of reporter gene expression is reported relative to the onset of the 34:37 
temperature cycle. 
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Troubleshooting 
Magnitude of signal: Here, problems are usually related to viral titer. We recommend 
routinely testing transfection efficiency and viral titer at the time of viral production by using 
a GFP-expressing control as described above. 
Low viral titer: Viral plasmids are large, and occasionally rearrange during bacterial 
expression. Also, calcium phosphate transfection is highly sensitive to pH, and this 
parameter should be regularly verified. Finally, 293T cells occasionally lose their ability to 
amplify viral plasmids, and should not be continuously cultivated. 
Unexplained cell death, slow growth, or senescence: Primary cell cultures are an excellent 
source of mycoplasma. New cultures should be tested prior to storage. 
Unusual period length or period length variance: Since the circadian clock is temperature-
overcompensated, increasing incubator temperature results in longer period lengths. 
(Even 0.5°C causes a period change of 30-60 minutes .) Hence, it is important that the 
incubator temperature be maintained rigidly constant for all except phase entrainment 
experiments. Abnormally high or low concentrations of serum also alter period length, but 
this effect is relatively minor within standard ranges (5-20%). 
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DISCUSSION 
The protocols used above measure circadian gene expression in adult dermal fibroblasts. 
In general, in both humans and mice, we have observed a correlation between the period 
length of this gene expression and behavioural phase (in humans) and the period of free-
running locomotor activity (in mice). An important question to discuss, though, is how good 
this correlation is (or isn’t). 
At a cellular level, period length in both the SCN and peripheral tissues is stochastic: 
individual SCN neurons in culture and fibroblasts in culture express circadian rhythms of 
widely different phases and different period length (Nagoshi et al., 2004; Welsh et al., 
1995). Luciferase-based measurement of fibroblasts as above yields a population-based 
measurement of the added luminescence of all cells in the plate. These differences are 
therefore not apparent in the overall average. At a population level, in most cases the 
mean of the circadian period length of SCN neurons or cultured fibroblasts is very similar 
to the mean of the period length of behavioral rhythms in the same strain of mouse (Liu et 
al., 1997; Yagita et al., 2001). 
However, for individual cells, cell-to-cell variance is much greater in fibroblasts and 
dissociated SCN neurons than it is in intact SCN slices. A possible explanation of this 
difference is that coupling occurs in SCN tissue that is lacking in dissociated neurons or in 
fibroblasts in culture. In this way, aberrances in individual cells are “corrected” by input 
from neighbors. Mathematical modelling of simple oscillator systems suggests that such 
mechanisms can have major stabilizing effects. As a result, with many clock gene 
mutations in mice, period length in fibroblasts or in dissociated SCN neurons is often more 
perturbed than in either intact brain slices or in animal behaviour. For periods within 
“normal” ranges, however, very good correlations are usually observed (Pagani et al., 
submitted). 
Coupling of SCN neurons occurs in multiple ways: conventional synapses, likely 
GABAergic (Wagner et al., 1997); electrical synapses (i.e. gap junctions) (Colwell, 2000); 
and neuropeptidergic coupling via vasoactive intestinal peptide (VIP) and its receptor, 
VPAC2 (Colwell et al., 2003; Cutler et al., 2003). Recent evidence suggests that 
neuropeptidergic signalling plays a dominant role, since mutations that impair it result in 
severely decreased precision similar to what is observed in dissociated SCN neurons, and 
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amplify the severity of point mutations in clock genes (Liu et al., 2007; Maywood et al., 
2006). 
As we have presented it, the primary utility of peripheral circadian clocks is to screen more 
easily for circadian differences between sets of human subjects. Hence, practically 
speaking, the differences mentioned above could even help: the effects of any given clock 
variations would be expected to be larger as observed in peripheral cells than as observed 
in behaviour.  
Relationship between the circadian oscillator and other pathologies 
A cellular method such as the one presented above, in which fundamental clock properties 
could be determined easily and precisely, could potentially permit an unbiased dissection 
of the relationship of circadian clock defects to unrelated pathologies such as depressive 
and affective disorders. As discussed in the introduction, these maladies are frequently 
accompanied by severe alterations in the timing of sleep episodes. Whether these are 
directly linked to changes in the circadian clock is difficult to establish by conventional 
means. By comparing cellular clock properties, it would be possible to find out if genetic 
alterations in the circadian clock are risk factors for these diseases. 
 Ex vivo models 
Another big advantage of cellular circadian models is the possibility to manipulate the 
human genome. It is possible in fact to re-create the genetic mutation of a disease to 
investigate the molecular mechanisms that determine certain behaviour. Vanselow and 
colleagues introduced a mutation in Per2, believed to be responsible for human FASPS, 
into fibroblasts, and were able to recapitulate the phase advance in the behavior of FASPS 
patients as an advanced phase of clock-gene transcription in synchronized FASPS 
fibroblasts. Subsequent molecular analyses allowed them to show effects of this mutation 
upon phosphorylation at multiple sites in the PER2 protein, and to further demonstrate that 
these modifications affected both PER2 protein stability and nuclear localization (Vanselow 
et al., 2006).  
Similarly, although fibroblasts are not themselves photosensitive, introduction of 
photopigments renders their circadian clocks sensitive to light. Exogenously supplied 
melanopsin acts as a sensory photopigment in fibroblasts and other cell types, where it 
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probably signals via a native G-protein signalling cascade to activate the calcium/cAMP-
responsive element-binding protein (CREB) (Melyan et al., 2005; Panda et al., 2005; 
Peirson and Foster, 2006; Qiu et al., 2005). Transcriptionally active phospho-CREB then 
binds to Per1 and Per2 promoter CRE sites and activates transcription, thereby altering 
the phase of the molecular oscillator (Lee et al., 2001; Meijer and Schwartz, 2003). 
Future potential 
Both for the circadian clock and for other systems, it is increasingly apparent that specific 
molecular defects cause a wide range of alterations in human behavior and physiology. 
Genetic studies have linked specific diseases to a wide range of cellular signaling 
pathways, and many of these are – like the circadian oscillator – conserved at a cellular 
level. Thus, in principle, they could be accessible to the same types of cellular analyses 
discussed above. Given the difficulties that revolve around the collection of human tissues, 
ex vivo analyses such as these could play an important future role in determining how 
molecular differences at an individual level contribute to variations in many aspects of 
physiology and behaviour. 
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ABSTRACT 
From circulation to digestion to excretion, a circadian clock synchronizes most aspects of 
mammalian physiology with the solar day. During normal ageing, this daily coordination 
gradually erodes, and during pathological ageing such erosion is exacerbated. Recent 
experiments suggest that therapies aimed at sustaining circadian function increase quality 
of life in elderly patients. Hence, a better understanding of the interactions between the 
circadian clock and ageing – at both cellular and systemic levels – could lead to direct 
benefits for aged individuals. 
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INTRODUCTION 
From archaebacteria to humans, a biological clock has governed most aspects of cellular 
and systemic function. In mammals, ten percent of all genes are expressed rhythmically in 
daily fashion, coordinated with the solar day. Hence, it is not surprising that nearly all 
aspects of physiology and behavior are governed by this “circadian” oscillator [1]. Within 
the circulatory system, heartbeat and blood pressure vary in diurnal fashion, and rhythmic 
expression of genes involved in fibrinolysis are believed to contribute to the prevalence of 
infarctus at morning hours [2]. Similarly, circadian detoxication of many xenobiotic 
substances is controlled by cyclic expression of cytochrome enzymes [3]; and daily 
variations in mood and alertness might be explained in part by circadian expression of ion 
channels, neuronal receptors, and hormones [4,5]. 
As the body ages, this coordination deteriorates in universal fashion: the circadian 
organization of the sleep-wake cycle is disrupted, and with it most other physiological 
manifestations of the circadian clock become less pronounced [6]. In situations of 
pathological ageing such as dementia and Huntington’s and Parkinson’s Diseases, initial 
disease stages are marked by abnormal daily behavior, and later stages are correlated 
with almost total loss of circadian function [7,8]. An understanding of this deterioration 
could therefore be of great assistance in increasing the quality of life for elderly individuals. 
Incorrectly, many of these disturbances are ascribed simply to “sleep difficulties”: in 
western countries one in five elderly people reports taking a sleep medication regularly [9]. 
While these may provide a momentary alleviation of fatigue, underlying causes remain 
unaddressed, leading to a chronic dependence upon these substances. 
HOW IS CIRCADIAN FUNCTION REGULATED? 
In all mammals including humans, the suprachiasmatic nucleus (SCN) of the brain 
hypothalamus acts as a central clock tissue, coordinating all aspects of overt daily 
physiology and behavior. However, its mechanism is cell-autonomous: each individual 
neuron of the SCN possesses a separate functional oscillator at the cellular level [10]. The 
individual clocks in each neuron are kept in phase with one another by intercellular 
communication involving neuropeptidergic signaling and electrical synapses [11,12]. The 
nucleus as a whole then synchronizes circadian timing throughout the body, probably 
through a combination of diffusible factors and direct connections to other brain regions 
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[13,14]. In fact, “slave” oscillators of similar or identical molecular mechanism to those in 
the SCN are present throughout the body as well. Dissociated cells of peripheral tissues 
such as fibroblasts appear to be able to keep time as accurately as SCN neurons in 
culture [15]. Regulation of daily physiology and behavior is probably a product of systemic 
regulation of some processes directly by the SCN, and indirect regulation of others directly 
by cellular clocks in other tissues [16]. Such a system has the potential benefit of 
temporary uncoupling between SCN and peripheral clocks. For example, if rodents are fed 
consistently at an abnormal time, their peripheral clocks in the liver, kidney, and other 
organs will change their circadian phase to reflect the new feeding time, but the SCN will 
continue to remain in synchrony with the solar day [17,18]. 
At a cellular level, the mammalian circadian oscillator is composed of interlocking feedback 
loops of transcription and translation. A variety of dedicated genes are used for this 
purpose: the products of the Clock and Bmal1 loci activate transcription of a set of 
afternoon-active genes including the Period and Cryptochrome family via cis-acting E-box 
elements present in the promoter regions of these genes. PER and CRY proteins then 
oligomerize to form a repressive complex that counteracts CLOCK:BMAL1 activation and 
shuts off their own transcription, so that the cycle can begin anew. Added robustness and 
control of this mechanism is provided by secondary feedback loops of transcription factors 
(e.g. the nuclear hormone receptors REV-ERB- and ROR-); by phosphorylation (e.g. 
casein kinases 1 and 2, GSK3, and likely multiple others); and by chromatin modifying 
factors, RNA-binding proteins, and cellular metabolic components like cAMP. [19]. 
Elegantly, because this clockwork is present in most cells of the body, it is also one way 
that is used to control circadian output directly: the same elements critical for transcription 
of clock genes are also present in the promoters of many clock-controlled genes (CCGs), 
where they drive circadian transcription using proteins from the clock itself [20]. 
ENTRAINMENT 
To better understand how circadian synchrony might be impaired in older individuals, it is 
important to understand how it is entrained in the first place. In the absence of external 
signals that entrain the clock, the mammalian circadian clock will “free-run” at its 
endogenous genetically-programmed circadian period. This period is approximately, but 
not exactly 24 hours. (In fact, that is why this biological clock is called “circadian” – from 
the Latin circa diem, or around a day.) Thus, without external timing cues, an organism will 
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eventually drift out of synchrony with the actual solar day. Preventing this are entrainment 
signals that come from the environment. In mammals, entrainment of the central clock in 
the SCN is a predominantly ocular process. Environmental light is transduced from the 
retina via both conventional rod and cone photoreceptors containing the photopigment 
rhodopsin, and via a special class of retinal ganglion cells containing the pigment 
melanopsin [21]. These cells project directly to the suprachiasmatic nucleus. Without these 
retinal cells – e.g. in some totally blind or enucleated individuals – the circadian clock “free-
runs”, leaving affected people with chronic jetlag-like symptoms [22]. 
Light transduction through the lens of the eye is reduced in elderly individuals, particularly 
in the short-wavelength range (<480nm) [23]. Elderly mice show much smaller light-
induced clock changes (“phase shifting”) than young ones [24], and elderly individuals 
attenuated phase advances by ocular bright light exposure in the morning [25]. In addition, 
there is a loss of retinal ganglion cells that transmit light signals to the circadian timing 
system in older animals of multiple species [26]. Hence, it has been speculated that one 
cause of circadian disturbances in elderly subjects is an inability to entrain properly to the 
environment. Such problems might be particularly acute in a clinical setting, where lighting 
can be irregular or even constant (e.g. the hospital ICU), or during nursing care when 
patients receive little natural light. Recent human studies provide evidence for this 
hypothesis, and show that the human circadian system is less sensitive to light in the 
elderly [27,28]. Moreover, practically speaking, bright diurnal lighting in nursing homes has 
improved behavioral circadian rhythms in residents and improved sleep quality [29], as 
well as cognitive performance and mood [30]. Similar results are seen for demented 
individuals [31]. By contrast, constant bright lighting might also have deleterious effects: at 
least in animal models, constant light can desynchronize SCN neurons [32], and, as 
discussed at the end of this review, impaired clockwork is linked to a variety of pathologies 
including cancer and immune dysfunction.  
The degree to which brain- and eye-related entrainment changes in the elderly are 
mirrored or relayed in peripheral tissues remains controversial: age-dependent changes in 
clock gene amplitude (e.g. Per2 and Per3 genes) can be observed in blood leucocytes and 
oral keratinocyes, but no age-dependent differences in phase-shifting in these cells 
[33,34]. This question of entrainment of peripheral organs is discussed more fully next. It is 
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clear, though, that relatively inexpensive and easy benefits can be obtained by insuring 
that elderly patients under clinical care receive adequate light in circadian fashion. 
SYSTEMIC CONSIDERATIONS 
As mentioned already, the SCN “master clock” is entrained by light, and it in turn entrains 
“slave” oscillators in most cells of the body via a myriad of redundant cues. One important 
class is nervous signals. The neurons of the SCN demonstrate spontaneous firing patterns 
in daily fashion [10,35], and project to many other brain nuclei [13], where they are 
presumed to be important for sleep-wake cycles and cognitive function. Paradoxically, 
however, the first line of communication from the SCN to centers controlling locomotor 
activity is probably hormonal: animal experiments show that implantation of SCN neurons 
encapsulated in porous plastic are still capable of rescuing rhythmicity in SCN-lesioned 
animals [14]. In peripheral tissues, the sympathetic nervous system also plays an 
important role, and has been shown to communicate timing signals directly to the adrenal 
gland and other tissues [36]. This signaling methodology is likely one of the methods by 
which daily rhythms of corticosterone synthesis are generated [37]. 
A second class of signals is indirect products of the regulation of other brain centers by the 
SCN. Body temperature is one important class: even though daily body temperature varies 
by only 1-4 degrees C in mammals, these faint daily fluctuations – probably controlled by 
SCN innervation of the preoptic anterior hypothalamus and by daily activity patterns – are 
sufficient to entrain peripheral tissues [38]. Similarly, daily patterns of feeding are likely 
cues for the entrainment of peripheral clocks in tissues throughout the body [17,18], as 
well as a separate “food-entrainable” brain oscillator that can control locomotor activity in 
the absence of the known circadian clock [39,40]. In animals, alterations of either of these 
classes of signals effectively “decouples” the central clock from oscillators in other tissues: 
either reversal of daily body temperature rhythms [38] or of daily feeding rhythms [17,18] 
can inverse the timing of local clocks in peripheral organs. The exact mechanism of this 
regulation remains unknown, but recent research proposes direct molecular coupling 
between metabolic cycles and the circadian oscillator via redox-regulated “sirtuin” proteins 
[41,42], and such a metabolic link could be a plausible signal, at least for food-based 
entrainment. In reverse, brain-regulated corticosterone rhythms probably serve as a 
stabilizing influence: in animals lacking the glucocorticoid receptor in the liver, liver clocks 
are much more rapidly shifted by alterations in daily feeding patterns [43]. 
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From these experiments, one can speculate that another way in which circadian 
oscillations might be dampened in elderly individuals might be through alterations of 
systemic entrainment pathways. For example, in one study aged rats showed normal 
entrainment of the SCN by light, but severely disrupted liver clock entrainment [44]. We 
hypothesize that well-characterized alterations in the hypothalamic-adrenal-pituitary (HPA) 
axis in elderly individuals might play a major role. For example, circadian oscillation of 
cortisol is dampened, peak levels are reduced, and evening levels are increased in older 
people [45]. This condition would act synergistically: not only would the direct circadian 
effects of cortisol upon digestion and detoxification be lost, but also any effects of irregular 
feeding and body temperature would have even greater effects upon the circadian 
oscillator because of impairment of parallel cortisol-based entrainment mechanisms. 
Multiple studies have shown that imposed regular routines of mealtime and exercise 
improve circadian consolidation of sleep-wake cycles in elderly individuals [29,46]. 
Physiologically speaking, meal and light routines might help substitute for the loss of 
internal circadian signals, and themselves act as timing cues. Under normal conditions in 
young, healthy individuals, factors such as meal timing are overpowered by systemic 
circadian cues, and therefore might play a less important role. (A similar situation exists in 
blind individuals: in the absence of the strong influence of ocular light, many subjects can 
be entrained to the 24-hour day by weak nonphotic timing cues that do not play a 
significant role for sighted individuals. [47]).  
CELLULAR CONSIDERATIONS 
As already described, virtually all cells in mammals have an independent circadian clock 
capable of sustained oscillations in isolation. Because each cellular oscillator is slightly 
different, though, circadian oscillations in dispersed cultures or tissue slices of peripheral 
cells rapidly dampen. The function of the redundant signaling described above is to 
synchronize all cellular clocks, thereby sustaining robust rhythms of gene expression and 
physiology at the tissue level. Recent studies suggest that there is a second function, 
though: to drive a subset of cellular circadian gene expression directly. Thus, genetically 
modified mice lacking a functional circadian clock in a particular organ lose circadian 
expression of a subset of genes (those coupled to the cellular oscillator) but still show 
circadian expression of others (those coupled to systemic mechanisms) [48,49]. Similarly, 
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tissue-specific rescue of a clock gene results in rescue of only a subset of physiological 
aspects of the underlying mutant strain [50]. 
The cellular heterogeneity of clock properties probably serves a definite function. Although 
the day length on our planet is fixed to 24 hours, the period of light during this time can 
vary dramatically in lateral clines. To cope with these differences, the circadian clock is 
able to track both light onset (dawn) and light offset (dusk). Because of cellular differences 
in the SCN, some of its cellular clocks are phased earlier, and thereby “track” dawn, and 
others are phased later to track dusk – a hypothesis formed long before the existence of 
cellular clocks was discovered [51], and recently confirmed in rodent SCN neural activity 
studies [52] and luciferase imaging experiments [53]. To keep SCN cells locally 
synchronized, neurochemical coupling mechanisms are used [12,54], and probably gap 
junctions as well [55]. Elimination of these components in mice results in dramatically 
dampened circadian oscillations. 
These cellular mechanisms comprise yet another way in which circadian rhythms could be 
altered in older individuals. It is possible that cellular clocks are themselves altered in aged 
cells, either intrinsically or due to increased release of inflammatory cytokines which are 
known to affect circadian gene expression [56,57]. Alternatively, changes in synaptic 
patterns and neurochemical coupling within the SCN could also result in alterations in 
cellular clock function [58,59]. Lending credence to this hypothesis, SCN electrical firing 
shows reduced circadian amplitude in older rats [60,61], and reduced sensitivity to the 
hormone melatonin [62]. Transplantation of a fetal SCN into aged hamsters improved 
behavioral rhythmicity [63,64]. 
CIRCADIAN ALTERATIONS IN THE ELDERLY: WORKING BACKWARDS 
A great deal of research has been done to characterize the specific physiological changes 
that occur as humans age, and some of these have already been mentioned above. The 
nature of these changes could permit us to understand better which of the mechanisms 
presented above might be responsible for the decline in circadian function in elderly 
individuals. 
Even based upon simple questionnaires, it is clear that from adolescence onward, human 
circadian clocks move earlier as individuals age. Between the ages of 20 and 80 years, the 
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timing of sleep shifts an average of two hours [65]. At the same time, sleep consolidation – 
i.e. the ability to sleep in long, unbroken nighttime bouts – is decreased. In addition, the 
total amount of slow-wave “deep” sleep decreases, and rapid-eye-movement “dream” 
sleep is more evenly distributed [66]. In short, there is a marked decrease in the “circadian 
amplitude” of sleep. Sleep patterns are believed to be the sum of two independent 
processes: a circadian one that programs human beings to sleep preferentially at night, 
and a homeostatic one that increases sleep pressure with increasing time awake [67]. In 
principle, the fragmentation of sleep could be caused either by a reduction in the strength 
of the circadian component, or by a change in the homeostatic component, and this 
question is actively debated at present. 
The reduction in circadian amplitude is not limited to sleep: it is universal, and results in a 
variety of endocrine consequences. Appetite is reduced during meals and inter-meal 
eating increases, and activity is increased during nighttime hours, especially during 
pathological ageing: dementia, Huntington’s, and Parkinson’s disease. Meanwhile, the 
circadian amplitude and magnitude of many hormones are reduced, especially melatonin, 
prolactin, and those of the HPA axis, as well as glucose [68]. Although some studies are 
contradictory on this point, body temperature may be both lower and oscillate with lower 
circadian amplitude [69]. Endothelial nitric oxide oscillations are also reduced, and may be 
responsible for the damping of circadian cardiac function [70]. In short, it is easy to 
imagine how circadian physiology might be attenuated. 
A thornier problem is what might shift phase. One obvious hypothesis to explain earlier 
phase would be a shortening of the period of the circadian oscillator. Intrinsic period 
shortening has been observed in aged rodents and nonhuman primates by some groups 
[71,72]. In humans, laboratory studies make this hypothesis unlikely: cross-sectional 
studies of younger and older adults under “forced desynchrony” – artificial lighting 
conditions that measure the intrinsic period of the circadian oscillator unaffected by 
external environment -- show no differences in average period length [73]. Interestingly, 
the same studies also show that the timing (“phase angle”) of sleep relative to the 
circadian clock (measured via the pattern of secretion of the circadian hormone melatonin) 
is earlier, and sleep is less consolidated [74,75]. It is this lack of sleep consolidation that 
has led other groups to speculate that sleep fragmentation is itself responsible for the 
circadian phaseshift [76]. 
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According to this idea, age-related changes in sleep structure and sleep consolidation 
reflect a reduction in the circadian force that opposes homeostatic sleep pressure [77]. 
This influence is particularly significant in the late evening, when the circadian drive for 
wakefulness is highest (i.e., the wake maintenance zone), and in the early morning hours 
when the circadian drive for sleep is at its maximum, thus leading to more sleep episodes 
in the evening and earlier morning wakening in elderly individuals. As consequence of this 
altered sleep-wake pattern, the elderly may expose themselves to more morning than 
evening light, which may result in an earlier circadian phase. 
This model works well in normal conditions, but it does not fully explain similar results 
studying sleep latency under “forced desynchrony” conditions that look at the free-running 
circadian oscillator [73]. We suggest that this paradox might be explained by hormonal 
changes, and that the same hormonal differences might also explain the reduced 
“circadian drive” discussed previously. Since many hormones phase-shift peripheral 
circadian clocks, alterations in their overall levels would be predicted to alter period in 
“free-running” conditions, and phase in an entrained environment. However, if these 
hormones do not act upon the SCN – due to the blood-brain barrier or a lack of the 
appropriate receptors – the result would be a shift in the phase of circadian physiology 
(controlled most directly by peripheral organs and brain regions) without a change in the 
free-running period of circadian behavior (controlled by the SCN). (See Figure 1.) 
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FIGURE 1. Interaction between master and peripheral clocks. In mammals, the master clock in the 
suprachiasmatic nucleus communicates timing information to other tissues in the brain and body via a 
redundant combination of signals: nervous innervation of other brain regions, secreted hormones, and 
indirect cues like body temperature and food intake (shown as black arrows leading out from the SCN), as 
well as by sympathetic innervation of peripheral organs (red arrow). Hormonal signals that influence 
circadian phase can in turn affect both peripheral organs and sleep-wake centers (blue arrows). We suggest 
that some of these hormones (e.g. glucocorticoids) cannot signal to the SCN (dashed blue arrow), though 
they can still affect sleep-wake centers. In older individuals, the circadian amplitude of signals from the SCN 
is decreased, resulting in sleep fragmentation and reduced amplitudes of circadian behavior and physiology. 
We propose that at the same time, changes in hormonal balance -- perhaps in the hypothalamic-pituitary-
adrenal axis -- would additionally alter the circadian phase of behavior. Because these hormones do not 
“feed back” to the SCN, they would not change circadian period length under free-running conditions. 
PATHOLOGICAL EFFECTS OF REDUCED CIRCADIAN FUNCTION IN OLDER 
INDIVIDUALS 
The obvious effect of decreased circadian amplitude is a decreased “quality of life”, 
probably driven by worse sleep and a feeling of less energy during active periods. An 
increasing number of mouse studies suggest that decreased circadian function might also 
have a direct effect upon lifespan. These studies fall into three classes. First, there are 
mouse studies showing that deletions of some clock genes (e.g. Bmal1, Per2) lead to 
decreased lifespan and increased cancer and other age-related pathologies [78,79]. 
Though interesting, the metabolic defects linked to deletions of these genes makes it 
unclear if their effects are gene-specific or clock-specific. Secondly, there are studies 
suggesting that circadian desynchrony per se – via chronic jetlag paradigms, for example 
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– lead to decreased lifespan [80] and increased cancer rate and tumor growth [81]. Finally, 
an increasing number of mechanistic studies tie the circadian clock intimately to questions 
of metabolism. They show for example that the circadian clock times cell division in adult 
animals [82], and that it regulates and is regulated by proteins sensitive to cellular 
reduction and oxidation like sirtuins, which have themselves garnered a great deal of 
interest as anti-ageing proteins [83]. Thus, the circadian clock may be fundamentally tied 
to the balance of factors that prevent cellular damage, and reduced circadian amplitude 
may therefore accelerate this process. 
Although not discussed herein, other pathological effects may also arise separately 
through the changes in sleep that come about during ageing. For example, sleep 
deprivation results in immune system dysfunction and chronic inflammation. Since these 
two effects are commonly observed in aged individuals who suffer from disturbed sleep, it 
is easy to hypothesize a causative link [84]. Other studies, however, suggest that 
according to cognitive parameters, healthy subjects actually tolerate sleep deprivation 
better than younger ones, belying the idea that they are “sleep-deprived” because of their 
altered sleep structure [85]. Further research is clearly needed upon this interesting 
question. 
PERSPECTIVE ON EXPERIMENTS AND TREATMENTS 
Because the synchronization of peripheral circadian oscillators can be driven by indirect 
cues such as mealtime and body temperature, some of the best current circadian 
therapies for elderly individuals may also be the simplest: timed regular activities and 
mealtimes, and bright daytime light. Multiple reports from clinical settings already suggest 
that these measures can help. More long-term, the susceptibility of peripheral clocks to 
multiple hormones may make hormonal therapies another viable option. Exactly which 
hormones might be effective – and which, if any, might be responsible for these changes 
in the first place – are experimentally testable hypotheses, particularly given easy access 
to peripheral clocks in some human tissues. Thus, it is likely that future experiments can 
not only help illuminate the causes of circadian dysfunction in the elderly, but also help 
alleviate it in a safe manner. 
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